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TABLE 1. Clinical features of Turner Syndrome  
 
 
> 80% of cases 
 Growth Retarded growth and reduced adult height 
  Bone age retardation 
 Ovaries Gonadal dysgenesis 
   
50-80% of cases  
 Face Micrognatia 
  Narrow maxilla and dental crowding 
 Ears Recurrent otitis media 
  Malformation and rotation of outer ear 
 Neck Low posterior hairline (40-60% of cases) 
 Skeleton Cubitus valgus 
 Liver Elevated hepatic enzymes 
  
20-50% of cases 
 Face Eye anomalies (i.e. epicanthus, ptosis) 
 Ears Hearing loss (30-90% of cases) 
 Neck Webbed neck 
 Chest Broad chest with widely spaced nipples (less 
frequent: inverted or hypoplastic nipples) 
 Skin Multiple pigmented naevi 
  Congenital lymphedema of hands and feet (25-
60% of cases) 
  Short fourth metacarpals 
 Skeleton Genu valgum 
 Heart and vessels Hypertension 
  Cardiovascular anomalies (i.e. bicuspid aortic 
valve, coarctatio aortae, aortic dilatation) 
 Kidneys Renal abnormalities (i.e. rotational abnormalities, 
double collecting system, horseshoe kidney) 
 Endocrine Glucose intolerance 
  Hypothyroidism (10-30%) 
  Obesity 
  
<20% of cases 
 Eyes Strabismus 
  Amblyopia 
 Skin Halo Naevus 
 Skeleton Congenital hip dislocation 
  Scoliosis 
  Osteoporosis 
 Nails Nail hypoplasia 
 Endocrine Diabetes Mellitus type 1 and 2 
 Other Gonadoblastoma 
  Inflammatory bowel disease 
  Colon cancer 
  Neuroblastoma 
  Juvenile rheumatoid arthritis 
  Liver disease 
  Coeliac disease 
 
Adapted from Ranke 54, Frias 55, Saenger 56, Gravholt 57, and Brazzelli et al. 58. 
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Introduction 
 
In 1938 Henry Turner described a syndrome characterised by short stature, 
lack of pubertal development, a webbed neck, low hair implantation, and 
cubitus valgus 1. Eight years previously, a German paediatrician named Otto 
Ullrich had described a similar patient in a German journal 2. In some 
countries, this has led the syndrome to be called the Ullrich-Turner 
syndrome. In 1959 Ford discovered that a 45, X karyotype caused Turner 
syndrome (TS) 3. We now know that Turner syndrome is caused by either a 
totally or partly absent second X chromosome. The resulting 
haploinsufficiency of certain pseudo-autosomal genes may be an explanation 
for its phenotype.  
Turner syndrome is characterised mainly by growth retardation, ovarian 
dysgenesis and organ malformations. The distribution and severity of its 
typical bodily features varies between individuals (Table 1). Associated organ 
malformations are mainly of the heart and kidneys. While 1 in 2000 live-born 
girls are diagnosed with TS, it is estimated that only 1% of all embryos with 
TS are born alive. The remaining 99% are aborted spontaneously 4, 5.  
Approximately 20% of the girls with TS are diagnosed during infancy, 
displaying typical features such as lymphoedema of the hands and feet and a 
webbed neck 6. A Danish study showed that 76% of TS cases are diagnosed 
before the age of five years, compared to 26% in the years before 1980 4. 
Possibly, the now more widely applied prenatal screening by maternal serum 
screening, nuchal translucency measurement by ultrasound, chorionic 
sampling, or amniocentesis is also responsible for the increase in TS cases 
diagnosed early. TS girls diagnosed at a later age are usually recognised by 
their growth retardation, absent pubertal development or in adulthood by 
infertility or recurrent pregnancy loss 6. A French study showed that almost 
5% of girls who visited a specialist due to growth retardation were diagnosed 
with TS 7.  
 
Height and bone age 
In the North-west of Europe, mean adult height of a woman with TS, without 
the use of growth-stimulating substances, is 1.47 m, approximately 25 cm 
below mean adult height in normal Dutch women 8, 9. The development of the 
short stature can be divided into several stages. Firstly, intra-uterine growth 
is retarded, resulting in a birth length several centimetres shorter than 
normal. Secondly, growth in the first years of life is slightly less than normal. 
In the next years of childhood, height deviates more markedly from the 
normal height curve 10. An absent growth spurt causes a further deviation 
from the normal curve. Due to the delayed closure of the epiphysial growth 
plates, TS women reach adult height at a later age, some even as late as at 
their early twenty’s 10. Previous studies showed that girls with TS are not 
growth hormone (GH) deficient 11-13. It has been suggested, however, that TS 
girls have a diminished sensitivity for growth factors 12, 14. Recent studies 
have identified a pseudoautosomal gene on the sex chromosomes, called the 
‘Short-stature Homeobox-containing gene’ (SHOX) 15, 16. Haploinsufficiency of 
this gene, which is seen in the majority of TS girls, might be responsible for 
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(part of) the short stature.  The function of the proteins it encodes for and 
the pathway to causing short stature are still under investigation.  
Bone maturation, expressed as bone age, appears to develop similarly to 
height. Up to the age puberty was supposed to start, bone age delay is 
approximately 1 year. Thereafter, bone age delay increases further. A 
possible explanation for this is the oestrogen deficiency resulting from the 
ovarian dysgenesis 17. 
Ovarian dysgenesis 
In utero the ovaries seem to develop normally in the first months. Then, 
without an apparent reason, most of the oocytes die before birth. This 
dysgenesis of the ovaries results in the appearance of the so-called streak 
gonads. Almost all women with TS are therefore infertile 18. Due to the 
resulting oestrogen deficiency, spontaneous pubertal development is absent. 
Still, some girls with TS produce enough oestrogen to have spontaneous 
breast development, although sometimes temporary, and, in a small 
percentage, even menstruate. An Italian study showed that 14% of the 45,X 
girls and 32% of the girls with a 46, XX cell-line mosaïcisme showed signs of 
spontaneous puberty 19. While spontaneous pregnancies have been described 
in TS, the chance of a child with a chromosomal malformation is increased 20. 
Possible pseudo-autosomal genes (on the X-chromosome) thought to be 
responsible for oogenesis and ovarian function are the USP9X and the 
DIAPH2 gene, respectively 21. Missing a second copy of these genes might 
cause the ovarian dysgenesis in Turner syndrome. 
 
Diabetes Mellitus and Cardiovascular disease 
Research has shown that untreated TS women have a predisposition for 
diabetes mellitus (DM) and cardiovascular disease (CVD) 22, 23. It has even 
been reported that CVD is the main cause of their reduced life expectancy 24, 
25. In addition, risk factors for CVD, such as hyperlipidaemia, hypertension, 
impaired glucose tolerance, and visceral obesity (high waist/hip ratio) occur 
more often in TS 25-29. This clustering of risk factors is known as metabolic 
syndrome or syndrome X.  
It has been suggested that the impaired glucose homeostasis in TS is caused 
by a metabolic defect in the non-oxidative pathways of intracellular glucose 
metabolism 23. Compared to age and body mass index matched normal 
women, however, one study demonstrated a reduced stimulated insulin 
response in TS women pointing to a beta-cell dysfunction as a possible cause 
for the impaired glucose homeostasis 30. The frequent co-occurrence of 
obesity with all of the previously mentioned risk factors for CVD suggests a 
possible causal link. The precise aetiology of the predisposition for CVD and 
its risk factors, however, remains unclear 31. 
 
Psychological development 
Most girls with TS have a normal intelligence. Several girls, however, have 
difficulty with mathematics and spatiality. IQ tests, in these girls, showed a 
low performal IQ compared to the verbal IQ 32. Psycho-socially, untreated 
girls with TS have been described as more immature, having a lower self-
esteem, poor concentration, and being hyperactive 33, 34. In adulthood, issues 
such as infertility, sexuality, and social awkwardness become issues of 
concern for TS women 35-37. Studies have found that for some TS women 
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inadequate coping mechanisms with these issues lead to a higher than 
expected prevalence of depression 35. 
 
GH and oestrogen treatment  
As early as the seventies, GH was used to treat short stature in TS, then with 
little success. By way of dose-response studies it was found that supra-
physiological dosages of GH led to better results than substitution dosages. A 
previous Dutch study, however, showed that after one year of GH treatment 
a waning effect occurred 38. Subsequent Dutch studies in mostly older girls 
(>11 years) with TS showed disappointing results 39, 40. In 1997 this led to a 
discontinuation of financing of GH treatment for TS in the Netherlands, until 
another Dutch study showed that using a higher dosage of GH in a group of 
older TS girls resulted in better height results 41. To optimise GH treatment in 
TS, in 1989 a new Dutch dose-response study was initiated with 68 young TS 
girls. To reduce the waning effect, a yearly stepwise increase in GH dose was 
used from 4 to 6 IU/m2/day in one group, and from 4 to 6 to 8 IU/m2/day in 
another, while one group remained on a GH dose of 4 IU/m2/day. Eight years 
of GH treatment resulted in a significant increase in height SD-score during 
childhood and adolescence in all GH dosage groups, with a modestly better 
result in both higher dosage groups 42. Although GH treatment for short 
stature in TS is now an accepted treatment in many countries, reports on 
final height are inconsistent 41, 43. 
Another clinical feature in most girls with TS, is the absence of spontaneous 
pubertal development, for which oestrogen substitution is necessary to 
induce puberty. Which age to start puberty induction is still an issue of 
debate. Several paediatricians believe oestrogen treatment should be 
postponed as long as possible to prevent it to stimulate the closure of the 
epiphysial growth plates. Both the professional experience of paediatricians 
and research in girls with TS, however, have shown that the psychological 
importance of inducing puberty at an age as close as possible to their peers 
34. In addition, in the Dutch dose-response study mentioned above, the 
initiation at normal pubertal age of a low dose of natural oestrogens did not 
interfere with the efficacy of GH treatment to normalise height during 
childhood and adolescence in the TS girls 44. 
As one of the side effects of GH treatment is that it increases insulin levels, 
one of the concerns regarding long-term GH treatment is its effect on 
carbohydrate metabolism. Another concern would be its effect on other risk 
factors for cardiovascular disease, such as hyperlipidaemia and hypertension, 
which also occur more frequent in women with TS 45, 46. Several studies, 
describing the effect of GH treatment on blood pressure or lipid levels in TS, 
showed either a positive effect or no effect 47-50. A previous data analysis of 
the Dutch dose-response study showed that glucose levels did not change 
while insulin levels rose during GH treatment. Mean systolic blood pressure 
during GH treatment remained in the high normal range, while mean diastolic 
blood pressure showed a slight decrease, and lipid levels showed a 
favourable change 45, 51.  
One of the reasons why GH treatment is given to TS girls is its assumed 
effect on their psychosocial development. Several studies have shown that 
treatment with oestrogens and/or GH treatment improved self-perception 
and behavioural problems 34, 52, 53. 
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Research questions and aims of the studies 
 
Previous data analyses have shown a positive effect of GH treatment on 
height gain in TS during childhood and adolescence. We still, however, did 
not know whether GH treatment would actually lead to a normalisation of 
final height. In addition, to optimise individual treatment with GH in future, 
we wanted to know which parameters were important to consider before 
initiating treatment. Possible parameters to include were GH dose and age to 
start treatment. Another question we wanted to answer was what is the 
effect on adult height of initiating oestrogen treatment at a pubertal age.  
Regarding side effects, we asked ourselves what the effect would be of 
discontinuation of GH treatment after long-term GH treatment on 
carbohydrate metabolism and risk factors for CVD.  
Regarding psychosocial development during long-term GH treatment, we 
wanted to know what the psychosocial functioning was after reaching adult 
height and, in comparison with previous studies, whether GH treatment and 
oestrogen treatment might have had an influence. 
To answer these research questions, the following aims were used: 
 
1. Evaluation of the effect of long-term GH treatment on adult height in 
60 girls with TS treated in a randomised dose-response trial 
comparing 3 dosage schedules.  
2. Assessment of the effect of low dose oestrogen treatment begun at a 
relatively young age on adult height in girls with TS during long-term 
GH treatment.  
3. Evaluation of several parameters to predict adult height SD-score to 
aid individual treatment with GH in girls with TS during long-term GH 
treatment. 
4. Investigation of carbohydrate metabolism in girls with TS after 
discontinuation of long-term GH treatment in a dose up to 8 
IU/m2/day (~ 0.090 mg/kg/day).  
5. Investigation of several factors that may predict development of CVD, 
such as blood pressure, body mass index and blood lipid levels in TS 
women after discontinuation of GH treatment. 
6. Evaluation of psychosocial functioning in a group of 50 TS women 
with adult height after long-term GH treatment. 
 
Outline of the thesis 
 
In this thesis results are presented of a randomised multi-centre dose-
response GH trial evaluating the efficacy, safety and psychosocial effect of 
long-term GH treatment in girls with TS. The TS trial included the first 
participants in 1989.  
Chapter 2 describes the effect of long-term GH treatment and of low dose 
oestrogen treatment begun at a relatively young age on adult height in 60 
girls with TS treated in a randomised dose-response trial comparing 3 dosage 
schedules. In addition, a prediction model on adult height SD-score is 
presented. Chapter 3 describes carbohydrate metabolism and several risk 
factors for CVD in girls with TS after discontinuation of long-term GH 
treatment. Chapter 4 describes psychosocial functioning in a group of 50 TS 
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women with adult height after long-term GH treatment. Chapter 5 discusses 
the results in relation to other literature and the implications of the results. In 
addition, it concludes and gives recommendations for future research. 
Chapter 6 summarises the TS part of the thesis in English and Dutch. 
 
Previous dissertations 
 
In his thesis entitled “Growth hormone treatment modalities in girls with 
Turner syndrome”, Rotterdam 1996, Arne van Teunenbroek described the 
four-year results of the TS trial. His successor, Theo C.J. Sas, investigated 
seven-year data of the TS trial. His thesis was entitled “Long-term growth 
hormone treatment in two growth disorders”, Rotterdam 1999. 
CHAPTER 1   Part ‘Turner Syndrome’: Introduction 
  18
  
 
   19
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
 
Part ‘Turner Syndrome’: Final height in girls with Turner syndrome 
after long-term GH treatment in three dosages and low dose 
oestrogens
CHAPTER 2  Part ‘Turner Syndrome’: Final height in TS after long-term GH 
 
  20
CHAPTER 2  Part ‘Turner Syndrome’: Final height in TS after long-term GH 
 
  21
Final height in girls with Turner syndrome after long-
term GH treatment in three dosages and low dose 
oestrogens 
 
Y.K. van Pareren, S.M.P.F. de Muinck Keizer-Schrama, T. Stijnen, T.C.J. Sas, 
M. Jansen, B.J. Otten, J.J.G. Hoorweg-Nijman, T. Vulsma, W.H. Stokvis-
Brantsma, C.W. Rouwé, H.M. Reeser, W.J. Gerver, J.J. Gosen, C. Rongen-
Westerlaken, S.L.S. Drop. 
 
Department of Paediatrics, division of Endocrinology, Erasmus University MC/ Sophia 
Children's Hospital, (Y.K.v.P., S.M.P.F.M.K.-S, T.C.J.S, S.L.S.D.), Rotterdam; 
Department of Epidemiology and Biostatistics, Erasmus University MC (T.S.), Rotter-
dam; Wilhelmina Children's Hospital (M.J), Utrecht; Sint Radboud University Hospital 
(B.J.O.), Nijmegen; Free University Hospital (J.J.G.H-N), Amsterdam; Academic 
Medical Centre /Emma Children's Hospital, (T.V.), Amsterdam; Medical University 
Centre (W.H.S.) Leiden; Beatrix Children's Hospital (C.W.R.), Groningen; Juliana 
Children's Hospital (H.M.R.), The Hague; Academic Hospital (W.J.G.) Maastricht; 
Rijnland Hospital (J.J.G.), Leiderdorp; Canisius-Wilhelmina Hospital (C.R-W.), Nijme-
gen, the Netherlands. 
 
Abstract 
 
Although growth hormone (GH) treatment for short stature in Turner 
syndrome is an accepted treatment in many countries, which GH dosage to 
use and which age to start puberty induction are issues of debate. This study 
shows final height (FH) in 60 girls with Turner syndrome treated in a 
randomised dose-response trial, combining GH Treatment with low dose 
oestrogens at a relatively young age. 
Girls were randomly assigned to group A (4 IU/m2/day ~ 0.045 mg/kg/day), 
group B (1st yr: 4 IU/m2/d, thereafter 6 IU/m2/d), or group C  (1st yr 4 
IU/m2/d, 2nd yr 6 IU/m2/d, thereafter 8 IU/m2/d). After a minimum of 4 
years of GH treatment, at a mean age of 12.7 (0.7) years, low dose 
micronised 17 β-oestradiol was given orally. After a mean duration of GH 
treatment of 8.6 (1.9) years, final height (FH) was reached at a mean age of 
15.8 (0.9) years. FH, expressed in cm or SD-score, was 157.6 (6.5) or -1.6 
(1.0) in group A, 162.9 (6.1) or -0.7 (1.0) in group B, and 163.6 (6.0) or –
0.6 (1.0) in group C. The difference in FH in cm, corrected for height SD-
score and age at start was significant between groups A and B (regression 
coefficient 4.1; 95% CI: 1.4, 6.9; P < 0.01), and groups A and C (coefficient 
5.0; 95% CI: 2.3, 7.7; P < 0.001), but not between groups B and C 
(coefficient 0.9; 95% CI: -1.8, 3.6).  Fifty of the 60 girls (83%) had reached 
a normal FH (FH SD-score > -2). After starting oestrogen treatment, the 
decrease in height velocity (HV) changed significantly to a stable HV, without 
affecting bone maturation (∆BA/∆CA). The following variables contributed 
significantly in predicting FH SD-score: GH dose, height SD-score (ref. 
normal girls) and CA at start, and HV in first year of GH treatment. GH 
treatment was well tolerated.  
In conclusion, GH treatment leads to a normalisation of final height in most 
girls, even when puberty is induced at a normal pubertal age. The optimal GH 
dosage to use depends on height and age at start of treatment, and first year 
height velocity.  
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FIGURE 1. Flow diagram of the progress through the phases of the trial 
Excluded (n=22) :
    Not meeting
    inclusion criteria (n=19)
    Other reasons (n=3)
Analysed (n=19)
Excluded from analysis :
(n=1) still treated
Lost to follow-up
(n=3) non-compliance
Group A
(n=23)
4 IU/m2/day
Analysed (n=20)
Excluded from analysis :
(n=1) still treated
Lost to follow-up
(n=2) non-compliance
Group B
(n=23)
4-6 IU/m2/day
Analysed (n=21)
Excluded from analysis :
(n=0) still treated
Lost to follow-up
(n=1) non-compliance
Group C
(n=22)
4-6-8 IU/m2/day
Randomised
(n=68)
Assessed for eligibility
(n=90)
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Introduction 
 
The most common clinical characteristic of Turner syndrome (TS) is short 
stature. The reason for the short stature is still under investigation. A recent 
study has shown that the aetiology of the growth retardation possibly lies in 
the haploinsufficiency of the SHOX gene 15. Although girls with TS are not 
growth hormone (GH) deficient 12, subnormal levels of GH and IGF-I have 
been reported 11, 42. It has been postulated that a diminished sensitivity for 
growth factors might explain their growth retardation 14, 59. Nevertheless, GH 
treatment in a supra-physiological dosage has been shown to accelerate 
growth 42, 60. Another clinical feature, in most girls with TS, is the absence of 
spontaneous pubertal development, for which oestrogen substitution is 
necessary.  Although GH treatment for short stature in TS is now an accepted 
treatment in many countries, reports on final height are inconsistent 41, 43, 
and which dosage to use and which age to start puberty induction are issues 
of debate.  
Previously, we have demonstrated that long-term GH treatment in TS leads 
to normalisation of height 42, 61. This study shows final height results in 60 
girls with TS treated in a randomised dose-response trial comparing 3 dosage 
schedules. In addition, we show the effect of low dose oestrogen treatment 
begun at a relatively young age. Thereby, we have constructed a prediction 
model for final height SD-score to aid individual treatment. 
 
Patients/Methods 
 
Study Subjects 
Sixty-eight previously untreated girls with TS were enrolled from 8 academic 
and 3 major non-academic paediatric departments in The Netherlands in an 
open randomised multi-centre GH dose-response study. Six girls dropped out 
of the study because of non-compliance and were lost to follow-up. Two girls 
were still treated with GH at time of analysis (24th January 2002) and had 
not yet reached final height, leaving 60 girls for analysis of final height (FH) 
in this study (Figure 1). As the 8 girls not used in the analysis (either lost to 
follow-up or have not yet reached FH) were normally distributed over the 
randomization groups (4/3/1) and the baseline clinical data showed no 
significant difference compared to the 60 girls with FH, selection bias was 
unlikely.  
The diagnosis was confirmed by lymphocyte chromosomal analysis. Three of 
the 68 girls had a prenatal diagnosis. Inclusion criteria were: a chronological 
age (CA) between 2 and 11 yr, height below the 50th percentile for healthy 
Dutch girls 62, and normal thyroid function. Exclusion criteria were: 
associated endocrine and / or metabolic disorders, growth failure caused by 
other disorders or emotional deprivation, hydrocephalus, previous use of 
drugs which could interfere with growth hormone treatment, and 
spontaneous puberty 63. Written informed consent was obtained from the 
girls and their parents or custodians. The study protocol was approved by the 
ethics committee of each participating centre. 
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Study Design  
At start of the study, a total of 15 patients per dosage group was calculated 
to be necessary to discover a true mean difference in height velocity of 1.0 
cm/year between dosage groups after two treatment years with a probability 
of 80% (based on a 2-sided t-test for paired observations). Based on this 
calculation, 68 girls were included from November 1989 until October 1990 in 
the study to evaluate the effect of augmentation of GH dosage on height 
velocity and final height. Sixty-eight girls were randomly assigned to three 
groups in blocks of 2, 4, or 6 (randomly chosen) in 4 strata defined by age 
and height SD-score at start. The sequence was concealed in envelopes until 
treatment was assigned. The treatment regiments were:  
 
A  (n=23) receiving 4 IU/m2 body surface/day (~ 0.045 
mg/kg/day), 
B  (n=23) receiving 4 IU/m2/day in the first year, followed by 6 
IU/m2/day (~ 0.0675 mg/kg/day) 
C  (n=22) receiving 4 IU/m2/day in the first year, 6 IU/m2/day in 
the second year, and thereafter 8 IU/m2/day (~ 0.090 
mg/kg/day). 
 
Biosynthetic human GH (Norditropin, Novo Nordisk A/S, Bagsvaerd, 
Denmark) was given subcutaneously once daily at bedtime using a pen 
injection system. Every 3 months the total GH dose was adjusted to the 
calculated body surface. According to the study protocol, the GH treatment 
was discontinued when height velocity was < 1 cm over 6 months, or on the 
decision of the patient due to satisfaction with achieved height. In the first 4 
years of GH treatment, no oestrogen for pubertal induction was given to the 
girls. After 4 yr of GH treatment, oestrogen treatment was started at the 
yearly visit after reaching the age of 12 yrs. In the girls who became 12 
years during the first 4 yrs of GH treatment, oestrogen treatment was started 
at 4 years of GH treatment. Five µg 17β-estradiol/kg body weight/day (~  
0.05 µg ethinyl oestradiol/kg/day), orally, was given in the first 2 years, 7.5 
µg /kg/d in the third year and 10 µg/kg/d thereafter (Tablets containing 0.1 
mg micronised 17β-estradiol were supplied for the study by Novo Nordisk 
A/S, Bagsvaerd, Denmark). Cyclic progesterone therapy (Duphaston® 5 
mg/d during the first 14 d of the month) was added after 2 years of 
oestrogen therapy. If puberty had developed spontaneously (Tanner breast 
stage ≥ 2) before start of oestrogen, no exogenous oestrogen was given.  
Height was measured in 8 academic and 3 major non-academic paediatric 
departments at baseline and subsequently every 3 months in the same 
department using a Harpenden stadiometer by 3 observers (A van 
Teunenbroek ‘89-’95, T Sas ‘95-’98, and Y van Pareren ‘98-’01). The mean of 
4 measurements was used for analysis. Final height (FH) was defined as the 
most recent available height after discontinuation of GH treatment (mean 0.5 
(0.2) years after discontinuation of GH treatment). Height was expressed as 
standard deviation score (SD-score) using the references for healthy normal 
Dutch girls (ref. normal girls) 9 or the references for North European 
untreated girls with TS (ref. TS) 8. Height velocity (HV) per year was defined 
as the increase in height in cm per year. HV SD-score was calculated using 
reference values for HV in North European untreated girls with TS 64. Target 
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height (TH) was adapted from Dutch reference data with addition of 4.5 cm 
for secular trend: TH = ½ x (Hmother + Hfather - 13 cm) + 4.5 cm 9. TH range 
was defined as the TH ± 1.3 SD and TH was expressed as SD-score 9, 65. 
During GH treatment pubertal stages were assessed according to Tanner 63. 
Bone age (BA) was determined by the same 3 observers according to the 
Tanner & Whitehouse radius, ulna, short-bones score 66. Bone maturation 
was expressed as the ratio of the change in BA to the change in CA ( ∆ BA/∆ 
CA). Adult height without GH treatment was calculated for each girl with the 
modified projected adult height method (mPAH), using the equation of Lyon, 
adapted to North European untreated girls with TS 8, 67, 68. To assess the gain 
in FH, FH was compared with the mPAH at start of GH treatment.  
 
Biochemical parameters and hormone assays 
Blood samples were taken at start of the study and subsequently every year, 
and 6 months after discontinuation of GH treatment for determination of the 
glycosylated haemoglobin, leukocytes, haemoglobin, creatinine, aspartate 
aminotransferase (ASAT), alanine aminotransferate (ALAT), Alkaline 
Phosphatase (AP), free thyroxin (T4), and thyroid-stimulating hormone (TSH) 
levels. Plasma insulin-like growth factor (IGF-I) levels were determined at 
start, at 6, 18, 30, and at 48 months, thereafter at every year visit until 
discontinuation of GH treatment, and 6 months after discontinuation of GH 
treatment. After centrifugation, all samples were frozen (-200C) until 
assayed. All measurements of IGF-I were performed in one laboratory by 
radioimmunoassay (RIA), as described previously 69 and were transformed to 
SD-scores using reference levels for healthy children determined in the same 
laboratory 70.  
 
Statistical Analysis 
Results were expressed as mean (SD), unless indicated otherwise. 
Differences between the dosage groups were tested by linear regression 
analysis with the variables age and height SD-score (ref. normal girls) at 
start of treatment and two dummy variables for dosage group. Differences in 
time between continuous variables were compared by paired 2-sided t-test 
for the whole group unless otherwise specified. A stepwise forward linear 
regression analysis was used to construct a prediction model for FH SD-score 
and gain in height (FH – mPAH in cm). The following potential predictor 
variables were used: bone age (BA), chronological age (CA), height SD-score 
(ref. normal girls), and IGF-I SD-score at start, GH dosage group, target 
height SD-score, karyotype (45,X or other), first year increase in alkaline 
phosphatase and in HV (in cm), and first 18 months increase in IGF-I SD-
score. Only the variables with a P-value < 0.05 were kept in the model. 
Subsequently, the squares of the remaining variables were tested for 
significance, after which the variables were tested for possible interactions. 
All correlations were partial correlations, adjusted for GH dosage. A P-value < 
0.05 was considered significant. All calculations were performed by SPSS 
version 9.0.  
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TABLE 1. Mean (SD) baseline clinical data 
 
 Group A Group B Group C 
Number of girls 19 20 21 
Chronological age (yr) 6.5 (1.9) 6.9 (2.3) 6.5 (2.4) 
Bone age (yr) 5.9 (2.1) 6.2 (2.5) 5.8 (2.4) 
Height SD-score  -2.9 (0.9) -2.7 (0.9) -2.7 (1.0) 
Height SD-score  0.0 (1.1) 0.3 (0.9) 0.2 (1.1) 
Maximal GH response  
(ATT)* (mU/L) 18.5 [4-67] 16.5 [5-74] 21.3 [3-66] 
Modified projected adult  
height (cm) 
145.7 (5.7) 147.2 (4.9) 146.6 (5.6) 
Target height (cm) 170.4 (6.6) 171.3 (6.0) 170.5 (5.6) 
Karyotype: 45,X 16 (84%) 19 (95%) 16 (76%) 
Karyotype: other 3 (16%) 1 (5%) 5 (24%) 
GH = growth hormone, ATT = arginine tolerance test. * Geometric mean [range] 
  
 
TABLE 2. Mean (SD) height data of 60 girls with Turner syndrome after long-
term GH treatment 
 
 
Group A 
(N = 19) 
Group B 
(N = 20) 
Group C 
(N = 21) 
Final height (cm) 157.6 (6.5) 162.9 (6.1)* 163.6 (6.0)** 
[Range] [143.1, 172.1] [152.4, 176.2] [153.3, 172.4] 
Final height SD-score  -1.6 (1.0) -0.7 (1.0)* -0.6 (1.0)** 
(ref. normal Dutch girls) [-3.8, 0.5] [-2.6, 1.1] [-2.1, 0.9] 
Height gain (cm) 11.9 (3.6) 15.7 (3.5)* 16.9 (5.2)** 
(FH minus mPAH) [2.8, 17.8] [8.1, 20.4] [7.2, 28.7] 
∆ Height SD-score  1.2 (0.6) 1.9 (0.5)** 2.1 (0.8)** 
(from start until FH) [-.2, 2.0] [0.9, 2.6] [0.3, 3.6] 
GH duration (yr) 8.9 (1.4) 8.3 (2.1) 8.7 (2.0) 
 [6.5, 11.1] [5.5, 12.0] [5.3, 11.5] 
FH = final height, mPAH = modified projected adult height. Linear regression analysis with 
correction for age and height SD-score at start (vs group A):  
* P < 0.01 ** P < 0.001  
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Results 
 
In Table 1 the pre-treatment clinical data of the 60 girls with final height are 
shown. Baseline clinical data were similar for the three GH dosage groups. 
After a mean duration of GH treatment of 8.6 (1.9) years, final height was 
reached at a mean age of 15.8 (0.9) years, and with a bone age of 15.5 (0.6) 
years. Forty-eight of the 60 girls had GH treatment duration of 7 years or 
more.  
Final height (FH) in cm was 157.6 (6.5) in group A, 162.9 (6.1) in group B, 
and 163.6 (6.0) in group C (Table 2). When translated to SD-score, using 
references for normal girls, FH was -1.6 (1.0) for group A, -0.7 (1.0) for 
group B, and –0.6 (1.0) for group C (Figure 2). The difference in FH in cm, 
corrected for height SD-score and age at start was significant between 
groups A and B (regression coefficient 4.1; 95% CI: 1.4, 6.9; P < 0.01), and 
groups A and C (coefficient 5.0; 95% CI: 2.3, 7.7; P < 0.001), but not 
between groups B and C (coefficient 0.9; 95% CI: -1.8, 3.6).  Fifty of the 60 
girls (83%) had reached a normal FH (FH SD-score > -2). Thirty-eight of the 
60 girls (63%) reached a FH within their TH range. 
The mean gain in final height in cm (FH - mPAH) in group A was 11.9 (3.6) 
cm, being significantly lower compared to 15.7 (3.5) cm in group B 
(regression coefficient 4.2; 95% CI: 1.5, 6.9; P < 0.01) and compared to 
16.9 (5.2) cm in group C (coefficient 5.2; 95% CI: 2.6, 7.8; P < 0.001), but 
the height gain in group B was not significantly different to group C 
(coefficient 1.0; 95% CI: -1.6, 3.6; P = 0.44) (Figure 3). Similarly, the mean 
increase in SD-score from start of GH treatment until FH in groups B and C 
was significantly higher compared to group A (coefficient 0.7; 95% CI: 0.31, 
1.11; P < 0.001), but the increase in group B was comparable to group C 
(coefficient 0.12; 95% CI: -0.27, 0.5; P = 0.5) (Table 2). 
 
Oestrogen effect 
Oestrogen treatment was started at a mean age of 12.7 (0.7) years. Tanner 
breast stage 2 was reached at a mean age of 12.9 (0.6) and stage 4 at a 
mean age of 14.8 (1.1). Height velocity (HV) before and after initiation of 
oestrogen treatment is depicted in Figure 4. To homogenize the group for 
age, only the girls who started oestrogen treatment at age 12 were analyzed 
(n=47). HV in the year after initiation of oestrogen treatment compared with 
the HV in the previous year showed no significant difference (HV0yr vs 
HV1yr). The downward trend in HV before initiation of oestrogen treatment, 
however, changed significantly to a stabile HV after initiation ( ∆ HV-1yr-0yr 
vs ∆ HV0-1yr; P < 0.05). Bone maturation ( ∆ BA/∆ CA) in the year before 
and in the year after initiation of oestrogen treatment was not significantly 
different (t=0 vs t=1 yr; Figure 4). GH dosage, GH duration before start of 
oestrogen, and height at puberty had no significant effect on the differences 
(between before and after initiation of oestrogen) in HV, in the change in HV, 
or in bone maturation.  
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FIGURE 2. Height SD-score for chronological age (ref. normal Dutch girls) during GH 
treatment for group A (white bars), group B (gray bars), and group C (black bars), 
respectively 
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FIGURE 3. Height gain (difference in cm between final height and modified projected 
adult height) for group A (n=19), group B (n=20), and group C (n=21), respectively.  
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Prediction model for final height SD-score and gain in height 
A stepwise forward linear regression analysis resulted in a model using the 
predictor variables GH dose, height SD-score (ref. normal girls) and CA at 
start of treatment, and HV in first year of GH treatment accounting for 75.6% 
of the variation in FH SD-score (residual SD 0.55). Table 3 shows the 
coefficients of the linear regression model. Variables, which showed a non-
significant effect on FH SD-score were IGF-I SD-score and BA at start, 
increase in IGF-I SD-score in first 18 months and increase in alkaline 
phosphatase in first year, TH SD-score, and karyotype (45,X yes or no). The 
model equation was: FH SD-score = -2.29 + 0.80 x Height SD-score at start 
+ 0.81 x Group C (yes=1/no=0)  + 0.68 x Group B (yes=1/no=0) + 0.24 x 
HV in 1st year (cm) + 0.087 x CA at start (yr). To explore the effect of CA at 
start on FH SD-score, a partial correlation was done, controlling for GH 
dosage. The result was a significant negative correlation between FH SD-
score and CA (r = -0.30, P < 0.05).  
When using the same predictor variables in a stepwise forward regression 
analysis to predict height gain (FH – mPAH in cm), the following model was 
obtained, after substitution of HV in 1st year in cm by HV SD-score (ref. TS) 
and age at start, and the addition of GH peak during ATT: height gain (cm) = 
10.95 (SE:2.58) + 1.15 (0.47) x HV SD-score in 1st year + 4.01 (1.18) x 
Group B (y/n) + 5.55 (1.16) Group C (y/n) – 1.57 (0.59) x Height SD-score 
at start – 1.04 (0.28) x CA at start (yr) – 0.083 (0.032) x GH peak (mU/L). 
The model explained 45.6% of the variation in height gain (residual SD 3.6 
cm). 
 
IGF-I levels 
Mean plasma IGF-I SD-score before, during and 6 months after 
discontinuation of GH treatment is shown in Figure 5. Mean plasma IGF-I SD-
score increased significantly from start of GH treatment until 7 years of GH 
treatment (P < 0.0001 for whole group), from -2.3 (1.5) to 1.9 (0.8) for 
group A, from –1.4 (1.2) to 2.5 (0.9) for group B, and from –1.9 (1.4) to 2.7 
(0.9) for group C. Although the increase from start until 7 years of GH 
treatment was not significantly different between groups A, B and C, we did 
find significantly higher IGF-I SD-score at 7 years of GH treatment in group C 
compared to group A (P < 0.05). After discontinuation of GH treatment IGF-I 
SD-score decreased significantly (P < 0.0001 for whole group) to a mean SD-
score of –0.6 (1.0) for group A, -0.1 (0.7) for group B, and –0.1 (0.9) for 
group C, the decrease being not significantly different between groups. IGF-I 
SD-score 6 months after discontinuation of GH treatment was not 
significantly different from zero (= mean IGF-I level for same age and sex 
reference population) for groups B and C, but lower than zero for group A (P 
< 0.05). 
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FIGURE 4. Height velocity and bone maturation before and after initiation of low dose 
oestrogen (E2) treatment for group A (circle), group B (triangle), and group C (square) 
in girls who initiated oestrogen treatment at age 12 years (n=47). The black signs 
indicate the height velocity and bone maturation after initiation of oestrogen treatment. 
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Safety 
No adverse events were detected that were considered to be GH related. 
Treatment was well tolerated. A previously published report, using the same 
study group to describe glucose tolerance during long-term GH treatment, 
showed no adverse effects on glucose levels 51. Furthermore, no significant 
differences in glucose and insulin levels between the GH dosage groups 
during long-term GH treatment were found 51. With the exception of two 
girls, glycosylated haemoglobin levels, but also leukocytes, haemoglobin, 
creatinine, ASAT, ALAT, alkaline phosphatase, free T4, and TSH levels 
remained within the normal range and none of the children developed 
diabetes mellitus. Two girls had abnormal laboratory findings: one girl 
developed autoimmune hypothyroidism and was treated with thyroid 
hormone during the study, another girl developed elevated levels of hepatic 
enzymes and hepatomegaly resulting from hepatic glandular malformations. 
 
Discussion 
 
In this paper we present final height results in 60 girls with Turner syndrome 
after long-term GH treatment in three dosages. We show that when puberty 
is induced at a normal age, a GH dosage of 4 IU/m2/day (group A), in Turner 
Syndrome (TS), leads to a mean final height (FH) of 157.6 cm, which is equal 
to an SD-score of -1.6 when using references for normal Dutch girls, whereas 
using 6 IU/m2/day (group B), leads to a significantly higher final height of 
162.9 cm (SD-score -0.7). Administration of an even higher dosage of GH (8 
IU/m2/day; group C) did not lead to a significant increase in attained final 
height compared to group B. As a result, 83% of the girls with TS reached a 
normal final height (FH SD-score above -2) and 63% reached a final height 
within their target height range (TH ± 1.3 SD). 
Our study shows that, when GH was started at a mean age of 6.6 years, the 
mean gain in FH (estimated by subtracting Lyon’s predicted adult height, 
adjusted for Dutch girls with TS (mPAH), from attained FH) varied between 
11.9 cm in group A to 16.9 cm in group C. The reason why previous studies 
reported a considerably lower gain in final height probably lies in the fact that 
they started GH treatment at an older age 43, 71, 72. This is confirmed by the 
finding that other studies, starting GH treatment at a younger mean age, also 
showed a greater gain in final height 60, 73, 74. In addition, in our study, we 
found that in a regression model, containing height velocity SD-score in the 
first year, height SD-score at start, GH peak, GH dosage, and a lower age at 
start predicted a greater gain in final height. Another factor that predicted FH 
gain was the dosage of GH. Our study showed that using a dosage of 6 or 8 
IU/m2/day instead of 4 significantly increased gain in FH. Using a dose of 8 
IU/m2/day, however, showed no advantage over 6 IU/m2/day for gain in FH. 
Our results are confirmed by two non-randomised studies showing a dose-
dependent increase in final height gain 75, 76.  
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TABLE 3. Variables in prediction model for Final height SD-score (N = 60) 
 
Independent  
variable 
Regression 
Coefficient 
SE P-value 
Height SD-score at start * 0.80 0.09 < 0.0001 
Group C # 0.81 0.18 < 0.0001 
Group B # 0.68 0.18 < 0.001 
First year height velocity** 0.24 0.06 < 0.01 
Age at start 0.087 0.04 < 0.05 
Regression equation: FH SD-score = -2.29 + 0.80 x Height SD-score at 
start + 0.81 x Group C (yes=1/no=0)  + 0.68 x Group B (yes=1/no=0) + 
0.24 x HV in 1st year + 0.087 x CA at start. 
* Using references for normal girls, # Group C 1=yes/0=no, Group B 
1=yes/0=no, ** In first year of GH treatment (cm/yr). 
 
 
 
FIGURE 5. IGF-I SD-score during GH treatment for group A (white bars), group B (gray 
bars), and group C (black bars), respectively. 
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Oestrogen treatment, in our study, was initiated from the age of 12 years to 
mimic normal pubertal development as much as possible. The result was a 
breast development about 2 years later than the 50th percentile in normal 
Dutch girls 9. In other studies, most girls start at a later age 71, 76, some of 
which even start oestrogen treatment at 15-16 years 60, 73. In our opinion, 
however, based on our professional experience and research 34, it is 
important for the psychological well being in girls with TS that puberty is 
induced at an age as close as possible to their peers.  
In addition, we show that starting a low dose of natural oestrogen at a 
relatively young age did not have a negative effect on height velocity (HV) 
and on bone maturation, and therefore possibly on height gain. Other 
studies, in contrast, found a decrease in height velocity and an increase in 
bone maturation leading to a decrease in height gain 73, 77. The reason why 
our results are in conflict with these studies, however, might be that a higher 
dose of oestrogen was used compared to our study. Another possible 
explanation might be that oestrogen treatment was started after at least four 
years of GH treatment. In these four years height SD-score for the whole 
group increased from – 2.7 at start of GH therapy to – 0. 9 at start of 
oestrogen treatment, showing that most of the catch-up had already 
occurred before oestrogen treatment was initiated. Confirming this 
explanation, Reiter et al. found that a longer duration of oestrogen-free GH 
treatment strongly predicted a greater gain in near final height 74. Our results 
therefore suggest that if GH is started at a young age final height will not be 
affected by early initiation of oestrogen.  
When analyzing the factors most likely to influence FH SD-score, we found 
that a model containing height SD-score at start using references for normal 
girls, GH dosage, first year height velocity (in cm), and age at start (in years) 
explained 76 percent of the variation in FH SD-score outcome (Table 3). To 
keep the model accessible for all clinicians peak GH level during ATT, which is 
often not available in clinical practice, was not tested as a potential predictor 
and HV was expressed in centimetres. The model can be used to decide 
which dosage to use by filling in the different variables. For example, a girl 
with TS, with a height SD-score at start of GH treatment of –3, a HV of 10 
cm/yr after 1 yr of GH treatment (1 year conventional dose of 4 IU/m2/d), 
and an age at start of 6 years, would attain a final height SD-score of –1.5 
when the GH dose is not increased, and a FH SD-score of –0.8 or –0.7 when 
the GH dose is increased by 50 or 100 percent. Illustrating the effect of 
height SD-score at start, in a second example, a similar girl with a height SD-
score at start of –4 would attain a FH SD-score of –2.6, -1.9, and –1.7, 
respectively. In a third example, using the same characteristics as in the first 
example, changing the HV in the first year to 8 cm/yr would result in a FH 
SD-score of –2.2, -1.6, and –1.4, respectively. As a forth and last example, 
when the girl is 10 years at start, with a lower 1st year HV of 8.5 cm/yr 
(mean 1st year HV in our study for that age, as 1st year HV decreases with 
age), and a similar height SD-score at start, she would attain a FH SD-score 
of –1.8, -1.1, and –1, respectively. Depending on one’s goal, for instance 
achieving a normal final height or reaching the target height range, the GH 
dosage could be adjusted accordingly.  
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Reasons why one might choose to increase the GH dosage are a low height 
SD-score at start, and/or a low HV in the first year. Examples two and three 
show that these variables might lead to a lower FH SD-score when using the 
conventional GH dose. Another reason for increasing the GH dosage is an 
older age at start, shown in a separate correlation-analysis between age at 
start and FH SD-score. In the model, however, we found a positive 
correlation between age at start and FH SD-score. This finding results from 
the adjustment for the other variables in the model, since both first year HV 
and height SD-score at start are negatively correlated with age at start (r = - 
0.54, r = - 0.41, respectively), In other words, older girls, due to their age, 
have a lower first year HV and height SD-score at start. Therefore, to explore 
the effect of age at start in the model, not only age at start, but also first 
year HV and height SD-score should be taken into account. Example four 
illustrates the relationship, showing a lower predicted FH SD-score compared 
to the first example. A higher GH dosage, however, not only leads to a 50-
100% increase in cost, but also leads to a higher IGF-I SD-score and the 
long-term effects of high IGF-I levels remain to be investigated 78, 79. In 
addition, we would like to emphasize that, although the model has a high 
prediction percentage, it does leave 24 percent to be explained by unknown 
factors. In addition, the predicted FH SD-score has a large prediction interval 
(residual SD of 0.54). 
In conclusion, GH treatment leads to a normalisation of final height in most 
girls, even when puberty is induced at a relatively normal pubertal age. The 
optimal dosage to use depends on height and age at start of treatment, and 
first year height velocity, although the very long-term safety of using a 
higher GH dosage remains to be investigated. 
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Effect of discontinuation of long-term growth hormone 
treatment on carbohydrate metabolism and risk factors 
for cardiovascular disease in girls with Turner syndrome 
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Epidemiology and Biostatistics, Erasmus University, Rotterdam (T.S.), The Netherlands 
 
Abstract 
 
GH treatment increases insulin levels, in girls with Turner syndrome (TS) who 
are already predisposed to develop diabetes mellitus and other risk factors 
for developing cardiovascular disease (CVD). Therefore, in the present study, 
we investigated carbohydrate metabolism and several other risk factors that 
may predict development of CVD in girls with TS after discontinuation of 
long-term GH treatment. Fifty-six girls, participating in a randomised dose-
response study, were examined, before, during, and 6 months after 
discontinuing long-term GH treatment in a dosage of 4 IU/m2/d (~ 0.045 
mg/kg/d), 6 IU/m2/d, or 8 IU/m2/d. After a minimum of 4 years of GH 
treatment low dose micronised 17 β-estradiol was given orally. Mean (SD) 
age at 6 months after discontinuation of GH Treatment was 15.8 (0.9) years. 
Mean duration of GH treatment was 8.8 (1.7) years. Six months after 
discontinuation of GH treatment, fasting glucose levels decreased and 
returned to pre-treatment levels. The AUC for glucose decreased to levels 
even lower than pre-treatment (P < 0.001). Fasting insulin levels and the 
AUC for insulin decreased to levels just above pre-treatment (P < 0.001 for 
both), although being not significantly different to the control group. No 
dose-dependent differences between GH dosage groups were found. At 6 
months after discontinuation impaired glucose tolerance (IGT) was present in 
1/53 girls (2%) and none of the girls developed diabetes mellitus type 1 or 2. 
Compared to pre-treatment, BMI SD-score had increased (P < 0.001), and 
systolic and diastolic BP SD-score had decreased significantly at 6 months 
after discontinuation of GH treatment (P < 0.001 for both), although 
remaining above zero (P < 0.001, P < 0.05, P < 0.005, respectively). 
Compared to pre-treatment, TC did not change after discontinuation of GH 
treatment, while the atherogenic index (AI: TC/HDL-c) and LDL-c had 
decreased and both HDL-c and triglyceride levels increased (P < 0.001 for AI, 
 
* The participating members of the Dutch Advisory Group on Growth Hormone were: M. Jansen, 
Wilhelmina Children's Hospital, Utrecht; B.J. Otten, Sint Radboud University Hospital, Nijmegen; 
J.J.G. Hoorweg-Nijman, Free University Hospital, Amsterdam. T. Vulsma, Academic Medical Centre 
/Emma Children's Hospital, Amsterdam; J. Stokvis, Medical University Centre, Leiden; C.W. Rouwé, 
Beatrix Children's Hospital, Groningen; H.M.Reeser, Juliana Children's Hospital, The Hague; W.-J. 
Gerver, Academic Hospital, Maastricht; J.J. Gosen, Rijnland Hospital, Leiderdorp; C. Rongen-
Westerlaken, Canisius-Wilhelmina Hospital, Nijmegen.
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LDL-c and HDL-c, P < 0.05 for triglyceride). Compared to the control group, 
AI, serum TC, and LDL-c levels were significantly lower (P < 0.001 for all), 
whereas HDL-c levels were significantly higher (P < 0.05).  
In conclusion, after discontinuation of long-term GH treatment in girls with 
TS, the GH induced insulin resistance disappeared, blood pressure decreased 
but remained higher than in the normal population, and lipid levels and the 
atherogenic index changed to more cardio-protective values.  
 
Introduction 
 
One of the main clinical features of Turner syndrome (TS) is short stature. 
Although girls with TS are not growth hormone (GH) deficient 12, GH 
treatment has been proven to lead to a considerable height gain in girls with 
TS in whom treatment with GH was started at a young age and were treated 
with supra-physiological dosages 42, 75. However, as GH treatment increases 
insulin levels, several authors have expressed their concern regarding long-
term effect of GH treatment in children with a predisposition for diabetes 
mellitus (DM) 45, 46.  
Besides DM, girls with TS are also predisposed to develop cardiovascular 
disease (CVD). It has even been reported that CVD is the main cause of their 
reduced life expectancy 24, 25. In addition, risk factors for CVD, such as 
hyperlipidaemia, hypertension and insulin resistance, occur more often in TS 
25-28.  
In the present study, we investigate carbohydrate metabolism in girls with TS 
after discontinuation of long-term GH treatment in a dose up to 8 IU/m2/day 
(~ 0.090 mg/kg/day). Furthermore, we investigate several factors that may 
predict development of CVD, such as blood pressure, body mass index and 
blood lipid levels.  
 
Subjects and Methods 
 
Study group and treatment regimens 
The study group comprised 56 girls with Turner syndrome (TS) who were 
examined 6 months after discontinuation of GH treatment. Fifty-four children 
had an oral glucose tolerance test (OGTT) at 6 months after discontinuation 
of GH. All girls had been part of a multi-centre GH dose-response study in 
The Netherlands, in which 68 girls were included. Inclusion criteria of the 
dose-response trial were described previously 51. In short: a chronological 
age between 2 and 11 yr, height below the 50th percentile for healthy Dutch 
girls, and a normal thyroid function. Of the original 68 girls, 6 girls were not 
examined at 6 months after discontinuation of GH treatment, and 6 girls 
were still treated with GH. Written informed consent was obtained from the 
girls and their parents or custodians. The study protocol was approved by the 
ethics committee of each participating centre. 
After stratification for chronological age and height SD-score for chronological 
age, girls were randomly assigned to group A (4 IU/m2/day ~ 0.045 
mg/kg/d), group B (1st yr: 4 IU/m2/d, thereafter 6 IU/m2/d), or group C  
(1st yr: 4 IU/m2/d, 2nd yr: 6 IU/m2/d, thereafter 8 IU/m2/d). Biosynthetic 
human GH (Norditropin®, Novo Nordisk A/S, Denmark) was given 
subcutaneously once daily. GH treatment was discontinued when height 
CHAPTER 3  Part ‘Turner Syndrome’: Effect of stop of long-term GH treatment on 
carbohydrate metabolism and risk factors for CVD 
  39
velocity was < 1 cm/ 6 months or when satisfied with their attained height. 
After a minimum of 4 yr of GH treatment, micronised 17 β-estradiol was 
given orally to the girls of 12.0 yr and older (5 µ g/kg body weight/day in the 
first 2 yrs, 7.5 µ g/kg/d in the 3rd yr, and thereafter 10 µ g/kg/d). After 2 
years of oestrogen treatment a progestagen was added (5 mg Duphaston®). 
The oestrogen dose was gradually increased to adult level (2 mg) after 
discontinuation of GH treatment. Five of the 56 girls had a repaired 
coarctation without a residual gradient, left ventricle hypertrophy or 
hypertension, 17 girls had a non-stenotic abnormal aortic valve, and none of 
the girls had a renal malformation that could influence blood pressure. One of 
the 56 girls, after repair of multiple congenital cardiac malformations, had a 
remaining left ventricle hypertrophy, which could explain her higher blood 
pressure during and after discontinuation of GH treatment.  
 
Study protocol 
At start of GH treatment (pre-treatment) and every 3 months after the start 
of GH treatment, all girls were seen at their local hospital for a physical 
examination. All underwent an oral glucose tolerance test (OGTT) after 
overnight fasting (in the three previous days 100 g of carbohydrate 
(FantomaltR); oral glucose load of 1.75 g glucose /kg body weight, maximum 
of 50 g) at pre-treatment, after 4 yr of GH treatment, and 6 months after 
discontinuation of GH treatment. Blood samples were analyzed at 0, 30, 60, 
90, 120, 150, and 180 min for plasma glucose and insulin levels. In addition, 
the following variables were described: (1) Impaired glucose tolerance (IGT) 
was defined according to The Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus 80: the 2-hour glucose level > 7.8 mmol/l 
(140 mg/dl) and < 11.1 mmol/l (200 mg/dl). (2) The 3-hour area under the 
curve for time-concentration (AUC) for glucose and insulin was calculated 
using the trapezoidal rule. (3) The ratio insulin/glucose at 30 minutes and the 
ratio at 120 minutes were calculated as an index for relative insulin 
resistance. Results were compared with the data of 24 normal adolescent 
girls aged 14.7 (0.98) years, selected on the basis of post-pubertal stage 
(Tanner breast stage 5) as described by Potau et al. (control group) 81. 
Height and body mass index (BMI: kg BW/(height)2) was expressed as SD-
score for sex and chronological age 8, 62. Systolic and diastolic BP was 
determined four times with a single Dynamap Critikon 1846SX in sitting 
position using a cuff size corresponding to the size of arm. Blood pressure 
(BP) was expressed as SD-score, using age and sex specific reference values 
82. A child was considered normotensive if BP was below the 90th percentile. 
Additional blood samples were taken at start of the study and subsequently 
every year for determination of glycosylated hemoglobin (HbA1c) levels. 
Serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), and 
high-density lipoprotein cholesterol (HDL-c) levels were determined after 
overnight fasting at start, at 4 years of GH treatment, and at 6 months after 
discontinuation of GH treatment. The atherogenic index was calculated as the 
ratio of TC to HDL cholesterol. TC, HDL-c, and LDL-c levels, and atherogenic 
index were compared with a Dutch control group of the same age and sex 83. 
After centrifugation, all samples were frozen (-20ºC) until assayed.  
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TABLE 1. Pre-treatment variables 
 
 Group A Group B Group C 
Number of girls 19 17 20 
Age at start of GH treatment 6.5 (1.9) 7.5 (1.9) 6.5 (2.4) 
Height SD-score*  
(Normal girls) 
-2.8 (0.9) -2.7 (0.8) -2.6 (1.0) 
Height SD-score* 
(TS girls) 
0.01 (1.1) 0.2 (0.9) 0.19 (1.1) 
Karyotype** 45,X 16 16 15 
 other 3 1 5 
Data expressed as mean (SD). * Height SD-score for sex and chronological 
age in normal girls 62 and in girls with Turner syndrome (TS) 8 at start of 
GH treatment.** Number of girls. 
 
TABLE 2. Carbohydrate data before, during, and after long-term GH treatment 
 
 GH 
Group A 
(n = 19) 
Group B 
(n = 16) 
Group C 
(n = 19) 
Whole group 
(n = 54) 
Start  4.4 (0.5) 4.6 (0.4) 4.6 (0.8) 4.5 (0.6) 
4 yrs 4.8 (0.5) 4.7 (0.6) 5.1 (0.9) 4.9 (0.7)# 
Fasting 
glucose* 
(mmol/l) Post 4.4 (0.5) 4.7 (0.4) 4.6 (0.7) 4.5 (0.5)$ 
          
Start 1072 (184) 1118 (172) 1096 (181) 1095 (177) 
4 yrs 1072 (122) 1154 (143) 1126 (188) 1116 (155) 
AUC glucose* 
(mmol/l x 180 
min) Post  953 (111) 975 (132) 962 (134) 963 (124)##$$ 
          
Start  4 (8) 4 (10) 5 (13) 4.5 (2.2) 
4 yrs  12 (23) 16 (38) 16 (45) 14.2 (3.3)## 
Fasting 
insulin** 
(mU/l) Post  11 (19) 11 (18) 11 (22) 10.7 (2.9)##$ 
          
Start  3863 (2411) 4858 (3284) 3941 (1626) 4205 (2482) 
4 yrs  7798 (3355) 14369 (15123) 9733 (3385) 10533 (9094)## 
AUC insulin* 
(mU/l x 180 
min) Post  6553 (2468) 5837 (3151) 5987 (2867) 6136 (2791)##$ 
          
Start  3.5 (10.7) 4.6 (10.2) 3.8 (6.6) 3.9 (7.4) 
4 yrs  7.4 (13.8) 11.8 (37.6) 9.8 (20.6) 9.4 (21.2)## 
Ratio 
ins/glu** 
30 min Post  7.8 (20.0) 7.1 (23.0) 6.5 (11.3) 7.1 (17.9)##$ 
          
Start  2.4 (7.5) 3.6 (9.6) 3.3 (6.4) 3.0 (7.5) 
4 yrs  6.5 (13.2) 8.7 (16.5) 7.6 (13.8) 7.5 (13.5)## 
Ratio 
ins/glu** 
120 min Post  5.6 (8.3) 3.8 (6.1) 4.8 (10.5) 4.7 (9.6)##$$ 
          
Start  4.8 (0.5) 4.9 (0.5) 4.8 (0.5) 4.9 (0.5) 
7 yrs 4.6 (0.5) 4.6 (0.7) 4.6 (0.4) 4.6 (0.5)## 
HbA1c* 
(% Hb) 
Post  4.3 (0.5) 4.3 (0.5) 4.3 (0.5) 4.3 (0.5)##$$ 
Data expressed as: * mean (SD). ** geometric mean (90th percentile). AUC = area under the curve 
calculated with the trapezoid rule. Paired t-test for whole group: ##P < 0.001 (vs start); $P < 0.01, $$P < 
0.001 (vs 4 yrs). 
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Assays 
The plasma glucose level was measured at the local hospital laboratories and 
plasma insulin was determined in one laboratory by radioimmunoassay (RIA) 
(Medgenix, Fleurus, Belgium) as described previously. Control samples were 
measured by a comparable RIA (R2 = 0.988; y = 0.397 + 0.925 * x) 81. 
HbA1c levels and lipid levels were measured in one laboratory as described 
elsewhere 45, 51. Lipid levels for the control group were measured by the same 
assays in the same laboratory 83. All blood sample measurements were 
performed in the same laboratories during the whole study period. 
 
Statistical analyses 
Results were expressed as mean (SD), unless indicated otherwise. For 
continuous variables with a skewed distribution a log-transformation was 
used. Differences between the dosage groups were tested by linear 
regression analysis with the variables age at start and two dummy variables 
for dosage group. Differences in time between continuous variables were 
compared by paired 2-sided t-test for the whole group. To test whether 
variables expressed in SD-score were different from zero a one-sample t-test 
was performed. Differences between the whole TS group and the control 
group for the carbohydrate variables were tested by 2-sided independent 
sample t-test. All correlations were partial correlations, adjusted for GH 
dosage. A P-value < 0.05 was considered significant. All calculations were 
performed by SPSS version 9.0.  
 
Results 
 
In Table 1 pre-treatment characteristics of the 56 children are shown. All GH 
dosage groups had similar pre-treatment characteristics. Mean (SD) age at 6 
months after discontinuation of GH treatment was 15.8 (0.9) years. Mean 
duration of GH treatment was 8.8 (1.7) years. Fourty-four of the 56 girls 
were treated with GH for 7 years or longer. 
Six months after discontinuation of GH treatment fasting glucose levels for 
the whole group had decreased significantly compared to 4 years of GH 
treatment (P < 0.01), after a significant increase from pre-treatment to 4 
years of GH treatment (P < 0.01), and returned to pre-treatment levels 
(Table 2). Mean glucose levels during OGTT are depicted for groups A, B and 
C in Figure 1. The 180-minute AUC for glucose at 6 months after 
discontinuation of GH treatment for the whole group decreased to levels even 
lower than pre-treatment (P < 0.001), after a small non-significant rise from 
pre-treatment to 4 years of GH treatment. Fasting glucose levels and the 
180-minute AUC for glucose for the whole group were not significantly 
different between the GH dosage groups (Table 2). No significant differences 
were found between the whole TS group at 6 months after discontinuation of 
GH treatment and the control group in fasting glucose or 120 minute AUC for 
glucose. As the control group had a 120-minute OGTT the 120-minute AUC in 
the TS group was used to compare data.  
Mean insulin levels during OGTT are depicted in Figure 2 for groups A, B and 
C. 
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FIGURE 1. Mean glucose levels during OGTT for group A, group B and for group C, before 
treatment (black circles), at 4 years of GH treatment (black diamonds), at 6 months after 
discontinuation of treatment (white triangles), and for the control group (white squares). 
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Post GHRx Controls 
 
 
 
 
 
 
 
 
 
 
FIGURE 2. Mean insulin levels during OGTT for group A, group B and for group C, before 
treatment (black circles), at 4 years of GH treatment (black diamonds), at 6 months after 
discontinuation of treatment (white triangles), and for the control group (white squares). 
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Fasting insulin levels (Table 2) and the AUC for insulin at 6 months after 
discontinuation of GH treatment for the whole group had significantly 
decreased compared to 4 years of GH treatment (P < 0.01 after log 
transformation, and P < 0.001, respectively), after a significant rise from 
pre-treatment to 4 years of GH treatment (P < 0.001), but both remained 
increased compared to pre-treatment levels (P < 0.001 for both) (Table 2). 
No significant differences between GH dosage groups were found for change 
in time for fasting insulin levels and change in time for AUC for insulin. 
Compared to the control group, the AUC for insulin at 6 months after 
discontinuation of GH treatment for the whole TS group showed no significant 
difference.  
The ratio for insulin to glucose at 30' (30' ratio) and 120' (120' ratio) for the 
whole group at 6 months after discontinuation of GH treatment decreased 
significantly compared to 4 years of GH treatment (both variables tested 
after log transformation; 30' ratio: P < 0.01; 120' ratio: P < 0.001), after an 
increase in both ratio’s from pre-treatment to 4 years of GH treatment (P < 
0.001 for both) (Table 2). Both the 30' ratio and 120' ratio at 6 months after 
discontinuation of GH treatment remained above pre-treatment values (P < 
0.001 for both). No significant differences between GH dosage groups were 
found for change in time for both ratio’s. 
At 6 months after discontinuation of GH treatment impaired glucose tolerance 
(IGT) was present in 1/53 girls (2%). The IGT in this girl was not present 
before or during GH treatment. None of the girls developed diabetes mellitus 
type 1 or 2. 
The HbA1c values for the whole group at 6 months after discontinuation of 
GH treatment had significantly decreased compared to 7 years of GH 
treatment (P < 0.001), while showing no significant differences between GH 
dosage groups. Throughout the years, all individual HbA1c levels remained 
within normal range. 
From pre-treatment to 7 years of GH treatment, BMI SD-score for the whole 
group had increased significantly (from –0.02 (0.88) to 0.90 (0.92), P < 
0.001). Compared to the mean BMI for the reference population (zero SD-
score), BMI SD-score was not significantly different at pre-treatment, but 
increased to values significantly above zero (P < 0.001) at 7 years of GH 
treatment. At 6 months after discontinuation of GH treatment, BMI SD-score 
had continued to increase slightly, compared to 7-year values (1.13 (0.97), P 
< 0.01). BMI SD-score at 6 months after discontinuation of GH treatment 
and the change in time for BMI SD-score was not significantly different 
between GH dosage groups.  
From pre-treatment to 7 years of GH treatment, systolic BP for the whole 
group did not change significantly, while diastolic BP showed a small decrease 
(P < 0.01), both remaining significantly higher than zero (P <  0.001, P < 
0.05) (Figure 3). At 6 months after discontinuation of GH treatment systolic 
BP SD-score had decreased significantly compared to 7 years of GH 
treatment (P < 0.05), while the decrease in diastolic BP SD-score did not 
reach significance. Compared to pre-treatment, both systolic and diastolic BP 
SD-scores had decreased significantly at 6 months after discontinuation of 
GH treatment (P < 0.001 for both), although BP SD-scores after 
discontinuation of GH treatment remained significantly higher than zero (P < 
0.05 for both).  
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 FIGURE 3. Mean (SD) systolic blood pressure (BP) SD-score and diastolic BP SD-score 
using age-matched reference values, before GH treatment, at 2, 4, 7 years of GH treatment, 
and at 6 months after discontinuation of treatment for group A (white bars), group B (gray 
bars), and for group C (black bars).  
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TABLE 3. Lipid levels before, during, and after GH treatment 
 
 GH 
Group A 
n = 19 
Group B 
n = 17 
Group C 
n = 20 
Whole group 
n = 56 
Controls*** 
n = 703 
Start 4.0 (0.7) 4.3 (0.8) 4.5 (0.9) 4.3 (0.8)   
4 yrs 3.8 (0.7) 4.1 (0.8) 4.0 (0.7) 4.0 (0.7)##   
TC* 
(mmol/l) 
 Post 4.1 (0.8) 4.5 (0.7) 4.1 (0.6) § 4.2 (0.7)## 4.7 (0.7) && 
            
Start 0.6 (0.1) 0.7 (0.1) 0.9 (0.2) 0.7 (0.2)   
4 yrs 1.0 (0.3) 1.0 (0.2) 1.2 (0.3) 1.1 (0.3)##   
HDL-c* 
(mmol/l) 
Post 1.3 (0.3) 1.4 (0.3) 1.5 (0.4) 1.4 (0.3)##$$$ 1.3 (0.3)& 
            
Start 2.6 (0.7) 2.9 (0.9) 2.9 (1.0) 2.8 (0.9)   
4 yrs 1.9 (0.7) 2.1 (0.6) 2.2 (0.7) 2.1 (0.7)##   
LDL-c* 
(mmol/l) 
Post 2.1 (0.6) 2.5 (0.6) 2.2 (0.6)@ 2.3 (0.6)##$$ 2.9 (0.7) && 
            
Start 1.0 (1.5) 0.9 (1.5) 0.9 (2.1) 0.9 (1.6)   
4 yrs 1.3 (3.2) 1.2 (2.6) 1.2 (2.2) 1.2 (2.5)##   
Trigl** 
(mmol/l) 
Post 1.3 (2.8) 1.0 (1.7) 0.9 (1.7) 1.1 (1.9)#$   
            
Start 7.1 (8.6) 6.4 (8.1) 4.9 (6.8) 6.0 (8.2)   
4 yrs 4.0 (5.6) 4.0 (5.6) 3.2 (4.6) 3.7 (5.5)##   Atherogenic 
index** 
Post 3.2 (4.0) 3.2 (4.3) 2.8 (3.8) 3.0 (4.0)##$$$ 3.6 (4.8) && 
Data expressed as: * mean (SD). ** geometric mean (90th percentile). TC = total cholesterol, HDL-c = 
high-density lipoprotein-cholesterol, LDL-c = low-density lipoprotein-cholesterol, Trigl = triglycerides, 
Atherogenic index = TC/HDL-c. *** Dutch control group of same age and sex 83.  
Paired t-test for change in time for whole group: # P < 0.05, ## P < 0.001 (vs start); $ P < 0.05, $$ P < 
0.01, $$$ P < 0.001 (vs 4 yrs);  
Linear regression analysis for change from 4 yrs of GH: @ P < 0.05 (group C vs group A and B, corrected 
for age at start); for change from start: § P < 0.01 (group C vs group A and B, corrected for age at 
start); for control group vs whole TS group:  & P < 0.05, && P < 0.001 (corrected for dosage group and 
age). 
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BP SD-scores at 6 months after discontinuation of GH treatment was not 
significantly different between dosage groups except for diastolic BP SD-score 
between groups B and C (lower in group C: P < 0.05). The changes in time 
for BP SD-scores, however, were not significantly different between GH 
dosage groups. At pre-treatment 19/53 (36%) of the TS girls had a systolic 
and/or diastolic blood pressure above +1.3 SD-score (~ 90th percentile for 
same age and sex), at 4 years 23/55 (42%), at 7 years of GH treatment 
19/44 (43%), and after discontinuation of GH treatment 14/53 (26%). 
Eleven of the 14 girls who had a BP above the +1.3 SD-score after 
discontinuation of GH treatment also had a BP above the +1.3 SD-score at 
pre-treatment, and/or at 4 years and/or at 7 years of GH treatment. 
Serum TC and LDL-c, levels after 4 years of GH treatment for the whole 
group decreased significantly compared to pre-treatment (P < 0.001 for all), 
while HDL-c and triglyceride levels had increased (P < 0.001 for both) (Table 
3). After discontinuation of GH treatment, TC, LDL-c, but also HDL-c levels 
had increased significantly compared to 4-year levels (P < 0.001, P < 0.001, 
and P < 0.01, respectively), whereas triglyceride levels decreased 
significantly (P < 0.05). Compared to pre-treatment, TC did not change at 6 
months after discontinuation of GH treatment, LDL-c had decreased and both 
HDL-c and triglyceride levels increased (P < 0.001 for LDL-c and HDL-c, P < 
0.05 for triglyceride). Discontinuation of GH treatment resulted in a decrease 
in atherogenic index (TC/HDL-c), compared to 4-year values (P < 0.001), but 
also compared to pre-treatment (P < 0.001). The changes in serum lipid 
levels were not significantly different between the GH dosage groups, except 
for the change in time for group C (decrease in stead of increase) in TC from 
pre-treatment to 6 months after discontinuation of GH treatment (group C 
versus group A or B: P < 0.01 for both) and a smaller increase in LDL-c from 
4 years of GH treatment to 6 months after discontinuation of treatment 
(group C versus group A or B: P < 0.05). Compared to the control group, 
serum TC and LDL-c levels were significantly lower in the whole TS group at 
6 months after discontinuation of GH treatment (P < 0.001 for both), 
whereas HDL-c levels were significantly higher (P < 0.05). Furthermore, the 
atherogenic index was significantly lower at 6 months after GH treatment, 
compared to the control group (after log transformation: P < 0.001).  
A significant correlation was found for the whole group when fasting insulin 
levels (log transformed) and the AUC for insulin was correlated with BMI SD-
score at 6 months after discontinuation of GH treatment, after correction for 
GH dosage group (r = 0.58, P < 0.001; r = 0.35, P < 0.05, respectively). No 
correlation was found for the whole group between the 30' ratio, 120' ratio, 
systolic or diastolic BP SD-score, TC, atherogenic index, or triglyceride levels 
and BMI SD-score at 6 months after discontinuation of GH treatment. The 
atherogenic index at 6 months after discontinuation of GH treatment, after 
correction for GH dosage, did not correlate with fasting insulin levels, AUC for 
insulin, systolic or diastolic BP SD-score at 6 months after discontinuation of 
GH treatment.  
 
Discussion 
 
In this article we describe the effect of discontinuation of long-term GH 
treatment on glucose and insulin levels, body mass index, blood pressure, 
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and serum lipid levels in girls with Turner syndrome. We show that both 
fasting and stimulated insulin levels, after an increase during GH treatment, 
returned to normal after discontinuation. In addition, we show that after 
discontinuation of GH treatment both systolic and diastolic blood pressure, 
and the atherogenic index (TC/HDL-c) had fallen. 
Fasting glucose levels increased during GH treatment and decreased after 
discontinuation of GH treatment, while stimulated glucose levels showed no 
change during GH treatment and decreased after its discontinuation. 
Furthermore, after ending GH treatment, insulin levels and the indices for 
relative insulin resistance (30' and 120' ratio’s for insulin / glucose) fell, but 
only to a point above pre-treatment levels. Similar results have been found 
previously in children with idiopathic short stature and in girls with TS after 
discontinuation of GH treatment 84, 85. Moreover, we show that stimulated 
insulin levels after discontinuation were comparable to normal post-pubertal 
girls. Several studies have shown that insulin sensitivity decreased during 
puberty, resulting in an increase in stimulated insulin levels 81, 86, 87. 
Subsequently, in post-puberty, although insulin levels were decreasing, they 
were still at a higher level than before puberty 86. These results might 
therefore imply that the reason why insulin levels and the indices for relative 
insulin resistance did not return to pre-treatment positions was that our 
study group was in its post-pubertal stage. Another explanation for the 
higher insulin levels and indices for relative insulin resistance after 
discontinuing GH might be the increase in body mass index (BMI) SD-score 
we found in our study group after discontinuation of GH treatment. Previous 
studies have shown a positive correlation between insulin levels and BMI in 
normal children and adults 88, 89. Supporting this explanation, in our study, 
we found a positive correlation between BMI SD-score and fasting and 
stimulated insulin levels after discontinuation of GH treatment. Several 
reports, however, have shown an increased prevalence of insulin resistance 
and IGT in untreated women with Turner syndrome 22, 23. Therefore, the 
higher insulin levels might also be a result of having Turner syndrome. The 
prevalence of impaired glucose tolerance in our study, however, was low (1 
girl). 
After discontinuation of GH treatment we found a decrease in blood pressure 
SD-scores, compared to pre-treatment. As this decrease has been corrected 
for age, it is unlikely that age could explain this decrease. A possible 
explanation might be the initiation of oestrogen treatment. Confirming this 
explanation, Gravholt et al. showed that the start of supplementation of 
natural oestrogens in combination with progestagens in adult women with 
Turner syndrome decreased ambulatory blood pressure 27. In another study 
on adult Turner syndrome women, however, no change in blood pressure was 
found after hormone replacement therapy was initiated 90. Another possible 
explanation might be a positive effect of GH treatment on blood pressure, 
which has been postulated to occur in children born small for gestational age 
91. Blood pressure after discontinuation of GH treatment, however, remained 
slightly higher than in girls matched for age. The reason why possibly lies in 
the fact that having Turner syndrome is a predisposition for hypertension 25. 
The aetiology of the predisposition, however, remains unclear 31. As we found 
a decrease in blood pressure compared to pre-treatment, it is unlikely that 
GH treatment was responsible for the higher blood pressure.  
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During the first 4 years of GH treatment we show a decrease in atherogenic 
index, TC, LDL-c, and an increase in HDL-c and triglyceride. Previous studies, 
studying lipid levels during GH treatment in Turner syndrome, showed either 
similar results during GH treatment 48, 49 or no effect 50. After discontinuation 
of GH treatment, compared to 4-year lipid levels, TC and LDL-c levels had 
increased compared to the decrease we found during treatment, while 
triglyceride levels had decreased slightly after an increase during GH 
treatment. Similar results were found in reports on the effect of 
discontinuation of GH in GH deficient adolescents 92, 93, thus possibly implying 
a GH-effect. HDL-c levels after discontinuation of GH treatment, however, 
showed a further increase. A possible explanation for this could be the 
induction of puberty with natural oestrogens and dydrogestagen, which has 
been shown to lead to an increase in HDL-c 94. A second explanation for the 
increase in TC, LDL-c and HDL-c after discontinuing GH might be the age-
effect as it has been established that after puberty, TC, LDL-c and HDL-c 
increase with age 95, 96. Interestingly, when we compared lipid levels after 
discontinuation of GH treatment, to a normal control group of similar age, we 
found that TC, LDL-c and AI levels were lower and HDL-c levels were higher 
in our study group. This indicated that, while previous reports on lipid levels 
in untreated girls and women with TS have shown conflicting results 
regarding the prevalence of dyslipidemia 26, 28, 29, 97, in our study group after 
long-term GH treatment, we found no evidence of dyslipidemia. 
As several studies have found that women with TS are predisposed to 
develop cardiovascular disease (CVD) 24, 25, and several risk factors for CVD, 
such as high blood pressure, dyslipidemia, and abdominal obesity, have been 
found to be more prevalent in TS, we analyzed our data for clustering of 
these CVD risk factors by way of correlations. Although, after discontinuation 
of GH treatment, we found a positive correlation between BMI SD-score and 
insulin levels, we could not detect any other correlations between the risk 
factors. In contrast, in a study on the effect of discontinuation of GH 
treatment in children of similar age, but born small for gestational age, a 
positive correlation between the atherogenic index, BMI SD-score, systolic 
and diastolic blood pressure SD-score, and fasting insulin was found 98. The 
lack of correlation between the cardiovascular risk factors in our group with 
Turner syndrome, however, suggested that in this group no clustering of risk 
factors was present. As a clustering of risk factors potentially increases the 
risk for cardiovascular disease 99, not only follow-up of all risk factors, but 
also evaluation of clustering should take place in the future. While we did not 
find evidence of clustering, we did find a positive correlation between insulin 
resistance and BMI. Although this relation is also found in normal children 89, 
100, insulin resistance does predispose for the development of diabetes 
mellitus type 2. We would therefore urge clinicians to do their utmost to 
prevent further weight gain in girls and women with TS. 
In conclusion, after discontinuation of long-term GH treatment in girls with 
TS the GH induced insulin resistance disappeared. Blood pressure decreased 
both during and after discontinuation of GH treatment but remained higher 
than in the normal population, while lipid levels and the atherogenic index 
after discontinuation of GH treatment, were more beneficial regarding the 
development of cardiovascular disease than in a normal control group.
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Abstract 
 
It is common practice in the case of Turner syndrome (TS) to treat short 
stature with GH treatment and to induce puberty with oestrogens at an age 
as close to normal puberty as possible. This approach in most cases leads to 
a height in the normal range in childhood, adolescence, and adulthood in TS. 
Little data is available, however, on its effect on psychosocial functioning. In 
the present study, we evaluated psychosocial functioning in a group of 50 
women with TS, after reaching final height in two multi-centre GH trials. 
Thirty-six girls participated in a randomised dose-response study (DRS) from 
mean (SEM) age 6.8 (0.4) years, and 14 girls participated in a frequency-
response study (FRS) from age 13.2 (0.4) years. After discontinuation of 
long-term GH treatment, these 50 girls were evaluated for psychosocial 
functioning at a mean age of 18.8 (0.3) years. GH was given in a dosage of 4 
IU/m2/d (~ 0.045 mg/kg/d), 6 IU/m2/d, or 8 IU/m2/d. After a mean GH 
treatment duration of 7.1 (0.4) years mean final height (ref. normal girls) 
was –1.2 (0.2) SD-score. 
Behavioral problem scores (Achenbach) of the TS women were comparable to 
normal Dutch peers. Although self-perception (Harter total scale: P < 0.01), 
and bodily attitude (Baardman: P < 0.05) was significantly less positive than 
for their normal Dutch peers, we found no evidence of depression. TS women 
rated their family functioning higher than their Dutch peers (P <0.0001), and 
had a slightly different coping pattern. 
These results show that even after reaching a height in most cases within the 
normal range and puberty induction at a pubertal age, some women with TS 
still experience psychosocial problems. It is likely, however, that GH and 
oestrogen treatment improved psychosocial functioning. Long term follow-up 
of these GH-treated patients will allow an evaluation of their life 
achievements. 
 
Introduction 
 
The most frequent clinical characteristics of Turner syndrome (TS) are short 
stature and the absence of spontaneous pubertal development. In most 
 
*H.M.K. is currently working at the Department of Developmental Psychology, Free University 
Medical Centre, Amsterdam. 
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countries it is common practice to treat short stature in TS with GH treatment 
in a supra-physiological dosage. In addition, oestrogens are given to induce 
puberty at an age as close to normal puberty as possible. This approach has 
been shown to increase and even normalize height in childhood, adolescence, 
and adulthood in TS 41, 76, 101-103. Little data is available, however, on the 
effect of this treatment strategy on psychosocial functioning. Untreated girls 
with TS have been described as being more immature, having a lower self-
esteem, poor concentration, and being hyperactive 33, 34.  
In the present study, we evaluated psychosocial functioning in a group of 50 
women with TS, after reaching final height in two multi-centre GH trials. 
 
Methods 
 
GH group 
All women who had participated in two GH trials (see below), had 
discontinued GH treatment for more than 6 months, and were able to fill in 
the questionnaires, were asked to participate in the psychosocial evaluation. 
Fifty women agreed to participate (response rate 50/69: 72%). Nineteen girls 
did not participate either because of practical reasons or because of losing 
interest in participating in a study. 
Both GH trials evaluated the effect of GH on long-term growth and ultimately 
on final height. At time of the psychosocial evaluation, all participants were 
prescribed hormone replacement therapy in an adult dose. 
 
Dose-response GH-trial 
Sixty-eight previously untreated Dutch girls with TS, aged between 2 and 11 
years, were enrolled in an open randomised multi-centre GH dose-response 
study. Biosynthetic GH (r-hGH NorditropinR, Novo Nordisk A/S, Denmark) 
was given subcutaneously once daily in a dosage of 4 IU, 6 IU , or 8 IU 
GH/m2 body surface area/day (~ 0.045-0.09 mg/kg /day). Puberty was 
induced at age 12 years (Study design as described previously 103). Six girls 
dropped out of the study and were lost to follow-up. Six girls had not 
discontinued GH treatment for more than 6 months and 4 girls were unable 
to fill in the questionnaires due to mental retardation, leaving 52 girls able to 
participate in the psychosocial evaluation.  
 
Frequency-response GH-trial 
Nineteen previously untreated Dutch girls aged 11 years or older, with TS 
were enrolled in an open randomised multi-centre GH frequency-response 
study. Biosynthetic GH (r-hGH NorditropinR, Novo Nordisk A/S, Denmark) 
was given subcutaneously once or twice daily in a total dosage of 6 IU 
GH/m2/d. Puberty was induced at start of trial (Study design as described 
previously 41). Two girls were unable to fill in the questionnaires due to 
mental retardation, leaving 17 girls able to participate in the psychosocial 
evaluation.  
The GH trials and the psychological evaluation were approved by the Ethics 
Committees of the participating centres in the Netherlands. Written informed 
consent was obtained from the parents or custodians of each child.  
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Normal population sample 
From a randomly selected population sample from three municipalities in the 
Netherlands (N=600, response rate 56%) only the females were selected for 
comparison (N=359) 104.  
 
Psychosocial evaluation 
In the GH group a psychosocial evaluation was performed after GH treatment 
had been discontinued for at least 6 months and (near) final height had been 
reached. Questionnaires for the GH trial groups and the Population sample 
were sent by post. 
 
General information. Data on occupational and educational levels were 
provided by both parents and adolescents. Parental occupational level (SES) 
ranged from 1 (lower occupation) to 3 (higher occupation). When both 
parents were employed the highest of both SES levels was used. For 
unemployment the lowest SES was used 105. 
 
Behavioral problems (YSR/YASR). Behavioral problems were measured by 3-
point scale standardized questionnaires from Achenbach, translated and 
validated in the Dutch language 104, 106, 107. For girls aged between 12 and 18 
years, the 119-item Youth Self-Report  (YSR; filled in by child) 108, 109 was 
used. For girls aged 18 years and older the 127-item Young Adult Self-Report 
(YASR; filled in by adolescent) was used 110. As both questionnaires were 
constructed in a similar way, results from three scales could be combined for 
analysis (Internalizing, Externalizing, and Total Problem score). To allow 
combination of test scales (YSR/YASR), z-scores were constructed using the 
Population sample data as reference 104. A higher test z-score indicated more 
problem behavior. 
 
Self-perception (HSPP). The inventory, called in Dutch "Hoe ben ik" and in 
English "Harter Self Perception Profile", was designed by Harter to describe 
sense of self-worth and capability in several areas, using 4-point scales 111, 
112. In the evaluation the 45-item adolescent-version (HSPP-a) was used. Ten 
scales (Scholastic competence, Social acceptance, Athletic competence, 
Physical appearance, Behavioral conduct, Global self-worth, Romantic appeal, 
Close friendship, Job competence, and Total HSP-score) were used for 
analysis (median α = 0.76). A higher test score indicated a more favorable 
self-perception. 
 
Child Depression Inventory (CDI). The American Child Depression Inventory 
was designed to measure depressive thoughts and feelings in a child 
population and was designed by Kovacs 113. Factor analysis of the Dutch 
version of the 27-item (3-point scales) “Gevoelens en Gedachten vragenlijst” 
produced one scale, the ‘Total depression scale score’ ( α = 0.86) 104. A 
higher score indicated more depressive thoughts and feelings. 
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Body Attitude Scale (BAS). The Dutch questionnaire “Lichaamsbelevings 
vragenlijst” is a 45-item questionnaire and uses a 5-point Likert scale to 
assess bodily attitude. It has been constructed and validated by Baardman et 
al 114. In an adolescent population three scales could be distinguished by 
factor analysis: ‘Appraisal’ ( 〈 = 0.94; e.g. ‘Are you satisfied with the way 
your body looks?’), ‘Attribution’ (〈 = 0.88; e.g. ‘Do you think people avoid 
you because of your appearance?’), and ‘Physical contact’ (〈 = 0.77; e.g. ‘In 
general, how much do you like touching people?’) 104. High test scores 
indicated positive bodily attitudes. 
 
Family Assessment Device (FAD). This shorter 12-item version of the General 
Functioning Subscale of the McMasters Family Assessment Device measured 
overall family functioning, using a 4-point scale. Reliability and validity were 
tested in the original language 115 and in Dutch 116. A higher test score 
indicated more positive family functioning. 
 
Coping (UCL). The "Utrecht Coping list" 117 was designed and validated in 
Dutch 118, 119. The 47-item 4-point scale list was made to measure 7 ways of 
coping with stressful events: Active approach (e.g. ‘In general, if I have a 
problem I tackle the problem immediately), Reassuring thoughts (e.g. ‘In 
general, if I have a problem I encourage myself’), Expression of emotion 
(e.g. ‘In general, if I have a problem I show I am annoyed’), Palliative 
reaction (e.g. ‘In general, if I have a problem I seek distraction from it’), 
Passive reactional pattern (e.g. ‘In general, if I have a problem I see dark 
clouds’), Seeking social support (e.g. ‘In general, if I have a problem I share 
it with someone’), Avoiding/Anticipating (e.g. ‘In general, if I have a problem 
I leave it the way it is’)(median α = 0.69). A higher test score indicated the 
coping style was more prominent. 
 
Statistical analysis 
All data were expressed as mean (SEM) unless otherwise specified. 
Differences in SES between the Population sample and the GH group were 
analyzed by logistic regression analyses. To analyze differences in results 
between the GH group and the Population sample regression analyses were 
used, corrected for age, GH trial (1 dummy variable: FRS=1) and GH dosage 
(2 dummy variables). SES (2 dummy variables) was only corrected for when 
significant. The effect FH, corrected FH, and the increase in height from start 
of GH treatment were estimated by the addition of final height SD-score, 
corrected FH SD-score and height SD-score at start to the regression models, 
with correction for age, GH trial, and GH dosage. Results from the regression 
analyses were shown as unstandardized coefficients (B) with their two-tailed 
p-values. All calculations were done by SPSS 9.0. A p-value of 0.05 was 
considered significant for comparison between the GH group and the normal 
sample. A p-value < 0.01 was considered significant for within GH group 
comparison because of multiple testing. 
CHAPTER 4   Part ‘Turner Syndrome’: Psychosocial status after long-term GH treatment 
  55
Results 
 
In Table 1 clinical data of the GH trials are shown for all women that 
participated in the psychosocial evaluation. We found no significant 
differences in clinical data between TS women participating in this 
psychosocial study and TS women who did not participate. Psychosocial data 
for the DRS and FRS were analyzed together (GH group). Correction for GH 
trial (FRS or DRS) and GH dosage did not have a significant influence on 
results. 
 
Social economic status (SES) 
In the GH group 35% had a low SES level, 20% an intermediate level, and 
46% a high level. The differences in SES between the GH group and the 
Population sample (33/34/33%, respectively) were not significant. Correction 
for SES did not significantly change any of the following results. 
 
Behavior (YSR/YASR) 
Internalizing, Externalizing, and Total problem behavior SD-scores were 
comparable to the population sample mean (Table 2). 
 
Self-perception (HSPP) 
Total HSP-scores (Table 3) were significantly lower than the Population 
sample scores (B=-0.30, P < 0.01), while GH dosage had no significant 
effect. To explain this result, we examined the remaining scale-scores, which 
are the components of the Total HSP-scores. Social acceptance, Athletic 
competence, and Romantic appeal scores were also significantly lower than 
the Population sample scores (B=-0.63 P < 0.001, B=-0.55 P < 0.01, B=-
0.40 P < 0.05, respectively). The remaining scale-scores were not 
significantly different to the Population sample scores. 
Child Depression Inventory (CDI) 
Total depression scale scores were not significantly different to the Population 
sample scores (Table 4).  
 
Body Attitude Scale (BAS) 
Attribution and Physical contact were scored slightly but significantly lower 
than the Population sample (B=-0.26 P < 0.05, B=-0.41 P < 0.05, 
respectively; Table 4). Appraisal scores, however, were not significantly 
different to the Population sample scores.  
 
Family Assessment Device (FAD) 
The Total FAD scale scores were significantly higher than the Population 
sample scores (B=0.77 P <0.0001; Table 4).  
 
Coping (UCL) 
Compared to the Population sample scores, only the scale Reassuring 
thoughts was significantly higher in the dose-response group (B=0.32 P < 
0.05). Scores for the scales Active approach, Expression of emotion, Palliative 
reaction, Passive reactional pattern, Seeking social support, and 
Avoiding/Anticipating were not significantly different to the Population sample 
(Table 5).  
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TABLE 1. Mean (SEM) clinical data for the girls who participated in the 
psychosocial evaluation and for the Population sample. 
 
GH 
Dose-response 
group: 
4-8 IU/m2/day 
Frequency-
response 
group: 
6 IU/m2/day 
Population 
sample 
Number of girls 36 14 359 
Chronological age  
at start GH trial (yr) 
6.8 (0.4)## 13.2 (0.4) - - 
Height SD-score  
at start (ref. Normal 
Dutch girls) 
-2.7 (0.2) -3.2 (0.3) - - 
Final height SD-score 
(ref. Normal Dutch 
girls) 
-1.0 (0.2) # -1.9 (0.2) - - 
Target height SD-
score 
-0.2 (0.2) -0.3 (0.2) - - 
Age start puberty  
(B2)(yr) 
12.7 (0.1) 13.2 (0.4) - - 
GH duration (yr) 8.5 (0.3)## 3.6 (0.2) - - 
Karyotype: 45,X 30 (83%) 10 (71%) - - 
Karyotype: other 6 (17%) 4 (29%) - - 
Age at psychosocial  
evaluation (yrs) 
18.2 (0.4)# 20.4 (0.4)** 17.1 (0.2) 
GH = growth hormone. One-way ANOVA: * P < 0.05 ** P < 0.001; two-tailed (GH 
group versus Population sample) # P < 0.01 ## P < 0.001; two-tailed (Dose-
response trial versus Frequency-response trial). 
 
TABLE 2. Mean (SEM) of the SD-scores of the YSR/YASR questionnaires for 
self-reported behavioral problems. 
 
 
GH 
group 
Population 
sample 
Internalizing SD-score 0.3 (0.1) 0.0 (0.1) 
Externalizing SD-score -0.1 (0.1) 0.0 (0.1) 
Total problem behavior 
SD-score 
0.1 (0.1) 0.0 (0.1) 
Regression analyses, corrected for age, GH trial, and GH 
dosage: No significant differences (GH group versus 
Population sample). 
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Correlations between tests 
To assess possible relations between the results, which were significantly 
different from the Population sample, partial correlations were done, 
corrected for GH dosage. The Total HSP score was significantly correlated to 
the Total FAD score (r=0.38, P = 0.01), the BAS Attribution score (r=0.61, P 
< 0.001) and the BAS Physical contact score (r=0.57, P < 0.001). No 
correlation was found between the Total HSP score and the UCL Reassuring 
thoughts score. Total FAD score was significantly correlated with the BAS 
Physical contact score (r=0.46, P = 0.001), while no correlation was found 
between Total FAD score and the BAS Attribution score, or the UCL 
Reassuring thoughts score.  
 
Effect of Final Height 
Final height (FH) SD-score or corrected FH SD-score, with or without 
correction for height SD-score at start, showed no significant effect on 
Behavioral SD-scores, Self-perception (Total HSP) scores, Depression scores, 
Bodily Attitude scores or Family functioning scale (FAD) scores. Correction for 
height SD-score at start did not affect results. 
 
Discussion 
 
Our study presents psychosocial functioning results of women with Turner 
syndrome (TS) after reaching final height (FH) in two GH trials. We measured 
psychosocial functioning by standardized questionnaires on behavioral 
problems, self-perception, depression, bodily attitude, family functioning, and 
coping. We show that after long-term GH treatment behavior of the TS 
women was comparable to normal Dutch peers. In contrast, we show their 
self-perception, and their attitude towards their bodies was slightly less 
positive than for their normal Dutch peers. We found no evidence of 
increased symptoms of depression, TS women rated their family functioning 
higher, and had a slightly different coping pattern compared to their Dutch 
peers.  
We show that self-rated problem behavior scores did not significantly differ 
from normal Dutch peers. Although we did not evaluate psychosocial 
functioning before start of GH treatment in our TS group, many studies have 
found that untreated adolescent girls with TS have more problem behavior 
than normal girls 53, 120. Our results therefore suggest an improvement in 
problem behavior, after reaching a final height within the normal range for 
most and puberty induction at a pubertal age. According to Ross et al. 
improvement in (parent-reported) behavioral problems could be explained by 
the oestrogen substitution alone 34. In other studies, similar improvement in 
behavior can be found after several years of GH treatment 52, 121.  
Regarding self-perception, our results show that after reaching a final height, 
in most cases, in the normal range while puberty was induced at a relatively 
normal age (12 years in the majority), self-perception total score was 
significantly lower than in normal Dutch girls. We found that the TS women 
feel they are less socially accepted, are less athletic, and have a lower 
romantic appeal than normal girls.  
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TABLE 3. Mean (SEM) of the 10 scale scores of the Harter Self-perception 
profile. 
 
 GH group Population sample 
Scholastic competence 2.7 (0.1) 2.9 (0.0) 
Social acceptance 2.5 (0.1)*** 3.0 (0.0) 
Athletic competence 1.9 (0.1)** 2.5 (0.0) 
Physical appearance 2.3 (0.1) 2.6 (0.0) 
Job competence 3.1 (0.1) 3.2 (0.0) 
Romantic appeal 2.2 (0.1)* 2.5 (0.0) 
Behavioral conduct 3.2 (0.1) 3.1 (0.0) 
Close friendship 3.1 (0.1) 3.3 (0.0) 
Global self-worth 2.8 (0.1) 3.0 (0.0) 
Total HSP 2.6 (0.1)** 2.9 (0.0) 
Regression analyses, corrected for age, GH trial, and GH dosage: 
* P < 0.05 ** P < 0.01 *** P < 0.001; two-tailed (GH group versus Population sample). 
 
TABLE 4. Mean (SEM) of the scores for the Child Depression Inventory (CDI), 
the Bodily Attitude Scale (BAS), and the Family Assessment Device (FAD). 
 
 GH group 
Population 
sample 
CDI Total depression scale 1.3 (0.0) 1.3 (0.0) 
BAS Appraisal  3.6 (0.1) 3.7 (0.0) 
BAS Attribution  4.4 (0.1)* 4.4 (0.0) 
BAS Physical contact 3.4 (0.1)* 3.5 (0.0) 
FAD Overall Family functioning 3.3 (0.1)*** 2.5 (0.0) 
Regression analyses, corrected for age, GH trial, and GH dosage: 
* P < 0.05 *** P < 0.001; two-tailed (GH group versus Population sample). 
 
TABLE 5. Mean (SEM) of the 7 scale scores of the Utrecht Coping List 
 
 GH group 
Population 
sample 
Active approach 2.3 (0.1) 2.4 (0.0) 
Reassuring thoughts 2.5 (0.1)* 2.4 (0.0) 
Expression of emotion 2.0 (0.1) 2.2 (0.0) 
Palliative reaction 2.4 (0.1) 2.2 (0.0) 
Passive reactional pattern 1.7 (0.1) 1.7 (0.0) 
Seeking social support 2.6 (0.1) 2.3 (0.0) 
Avoiding/Anticipating 2.1 (0.1) 2.1 (0.0) 
Regression analyses, corrected for age, GH trial, and GH dosage: 
* P < 0.05; two-tailed (GH group versus Population sample). 
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Similar finding have been reported in untreated girls and women with TS 122, 
123. Several studies, however, have shown that treatment with oestrogens 
and/or GH treatment improved self-perception 34, 52, 53. Whether, in our 
study, scores for self-perception were even lower before start of GH 
treatment, we cannot say. But, even if scores had improved during the GH 
trials, they did not normalize. A possible reason why self-perception remained 
lower than normal could be the insecurity brought about by having typical 
physical TS features. Another reason might be the incidental observation of 
both parents and clinicians that some girls seem to lack social graces. To 
substantiate this observation, a recent study showed TS women have an 
impairment in recognizing emotions on someone’s face compared with 
normal women, possibly indicating anomalies in amygdala function 124. 
Another reason why our TS group feels less athletic might be because they 
actually have a restriction in movement. Nijhuis- van der Sanden et al. found 
that, although TS girls move with the same accuracy as their normal peers, 
they move with a significantly lower speed and conclude that TS girls have a 
problem in execution of movement 125. Due to the age of the participants 
(mean age of 18 years) the role of infertility was not investigated. Based on 
our professional experience, infertility has a larger role on self-perception 
later in life. 
Several studies have found evidence of depression in TS women who were 
untreated or only treated with oestrogens 36, 126. In our group of TS women, 
after long-term GH treatment and oestrogen substitution at a pubertal age, 
the results of the questionnaire show no significant signs of depression. A 
previous study on adolescent girls with TS treated with GH (100%) and 
oestrogen (61%) described severe depressive symptoms in 20% 127 of the 
girls. The factor related to these symptoms was teasing by peers about their 
physical appearance. Rickert et al., however, did not show any data on height 
gain or pubertal development during GH and oestrogen treatment. Therefore, 
the discrepancy in results might be explained by differences in height gain or 
pubertal development. Since we found no evidence of depression, this might 
indicate the girls suffered less from teasing as a result of adequate GH and 
oestrogen treatment. 
Furthermore, our results show that after GH treatment and puberty induction 
TS women appraise their bodies similarly to their peers. Other studies have 
shown that TS girls and women when untreated score their physical 
appearance significantly lower than their peers 122, 128. Interestingly, the TS 
women have a small but significant tendency to attribute problems to their 
appearance and avoid physical contact. Although our group was adequately 
treated with GH and oestrogen, we did not treat the typical physical TS 
features, other than short stature and absent pubertal development. It is 
therefore not surprising that they still feel insecure about their appearance. 
Previous studies found girls with TS are often overprotected by their parents 
52. Overprotection, however, is also seen in other patient groups with short 
stature 129. One of the reasons for parents to overprotect is lack of peer 
relations of their children. On the other hand, children with poor peer 
relations rely more on family functioning 130. Several studies describe an 
increase in family functioning, parallel to an increase in self-concept and a 
decrease in behavioral problems during GH treatment 52, 53. In our study, 
after reaching a final height within the normal range in most cases and 
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puberty induction at a relatively normal age, we found that TS women have a 
better family functioning than peers. This might indicate that these TS 
women still lack peer relations and take refuge in their family as a way of 
coping with problems 53. Another explanation might be that, as a result of 
past medical and psychosocial problems these TS women and their family 
have faced, their family actually functions better than peer families. Rovet et 
al, in their controlled GH trial, found an increase in family functioning and 
explained this as a greater involvement of the parents due to the GH 
treatment 52. 
Commonly, girls and women with TS are described as withdrawing from 
social interaction as a way of coping with problems 53, 131. Interestingly, we 
show that women with TS, after long-term GH and oestrogen treatment, 
have only a slightly different coping strategy than their peers. They used 
more Reassuring thoughts to cope with problems, while they used strategies 
such as Avoiding problems but also Active approach and Expression of 
emotions as often as their peers. These results seem to indicate that, in 
general, TS women, after adequate GH and oestrogen treatment, have a 
‘normal’ coping strategy.  
When we looked at the relation between our results, we found that TS 
women, who have a good self-perception, also have a good family 
functioning, attribute problems less to their appearance and enjoy physical 
contact. These results strengthen the common suggestion that these TS 
women rely on family functioning more than other women 130, which for them 
leads to a more favorable self-perception and bodily attitude. Previous 
studies have described that the TS women rely on their families more than 
other women as a way to avoid problematic situations 53, 130. In the GH 
group, we show that these women avoid problems similarly to their peers.  
As mentioned before, several studies show more behavioral problems in 
untreated TS girls and a decrease in problems during GH treatment 52, 53. 
Similarly, for self-perception, an improvement has been found during GH and 
oestrogen treatment 52, 53. Although it is therefore likely that in our study, GH 
and oestrogen treatment has had a positive effect on psychosocial 
development, we did not find significant relationships between test scores 
and (corrected) final height or a GH dosage effect. This might also indicate 
that GH treatment did not influence psychosocial functioning. Another 
explanation for this might be that the GH treatment regimen in the trials, 
regardless of the dosage, achieved its optimal effect on psychosocial 
functioning. Similarly, in short children born small for gestational age, while 
longitudinal results show a significant increase in psychosocial functioning 
during GH treatment, results did not differ between GH dosage groups 132. In 
the present study, however, we are unable to show the extent of the effect of 
GH treatment, as we have no psychosocial data of start of the GH trials.  
In conclusion, after long-term GH treatment behavior of the TS women was 
comparable to normal Dutch peers. Although their perception of themselves 
and their attitude towards their own bodies was slightly less positive than for 
their normal Dutch peers, we found no evidence of depression. In addition, 
TS women rated their family functioning higher, and had a coping pattern 
very similar to their Dutch peers. TS women with a more positive self-
perception, also had a better attitude towards their bodies and had a better 
functioning family. These results show that even after reaching a height 
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within the normal range and puberty induction at a pubertal age, some 
women with TS still experience psychosocial problems. It is, however, likely 
that GH and oestrogen treatment improved psychosocial functioning. Long 
term follow-up of these GH-treated patients will allow an evaluation of their 
life achievements. 
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General Discussion and Conclusions 
 
 
In this chapter we discuss the results of a randomised multi-centre dose-
response growth hormone (GH) trial evaluating the efficacy, safety and 
psychosocial effect of long-term GH treatment in Turner syndrome (TS). The 
TS trial consisted of 68 untreated girls with TS who participated from 1989 in 
a GH trial using 4, 6, or 8 IU GH/m2/day (~ 0.045, 0.067, or 0.090 
mg/kg/day). Eleven paediatric departments in The Netherlands participated 
in this trial. In this chapter, we start by discussing the results of the TS trial. 
Finally, conclusions are drawn from the discussion and recommendations for 
future research are given. 
 
Evaluation of the effect of long-term GH treatment on final height in 
60 girls with TS treated in a randomised dose-response trial 
comparing 3 dosage schedules 
 
Although GH treatment for short stature in TS is now an accepted treatment 
in many countries, reports on final height are inconsistent and which dosage 
to use is an issue of debate 41, 43. Previously, Th. Sas, in his thesis entitled 
“Long-term growth hormone treatment in two growth disorders”, Rotterdam 
1999, demonstrated that long-term GH treatment in TS leads to 
normalisation of height during childhood and adolescence 42. In this thesis, in 
chapter 2 we showed that 83% of the 60 TS girls, who started GH treatment 
at a mean age of 6.6 years, reached a normal final height (FH SD-score 
above -2), while 63% reached a final height within their target height range 
(TH ± 1.3 SD). The mean final height using a conventional GH dosage of 4 
IU/m2/day was 157.6 cm, which is equal to an SD-score of  -1.6 when using 
references for normal Dutch girls. Final height varied between 150.4 cm and 
171.7 cm (5th and 95th percentile). The mean gain in final height varied 
between 11.9 cm and 16.9 cm, depending on the GH dosage used 
(estimation based on Lyon’s predicted final height, adjusted for Dutch girls 
with TS). For all three dosage-groups together, gain in final height varied 
between 7.2 cm and 20.4 cm (5th and 95th percentile). These results are not 
confirmed by most other studies on final height in TS 43, 71. They found a 
considerably lower gain in final height. Other studies, however, starting GH 
treatment at a younger mean age, also showed a greater gain in final height 
60, 73, 74, 133. In addition, we found that in a regression model a lower age at 
start predicted a greater gain in final height. Therefore, one of the reasons 
for these conflicting results probably lies in the age at which GH treatment is 
started. Other reasons might be the higher dose of oestrogens used in most 
studies and/or the difference in oestrogen-free GH treatment period (see 
next paragraph).  
A second factor that predicted final height gain was the GH dosage. Our 
study showed that using a dosage of 6 or 8 IU/m2/day instead of 4 
IU/m2/day significantly increased gain in final height. Using a dose of 8 
IU/m2/day, however, showed no advantage over 6 IU/m2/day for gain in final 
height. Two non-randomised studies showed a similar dose-dependent 
increase in final height gain 75, 76. A higher GH dosage of 6 IU/m2/day, 
however, leads to a 50% increase in cost of treatment. But does the extra 
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gain in final height of approximately 3 ½ cm justify the increase in cost? 
Previously, we mentioned our finding that age at start predicted final height 
gain. Therefore, one justification for using a higher GH dosage could be to 
prevent a disappointing final height when GH treatment is initiated at an 
older age. In addition, a higher GH dosage also leads to higher IGF-I levels. 
We showed that at 7 years of GH treatment the highest dosage group had 
significantly higher IGF-I levels compared to the lowest dosage group. Recent 
studies have shown a potential danger of having high circulating IGF-1 levels. 
One study found that men (Physicians' Health Study) with higher IGF-1 levels 
in their blood had an increased risk of developing colorectal cancer after 14 
years follow-up 78. Another study found that after 7 years of follow-up, high 
circulating IGF-1 levels in nurses (Nurses’ Health Study cohort) were 
associated with an increased risk of breast cancer 79. These studies, however, 
did not show a causal relationship but only an association between high 
circulating IGF-1 levels and cancer. Therefore, whether GH-induced high  
IGF-I levels during childhood and adolescence might lead to an increased risk 
of cancer remains to be investigated. Pending these investigations, however, 
high dosages of GH should be given with caution. 
 
Assessment of the effect of low dose oestrogen treatment begun at a 
relatively young age on final height in girls with TS during long-term 
GH treatment 
 
Which age to start puberty induction is also still an issue of debate. Several 
paediatricians believe oestrogen treatment should be postponed as long as 
possible to achieve the highest possible height gain. Both research and 
professional experience of paediatricians, however, have shown the 
psychological importance of inducing puberty at an age as close as possible 
to their peers 34, 134. In chapter 2 we show that starting a low dose of natural 
oestrogens at a normal pubertal age of 12 ½ years did not have a negative 
effect on height velocity and on bone maturation. Other studies, in contrast, 
found a decrease in height velocity and an increase in bone maturation 
leading to a decrease in height gain 73, 77. An explanation for the different 
results might be the higher dose of oestrogens used. Another might be the 
difference in time-period between start of GH treatment and start of 
oestrogen treatment. In our study oestrogen treatment was started after at 
least four years of GH treatment while height had already increased by 
almost 2 SD-score. As most of the catch-up had already occurred before 
oestrogen treatment was initiated, a possible small negative effect might 
become less important. Confirming this explanation, Reiter et al. found that a 
longer duration of oestrogen-free GH treatment strongly predicted a higher 
gain in near final height 74. Massa et al., however, in an analysis of the 
Belgian growth database of GH-treated TS girls, showed that, when using a 
low dose of ethinyl oestradiol, not the oestrogen free period, but the duration 
of treatment with GH and oestrogen predicted final height outcome in older 
TS girls (mean age of 11.6 years at initiation of GH treatment) 135. In a Dutch 
study by Sas et al. in 19 girls with TS starting GH at an older age (mean (SD) 
13.6 (1.7) years) mean (SD) attained final height was 155.5 (5.4) cm, while 
13 of the 19 girls had a final height gain of more than 5.0 cm. In this study 
puberty was induced from start of GH treatment by a low dose of oral ethinyl 
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oestradiol. This study shows that simultaneous initiation of GH and low dose 
oestrogens, can lead to a substantial gain in final height without having to 
postpone puberty 41. Therefore, the initiation of oestrogen treatment in older 
TS girls does not have to be postponed to a later age. Possible factors that 
might lead to reconsider postponing puberty in individual cases might be a 
very small stature and/or an older bone age 41. In these cases, however, the 
individual psychological importance of inducing puberty at an age as close as 
possible to their peers, should also be taken into consideration. 
 
Evaluation of several parameters to predict final height SD-score to 
aid individual treatment with GH in girls with TS during long-term GH 
treatment 
 
When analysing the factors most likely to influence final height SD-score, we 
found that a regression model containing height SD-score at start, GH 
dosage, age at start, and first year height velocity explained 76 percent of 
the variation in final height SD-score. Our study showed that an increase in 
GH dosage might be worthwhile when a TS girl, for her age, has a low height 
SD-score at start, and/or a low height velocity in the first year of GH 
treatment. Without the influence of height SD-score at start and first year 
height velocity, age at start and final height SD-score showed a negative 
relationship. Therefore, another reason for increasing the GH dosage might 
be an older age at start of GH treatment. In other studies the same factors 
were found to predict final height or height gain after GH treatment 41, 133, 136. 
In contrast, in an analysis of the growth database of GH-treated TS girls, one 
study found no relationship between age at start GH treatment and final 
height outcome 135. Since this result has not been confirmed by other studies, 
it should not lead to postponing GH treatment. Both clinical observations and 
research have shown clear psychosocial implications of short stature during 
childhood in TS girls 52, 53. Parameters that did not predict final height, among 
others, were karyotype (45, XO or other) and the increase in alkaline 
phosphatase in the first year of GH treatment. Several studies on natural 
growth in TS girls found a positive correlation between Xp disomy and final 
height 137, 138. In our study only 9 girls had a karyotype other than 45, XO, all 
having different mosaic karyotypes. Therefore, whether GH treatment in girls 
with Xp disomy leads to a higher final height, we cannot say.  
By filling in the different parameters, the model can also be used to aid 
clinicians to decide which dosage to use. For example, a girl with TS, with a 
height SD-score at start of GH treatment of –3, a first year height velocity of 
10 cm/yr (1 year conventional dose of 4 IU/m2/d), and an age at start of 6 
years, would attain a final height SD-score of –1.5 when the GH dose is not 
increased, and a FH SD-score of –0.8 or –0.7 when the GH dose is increased 
by 50 or 100 percent. Depending on one’s goal, for instance achieving a 
normal final height or reaching the target height range, the GH dosage could 
be adjusted accordingly. A higher GH dosage, however, leads to a 50-100% 
increase in cost, while the cost of long-term GH treatment is already 
considerable. In addition, a higher GH dosage also leads to a higher IGF-I 
SD-score while the long-term effects of GH-induced high IGF-I levels on the 
development of cancer remain to be investigated 78, 79. To further optimize 
the model for clinical use it is crucial to validate it on other TS patient groups. 
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Although the model has a high prediction percentage, it does leave 24 
percent to be explained by unknown factors. Furthermore, the predicted FH 
SD-score has a large prediction interval (residual SD of 0.54). A possible 
factor that may have contributed to the variation in final height and height 
gain is the origin of the X-chromosome (paternal or maternal). Chu at al. 
found a strong correlation between height SD-score of TS girls and their 
mothers, when the TS girls X-chromosome originated from their mother 139. 
Other factors that may have contributed are unknown genetic aberrations, or 
non-compliance. 
 
Investigation of carbohydrate metabolism in girls with TS after 
discontinuation of long-term GH treatment in a dose up to 8 
IU/m2/day (~ 0.090 mg/kg/day) 
 
As GH treatment increases insulin levels, several authors have expressed 
their concern regarding long-term effect of GH treatment in children with a 
predisposition for diabetes mellitus such as girls with TS 25, 45, 46. In chapter 3 
we show that in TS girls, the increased fasting and stimulated insulin levels 
returned to normal after discontinuation of long-term GH treatment. 
Similarly, fasting glucose levels increased during GH treatment and 
decreased after discontinuation of GH treatment, while stimulated glucose 
levels showed no change during GH treatment. In addition, we found no 
evidence of a dose-dependent increase in glucose or insulin levels between 
the GH dosage groups.  
Although insulin levels after discontinuation of GH treatment remained above 
pre-treatment levels, results were comparable to a similar aged group of 
normal girls 83. The reason for the rise in stimulated insulin levels, both in 
normal and in TS girls after GH treatment, is that during puberty insulin 
sensitivity decreases 81, 86, 87. A number of authors, however, have described 
an increased prevalence of insulin resistance in untreated women with Turner 
syndrome 22, 23. Therefore, although the TS girls might have had a pubertal 
insulin resistance, the higher insulin levels might also be a result of having 
TS. In contrast, one study demonstrated that TS women (n=49), by 
comparing results of intravenous glucose tolerance tests (IVGTT) to those of 
age and body mass index matched normal women, have an increased insulin 
sensitivity and a reduced stimulated insulin response 30. This might point to 
beta-cell dysfunction as a cause for impaired glucose tolerance and DM in TS. 
 
Investigation of several factors that may predict development of 
cardiovascular disease, such as blood pressure, body mass index and 
blood lipid levels in TS women after discontinuation of GH treatment 
 
Besides DM, girls with TS are also predisposed to develop cardiovascular 
disease (CVD). CVD is thought to be the main cause of death in TS 24, 25. In 
addition, risk factors for CVD, such as hyperlipidaemia, hypertension, obesity, 
and impaired glucose tolerance occur more often in TS 25-28. In chapter 3, 
after discontinuation of GH treatment, we show a decrease in age-corrected 
blood pressure, compared to pre-treatment. Blood pressure, however, 
remained slightly higher than in peers. Some think that having Turner 
syndrome predisposes for hypertension 25. The aetiology of the 
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predisposition, however, remains unclear 31. The decrease in blood pressure 
during treatment makes GH an unlikely cause. In addition, we found that in 
the first four years of GH treatment lipid levels became more favourable 
regarding the risk for CVD. After discontinuation of GH treatment, compared 
to the lipid levels in a group of normal children with a similar age, we found 
that lipid levels in the TS girls were still more favourable regarding the risk 
for CVD than in the normal peers. As most risk factors seem to have an 
independent influence on the development of CVD, clustering of several risk 
factors in TS girls would increase their chance of developing CVD. We found a 
positive correlation between BMI SD-score and insulin levels, but could not 
detect any other concurrence between the risk factors. It is not surprising we 
found a relation between BMI SD-score and insulin levels, as such a 
relationship is also found in normal children 89, 100. Both risk factors, however, 
increase the chance of developing diabetes mellitus, while having TS possibly 
already predisposes for diabetes mellitus. We would therefore urge clinicians 
to do their utmost to prevent further weight gain in girls and women with TS. 
 
Evaluation of psychosocial functioning in a group of 50 TS women 
with final height after long-term GH treatment 
 
In the previous chapter we showed that GH treatment and induction of 
puberty at a normal pubertal age, in most cases, normalised final height in 
TS. The effect of such a treatment strategy on psychosocial functioning, 
however, has been relatively underreported. In chapter 4 we show that, after 
long-term GH treatment, behaviour in the TS women was comparable to 
normal Dutch peers. In contrast, we show that self-perception was 
significantly less positive than for their normal Dutch peers and they have a 
small but significant tendency to attribute problems to their appearance and 
avoid physical contact. In addition, we found no evidence of depression, TS 
women rated their family functioning higher, and had a slightly different 
coping pattern compared to their Dutch peers. TS women with a more 
positive self-perception, also had a better attitude towards their bodies and 
had a better functioning family. This seems to emphasise the importance of 
family functioning for these women. When looking at psychosocial functioning 
in untreated adolescent TS girls, more problem behaviour and a lower self-
esteem than in normal girls have been described 53, 120 122. Some even found 
signs of depression in untreated adolescent and adult TS women 36, 126 127. 
Several studies show a positive effect of short-term GH and/or oestrogen 
treatment on problem behaviour and self-perception 52, 53. In our study after 
long-term GH treatment, problem behaviour was comparable to normal 
peers, while self-perception and bodily attitude was less positive than for 
peers. Although most attained a normal height, we did not treat the other 
physical TS features. These other features of TS might be responsible for the 
less favourable results on self-perception and bodily attitude. Another reason 
might be the observed lack in social graces in some girls with TS. Lawrence 
et al. showed that TS women have trouble recognising facial emotions. He 
postulated that this was caused by anomalies in amygdala function 124.  
Part of measuring self-esteem is perceived athletic competence. This was one 
of the categories the TS women scored less positive than normal. Nijhuis- 
van der Sanden et al. found that, although TS girls move with the same 
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accuracy as their normal peers, they move with a significantly lower speed 
125. Therefore, a possible reason for this result might be their problem in 
execution of movement. 
 
Conclusions 
 
GH treatment leads to a normalisation of final height in most girls. Using a 
dose of 8 IU/m2/day showed no significant advantage over 6 IU/m2/day for 
gain in FH. If GH is started at a young age final height will not be affected by 
early initiation of oestrogen. The optimal dosage to use depends on height 
and age at start of treatment, and first year height velocity. As twenty-four 
percent of the variance in final height remains unexplained, detailed 
phenotypic, genetic, and family data on GH-treated TS girls are required to 
find other predictive factors. High dosages of GH should be given with 
caution, not only because of the considerable increase in cost of treatment, 
but also because the very long-term safety of using a higher GH dosage 
remains to be investigated. 
After discontinuation of long-term GH treatment in girls with TS the GH 
induced insulin resistance disappeared. The decrease in blood pressure both 
during and after discontinuation of GH treatment suggests a positive effect of 
GH and oestrogen treatment in TS. Lipid levels, after discontinuation of GH 
treatment, were more beneficial regarding the development of cardiovascular 
disease than in a normal control group, suggesting a positive effect of GH 
and oestrogen treatment in TS. The positive correlation between insulin 
resistance and BMI, together with the predisposition in TS for insulin 
resistance, should urge clinicians to do their utmost to prevent further weight 
gain in girls and women with TS. 
Even after normalisation of height and puberty induction at a pubertal age, 
some TS women still experience psychosocial problems. Although it is likely 
that GH and oestrogen treatment improved psychosocial functioning, it did 
not normalise it for some women. Whether GH treatment also has an effect 
on their life achievements in the future, further follow-up will show. 
 
Recommendations and future research 
 
For most girls, long-term GH treatment using a dose of 4 IU/m2/day (~ 0.045 
mg/kg/day) in girls with TS will lead to a normal final height. Using a dose of 
8 IU/m2/day showed no significant advantage over 6 IU/m2/day for gain in 
FH. Factors that might lead to consider an increase in GH dosage to 6 
IU/m2/day are very short height and older age at start of treatment, and low 
first year height velocity. In line with our recommendation, the 2005 
guidelines of the Dutch Advisory group on Growth Hormone state that usage 
of a higher dose of 6 IU GH/m2/day should be limited to girls older than 11 
years with a height beneath the -2 SD-score for normal girls of the same age.  
In our study, early initiation of oestrogen does not have an apparent negative 
effect on final height. If GH is started at a young age, puberty induction can 
be started at 12 years of age. In case of late discovery of TS, low dose 
oestrogens can be started as soon as GH treatment is initiated, unless the 
girl is very short and/or has an older bone age. To optimise treatment results 
but also to prevent unduly expectations of GH treatment 134, GH treatment 
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should become more individualised. To find the best treatment strategy for 
each girl, more detailed data should be collected, based on larger groups of 
girls with TS. Potential genetic predictors might be, for instance, low 
frequency mosaicism or parental origin of the X chromosome. On the other 
hand, sub-clinically present autoimmune diseases, such as celiac disease, 
might have a negative effect on GH-induced height gain. The aim would be to 
create an advanced prediction model to aid the individualisation of treatment.  
High dosages of GH, however, should be given with caution, not only because 
of the considerable increase in cost of treatment, but also because the very 
long-term safety of using a higher GH dosage remains to be investigated. 
Recent studies have shown a potential danger of high circulating IGF-1 levels 
78, 79. Whether the relationship between high circulating IGF-1 levels and 
cancer is causal, remains to be investigated. Until causality can be ruled out, 
epidemiological studies on individuals treated with recombinant GH should 
monitor for an increased risk of colorectal or breast cancer in this group, 
keeping in mind the increased risk for colon cancer already present in TS, 
and the association between breast cancer and oestrogen treatment in post-
menopausal women. 
After discontinuation of long-term GH treatment in girls with TS the GH 
induced insulin resistance disappeared. A recent study suggested a beta-cell 
dysfunction as a cause of the increased prevalence of diabetes mellitus in TS 
women 30. Studies on beta-cell function in other TS patient groups might 
confirm these results and could focus on the aetiology behind the 
dysfunction.  
Results after discontinuation of GH treatment suggest a positive effect of GH 
and oestrogen treatment on blood pressure and lipid levels in TS. Whether 
the positive effect will remain on the long-term and will affect the prevalence 
of CVD in TS, remains to be investigated. Epidemiological studies on a large 
group of GH treated TS women will show whether long-term GH treatment 
will lead to a significant reduction in CVD. 
After discontinuation of GH treatment, blood pressure remained slightly 
higher than in peers. The aetiology of the predisposition for hypertension in 
Turner syndrome, however, is unclear. In addition, no research has been 
done on the effect of current treatment strategies for hypertension in TS. 
Future studies should be aimed at finding the causes for hypertension in TS 
and optimising its treatment. 
Regarding the clustering of risk factors for diabetes mellitus type 2 and CVD, 
we found a positive correlation between BMI SD-score and insulin levels. It is 
still under debate whether obesity, observed more frequently in TS women, is 
solely responsible for the predisposition for diabetes mellitus type 2 or 
whether missing a second sex-chromosome, i.e. having TS, attributes by 
causing insulin resistance and/or beta-cell dysfunction 22, 23, 30. Investigating 
the cause for the predisposition will aid in preventing diabetes mellitus type 2 
in TS. In addition, we should find out why women with TS are more obese 
than normal women. Epidemiological studies and clinical observational 
studies can help find risk factors for obesity in TS which should result in an 
obesity prevention programme for TS girls and women. 
After normalisation of height and puberty induction at a pubertal age, most 
women have an improved psychosocial functioning compared to previous 
studies on untreated TS women. Some TS women, however, still experience 
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psychosocial problems. Having TS is associated with several factors that 
potentially influence psychosocial functioning, other than short stature. In the 
discussion we mention the typical facial features of TS, the deficit in 
recognition of facial emotion, and the problems in execution of movement 124, 
125. It would be important to determine which factors significantly influence 
the psychosocial status to optimise the treatment strategy for TS. 
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Summary 
 
The most common clinical characteristic of Turner syndrome (TS) is short 
stature. Although girls with TS are not growth hormone (GH) deficient, 
studies show that long-term GH treatment in TS leads to normalisation of 
height during childhood. In this chapter the results and conclusions are 
summarised of the multi-centre randomised dose-response growth hormone 
(GH) trial evaluating the efficacy, safety and psychosocial effect of long-term 
GH treatment on girls with TS. The TS trial was an open trial consisting of 68 
untreated girls, aged between 2 and 11 years, with TS. The girls were 
randomly assigned to a group using 4 IU GH/m2/day, to a group using 4 IU 
GH/m2/day in the first year, and 6 IU GH/m2/day in the years thereafter, or 
to a group using 4 IU GH/m2/day in the first, 6 IU GH/m2/day in the second, 
and 8 IU GH/m2/day in the years thereafter  (~ 0.045, 0.067, or 0.090 
mg/kg/day). After at least 4 years of GH treatment, at a minimum age of 12 
years, a low dose of micronised oestradiol was given to induce puberty. 
Chapter 1 introduces the characteristics and incidence of TS. In addition, it 
describes the development of height and bone maturation, the risk for 
diabetes mellitus type 2 and cardiovascular disease, and the psychosocial 
development in untreated TS girls and in TS girls treated with GH and 
oestrogens. Subsequently, it describes longer-term results of GH treatment 
and oestrogens on height in girls with TS. 
Chapter 2 presents the results after long-term GH treatment (mean duration 
8 years) and oestrogen treatment on final height, bone maturation and 
plasma IGF-I  in 60 TS girls. We show that in TS a GH dosage of 4 IU/m2/day 
combined with a puberty induction at a normal age, leads to a normal final 
height (FH) for most girls. Eighty-three percent of the girls with TS reach a 
normal final height and 63% reach a final height within their target height 
range. A higher dose of 6 IU/m2/day (group B) leads to a final height that is 
slightly higher than for group A. Administration of an even higher dosage of 
GH (8 IU/m2/day; group C) does not lead to a further increase in final height. 
Starting a low dose of natural oestrogen at a relatively young pubertal age 
has no apparent negative effect on height gain. Factors that seem to predict 
final height SD-score are height SD-score at start, GH dosage, age at start, 
and first year height velocity. 
Chapter 3 shows the effect of discontinuation of long-term GH treatment on 
carbohydrate metabolism, body mass index, blood pressure, and serum lipid 
levels in girls with TS. After discontinuation, the effect of GH treatment on 
carbohydrate metabolism disappears. Girls with a higher body mass index, 
however, have a less favourable carbohydrate metabolism after 
discontinuation of GH treatment. Compared to pre-treatment blood pressure 
and lipid levels change favourably after discontinuation of GH treatment. 
Chapter 4 describes psychosocial functioning of women with Turner syndrome 
(TS) after long-term GH treatment. After long-term GH treatment, behaviour 
of most TS women is comparable to peers. Self-perception and their attitude 
towards their bodies is slightly less positive than for their peers. We find no 
evidence of depression. TS women rate their family functioning higher, and 
have a slightly different coping pattern compared to peers. In comparison 
with previous literature data, GH and oestrogen treatment seem to improve 
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psychosocial functioning, for most women. Some women, however, still 
experience psychosocial problems.  
Chapter 5 discusses the results presented in the previous chapters and 
relates them to relevant literature. In addition, conclusion are drawn and 
recommendations are given together with suggestions for future research. 
Finally, Chapter 13 synthesises the results from the TS trial and the SGA trial 
and discusses the similarities and differences. 
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Samenvatting 
 
Het meest voorkomende klinische kenmerk van het Syndroom van Turner 
(TS) is een kleine gestalte. Hoewel meisjes met TS geen groeihormoon (GH) 
tekort hebben, blijkt uit onderzoek dat langdurige GH behandeling leidt tot 
een normalisatie van de lengte als kind. In dit hoofdstuk worden de 
resultaten en conclusies samengevat van een gerandomiseerd dosisrespons 
onderzoek dat heeft gelopen op verschillende kinderafdelingen verspreid door 
Nederland. Het onderzoek evalueerde het effect en de veiligheid van 
langdurige GH behandeling van meisjes met TS. De doseringen van het GH 
werden ad random toegekend aan drie groepen van onbehandelde meisjes 
tussen de 2 en 11 jaar: Groep A (4 IU/m2/dag), Groep B (4 IU/m2/dag in het 
eerste jaar en vervolgens 6 IU/m2/dag in de volgende jaren), Groep C (4 
IU/m2/dag, 6 IU/m2/dag in het tweede jaar, en vervolgens 8 IU/m2/dag in de 
volgende jaren) . Zowel bij de 68 patiënten als hun behandelaars was de 
dosering bekend. Na minimaal 4 jaar GH behandeling en het bereiken van het 
twaalfde levensjaar, kregen de meisjes een lage dosering gemicroniseerd 
oestradiol om in de puberteit te komen.  
 
Hoofdstuk 1 introduceert de kenmerken van TS en de frequentie van 
voorkomen. Het beschrijft verder de lengte- en botontwikkeling, het risico op 
diabetes mellitus type 2 en hart en vaatziekten, en de psychosociale 
kenmerken van onbehandelde en met GH behandelde meisjes met TS.  
Hoofdstuk 2 laat de resultaten zien van langdurige GH behandeling 
(gemiddelde 8 jaar), later aangevuld met oestrogeen behandeling, op 
eindlengte, botontwikkeling, en IGF-1 concentraties in 60 meisjes met TS. Uit 
de resultaten blijkt dat bij de meeste meisjes een GH dosis van 4 IU/m2/dag 
met een puberteitsinductie op normale leeftijd leidt tot een normale 
eindlengte. Van de hele groep heeft 83 procent van de meisjes met TS een 
normale eindlengte behaald en 63 procent een eindlengte in hun target 
height interval (eindlengte gebaseerd op ouderlengte). Hogere dosering van 
GH (groep B) resulteert in een iets langere eindlengte dan in groep A, terwijl 
de hoogste dosering geen verdere toename laat zien in eindlengte. De start 
van een lage dosis oestrogenen in relatief jonge meisjes met TS laat 
ogenschijnlijk geen effect zien op lengtewinst. Factoren die eindlengte 
voorspellen zijn lengte bij start, gecorrigeerd voor leeftijd en geslacht (lengte 
SD-score), GH dosis, leeftijd bij start, en lengtewinst in eerste jaar. 
Hoofdstuk 3 beschrijft het effect van het staken van de GH behandeling op 
het koolhydraat metabolisme, op de body mass index (BMI), op de 
bloeddruk, en op het vetgehalte in het bloed. Na staken van de behandeling 
blijkt het effect van GH op het koolhydraat metabolisme te verdwijnen. 
Meisjes met een hoog BMI laten een negatief effect zien op het koolhydraat 
metabolisme. Vergeleken met voor de GH behandeling, hebben de meeste 
meisjes na de behandeling een betere bloeddruk en vetgehalte.  
Hoofdstuk 4 presenteert het psychosociaal functioneren van vrouwen met TS 
na langdurige GH behandeling. Hierin laten we zien dat na langdurige GH 
behandeling het gedrag van de meeste vrouwen met TS vergelijkbaar is met 
hun leeftijdsgenoten. Hun zelfbeeld en lichaamsbeeld blijkt iets negatiever te 
zijn dan voor hun leeftijdsgenoten. We hebben geen aanwijzingen gevonden 
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voor depressie. Vrouwen met het TS hebben een positiever beeld van het 
functioneren van hun gezin/familie en hebben een iets verschillend 
copinggedrag dan hun leeftijdsgenoten. Vergeleken met eerdere studies van 
onbehandelde vrouwen met TS, zijn er duidelijke aanwijzingen dat 
behandeling met GH en oestrogeen een positief effect heeft op het 
psychosociaal functioneren van de meeste vrouwen met TS. Een aantal 
vrouwen heeft echter nog steeds psychosociale problemen. 
Hoofdstuk 5 bediscussieert de resultaten van de voorgaande hoofdstukken en 
betrekt daarin relevante literatuur. Daarnaast worden er conclusies getrokken 
en suggesties gedaan voor toekomstig onderzoek. 
Als laatste wordt er in Hoofdstuk 13 een vergelijking gemaakt tussen de 
resultaten van het TS onderzoek en het SGA onderzoek. 
   79
 
 
 
 
 
 
Part ‘Small for Gestational Age’ 
   80
   81
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 7 
 
Part ‘Small for Gestational Age’: Introduction
Chapter 7   Part ‘Small for Gestational Age’: Introduction 
  82
 
 
 
 
 
TABLE 1.  Factors associated with SGA. 
 
 
 
 Foetal factors 
 Chromosomal abnormalities 
 Genetic diseases 
 Congenital anomalies 
 
 Maternal factors 
 Hypertension 
 Renal disease 
 Diabetes mellitus 
 Collagen vascular diseases  
 Maternal hypoxemia  
 Infection 
 Nutritional status 
 Cigarette smoking 
 Substance abuse 
 Therapeutic drugs 
 
 Uterine/placental factors 
 Gross structural placental defects 
 Insufficient uteroplacental perfusion 
 Suboptimal implantation site 
 
 Demographic factors 
 Maternal age (Very young or older) 
 Maternal height 
 Maternal weight 
 Maternal and paternal race 
 Parity (Nulliparity, Grand multiparity) 
 Previous delivery of SGA infants 
 
 Environmental factors 
 Altitude 
 Other 
 Multiple gestation 
 
Adapted from Bernstein and Divon 189. 
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Introduction 
 
Children born small for gestational age 
Until recently, several definitions have been used for small for gestational age 
(SGA), such as a birth weight and/or length below the 10th, or 3rd percentile 
for gestational age. In the Netherlands, SGA has been defined as a birth 
length of 2 or more standard deviations (SD) below the mean for gestational 
age from 1989 onwards 140. The reference data from Usher and McLean are 
used for calculation of SD scores  141. In 2002, an international consensus on 
the definition of SGA was reached by the International Small for Gestational 
Age Advisory Board, defining SGA as a birth weight and/or length of 2 or 
more standard deviations (SD) below the mean for gestational age 142.  
Several associated factors have been mentioned as possible causes for the 
development of SGA. These factors can be divided into groups, such as 
maternal, foetal, and/or placental factors as shown in table 1. Maternal 
factors are, for instance, smoking, nutritional state, or several diseases. 
Foetal factors are chromosomal or congenital abnormalities, and placental 
factors are infarctions or placental development aberrations.  
 
Postnatal growth 
During the first two years of life, 10% of the children born SGA do not catch-
up in height and have an increased risk to reach an adult height of 2 SD or 
more below the average height 140, 143. According to the above definition of 
SGA, 1 in 43 (2.3%) of all live-born infants are born SGA per year. For the 
Netherlands this percentage could be translated into 4,648 children born SGA 
per year (2.3% of 202,083 life-born infants in 2002, Central Bureau of 
Statistics, www.cbs.nl). 10% of these children, approximately 460 per year, 
could be defined as persistently short children born SGA. Part of this group 
has an identified congenital or genetic cause for persistent short stature. This 
thesis focuses on persistently short children born SGA without a known 
congenital or genetic cause for their short stature, except for Silver-Russell 
syndrome. Of the total short population, it has been estimated that about 
22% are born SGA 143.  
 
Short children born SGA 
The first 2 years of life are the most critical for determining whether a child 
born SGA will show adequate catch-up growth. After these 2 years short 
stature will most likely persist into adulthood 143. The pathophysiology of 
inadequate postnatal catch-up growth is not yet understood. Given the 
heterogeneity of the SGA group, factors that attribute to the lack in postnatal 
catch-up will vary. Possible causes are low GH levels, low sensitivity to GH, 
low sensitivity to IGF-1, or a combination of these factors 144-146. Associations 
between the extent of catch-up growth and parental height would suggest a 
genetic cause for short stature after being born SGA 143. 
 
Bone maturation 
Generally, bone development in early childhood after being born SGA 
progresses slowly. Longitudinal studies in children with Silver-Russell 
syndrome and pre-treatment data from several GH trials, confirm this 147-150. 
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By late childhood, the delay in bone maturation is followed by a spontaneous 
acceleration to an age appropriate bone age 147, 151. The acceleration of bone 
maturation, however, is not associated with an adequate catch-up in height 
and adult height 152.  
 
Physical appearance 
Most short children are lean in prepuberty but many gain weight during 
puberty 150, 153. Their hands and feet, shoulders and pelvis are on average in 
the upper range of normal for their stature 154. A subgroup of short children 
born SGA has typical features of Silver-Russell syndrome, with frontal 
bossing, a triangular face, clinodactyly, and asymmetric extremities 148. 
Natural growth in these children is comparable with that of short children 
born SGA without these features. For that reason, children with Silver-Russell 
syndrome are not excluded from trials studying growth in children born SGA. 
 
Diabetes mellitus and cardiovascular disease 
Epidemiological studies have found a propensity to diseases such as diabetes 
mellitus type 2 and cardiovascular disease in adults born with a low birth 
weight 155, 156. Whether these associations depend on other factors such as 
developing obesity or adequate catch-up growth in childhood is under 
investigation 157-159. Barker et al. suggested that the aetiology for the 
associations lies in the timing of the intrauterine growth retardation 160. They 
hypothesise that foetal structure and function can be altered in response to 
adverse intrauterine influences during critical time windows. When the 
adverse influence, in this case malnutrition is timed during such a critical 
time, the foetus will develop a predisposition for adult disease. Gluckman and 
Hanson postulate reduction of foetal size is not the causal trigger but a non-
obligatory side effect of the adverse influence 161. Malnutrition is only one 
example of an adverse intrauterine influence that changes the receptiveness 
for adult disease 161-163. The foetal insulin hypothesis by Hattersley and Tooke 
focuses on a genetic explanation for the association between low birth weight 
and adult disease 164. They postulate genetic factors causing insulin 
resistance, affecting both prenatal growth and adult disease. 
 
IQ and psychosocial development 
Clinical studies in children born SGA have found a susceptibility for lower 
intelligence, poor academic performance, low social competence, and 
behavioural problems 165-171. Possible physiological explanations are 
intrauterine malnutrition affecting brain development or relative deficiency of 
the GH-IGF-1 axis 172-174. Intellectual and psychosocial capacity seem to be 
more reduced in case of an inadequate catch-up growth in height after being 
born SGA 171. It can be debated, however, whether persistence of short 
stature in SGA individuals is the key factor to this relationship, or just a 
coinciding factor 175-177. 
 
Growth hormone treatment 
In the early seventies growth hormone (GH) treatment was initiated as a 
treatment for short stature in children born SGA. Mainly due to the low 
frequency of administration and low dosage used, at that time, GH  
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treatment had little success 178. In the late eighties, however, it became 
apparent that daily GH treatment in a higher dosage caused a significant 
catch-up growth in height in short children born SGA at least on the short 
term 179-181. In 1991, a Dutch multi-centre randomised double-blind dose-
response trial (3 IU versus 6 GH/m2/day) was started to investigate the 
efficacy of GH treatment until final height. A previous report on this trial 
showed that five years of continuous GH treatment in short children born 
SGA resulted in a normalisation of height during childhood with a slightly but 
significantly better catch-up in height in the children of the higher dosage 
group 150. Interestingly, the SGA children diagnosed as partially growth 
hormone deficiency, who were also included in the trial, showed a similar 
catch-up in height as the non-GHD children born SGA 150. Recent reports on 
final height, however, are inconsistent 182, 183. 
During the first years of GH treatment, bone maturation accelerated during 
late childhood, similar to untreated SGA children of that age, resulting in 
either a normalisation of bone age or an advance 150, 184.  
Since low birth weight has been associated with the development of diabetes 
mellitus type 2 and cardiovascular disease in later life, it is important to 
monitor the effect of GH treatment on risk factors for these diseases in 
children born SGA. In other patient groups, it was shown that GH treatment 
increased post-prandial insulin levels, probably due to a reduction in insulin 
sensitivity 185. As expected, in SGA children a similar increase in insulin levels 
was found during GH treatment 186. In a previous report from the Dutch SGA 
trial the expected increase in insulin levels during GH treatment was not 
accompanied by higher fasting glucose levels 91.  
In the Dutch SGA trial mean systolic blood pressure was elevated before start 
of GH treatment and significantly decreased to normal during GH treatment, 
while mean diastolic blood pressure significantly decreased to the low normal 
range. This decrease resulted in a normal blood pressure during at least 6 
years of GH treatment, while lipid levels also showed a favourable change 154. 
In other patient groups, such as Turner syndrome, either a positive effect or 
no effect on blood pressure or lipid levels was found 47-50.  
It is generally assumed that catch-up in height due to GH treatment will have 
a positive psychosocial effect, but only a few GH studies in other patient 
groups included a psychosocial evaluation during GH treatment. The majority 
of these studies showed a positive psychosocial result of GH treatment 53, 187. 
The first data of the Dutch GH trial on intelligence and psychosocial 
functioning showed a significant increase during 2 years of GH treatment in 
total IQ-score, in ‘social acceptance’ scores, and in ‘general self-worth’ scores 
169, 188. 
 
Research questions and aims of the studies 
 
Short children born small for gestational age 
Previously, data analyses showed a positive effect of 5 years of GH treatment 
on height gain in prepubertal short children born SGA. We still, however, had 
to investigate whether GH treatment would lead to a normalisation of final 
height. In addition, to optimise individual treatment with GH in future, we 
wanted to know which parameters were important predictors for long-term 
growth response. Regarding side effects, we wanted to evaluate the effect of 
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discontinuation of GH treatment after long-term GH treatment on 
carbohydrate metabolism and several risk factors for the development of 
diabetes mellitus type 2 and cardiovascular disease (CVD) in later life.  
Regarding psychosocial development during long-term GH treatment, we 
wanted to know if and to what extent long-term GH treatment had an effect 
on intelligence, behaviour, and self-perception over the years and after 
reaching final height. 
To answer these research questions, the following aims were identified: 
 
1. Evaluation of the effect of long-term continuous GH treatment on 
final height in 54 short children born SGA without spontaneous catch-
up growth, treated in a randomised, double-blind, dose-response GH 
trial with either 3 or 6 IU GH/m2/day (1 or 2 mg/m2/day; 0.033 or 
0.067 mg/kg/day). 
2. Determination of variables that predict final height SD-score. 
3. Assessment of carbohydrate metabolism in short children born SGA 
after discontinuation of long-term GH treatment, compared to data 
before and during treatment.  
4. Investigation of several risk factors for the development of DM type 2 
and CVD by measuring blood pressure, body mass index and blood 
lipid levels in short children born SGA after discontinuation of GH 
treatment, compared to data before and during treatment. 
5. Longitudinal evaluation of IQ, behaviour, and self-perception in a 
group of short children born SGA at start, during and after long-term 
GH treatment. 
 
Outline of the thesis part SGA 
 
In this thesis part SGA results are presented of a randomised multi-centre 
dose-response GH trials evaluating the efficacy, safety and psychosocial 
effect of long-term GH treatment in short children born SGA without 
spontaneous catch-up growth. The trial included the first participants in 
1991.  
In Chapter 7 the field of SGA is introduced. Chapter 8 describes the effect of 
long-term continuous GH treatment on final height in 54 short children born 
SGA without spontaneous catch-up growth. In addition, a model with 
predictive factors for final height SD-score is presented. Chapter 9 describes 
carbohydrate metabolism and several risk factors for DM type 2 and CVD in 
short children born SGA during and after discontinuation of long-term GH 
treatment. Chapter 10 describes IQ, behaviour, and self-perception in short 
children born SGA during and after long-term GH treatment. Chapter 11 
discusses the results of the SGA trials in relation to other literature data and 
the implications of the results. In addition, it concludes and gives 
recommendations for future research. Chapter 12 summarises the SGA part 
of this thesis in English and Dutch. 
 
Previous dissertations 
 
W. de Waal published baseline and first-year results of the study in his thesis 
entitled “Influencing the extremes of growth”, Rotterdam 1996. I. van der 
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Reyden-Lakeman presented results on IQ and psychosocial functioning during 
the first two years of GH treatment in her thesis entitled “Growing pains? 
Psychological evaluation of children with short stature after intrauterine 
growth retardation, before and after two years of growth hormone 
treatment”, Rotterdam 1996. Th. C.J. Sas, in his thesis entitled “Long-term 
growth hormone treatment in two growth disorders”, Rotterdam 1999, 
described 7-year data of the TS trial and 5-year data of the SGA trial.  
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Part ‘Small for Gestational Age’: Final height after long-term, 
continuous GH treatment in short children born small for gestational 
age (SGA): Results of a randomised, double-blind, dose-response GH 
trial
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Abstract 
 
The GH-dose-response effect of  long-term continuous growth hormone (GH) 
treatment on final height was evaluated in 54 short children born SGA, 
participating in a randomised double-blind dose-response trial. Patients were 
randomly and blindly assigned to treatment with either 3 IU (group A) or 6 IU 
GH/m2/d (group B)(~0.033 or 0.067 mg/kg/d, resp.). Mean (SD) birth 
length was –3.6 (1.4), age at start 8.1 (1.9) years and height SD-score at 
start  –3.0 (0.7). Seventeen of the 54 children were partially GH deficient 
(stimulated GH peak 10-20 mU/l). Fifteen non-GH treated, non-GH deficient, 
short children born SGA, with similar inclusion criteria, served as controls 
(mean (SD) birth length –3.3 (1.2), age at start 7.8 (1.7) years and height 
SD-score at start –2.6 (0.5)). 
GH treatment resulted in a FH above -2 SD-score in 85% of the children after 
a mean (SD) GH treatment period of 7.8 (1.7) years. Mean (SD) FH SD-score 
was -1.1 (0.7) for group A and -0.9 (0.8) for group B, resulting from a mean 
(SD) gain in height SD-score of 1.8 (0.7) for group A and 2.1 (0.8) for group 
B. No significant differences between group A and B were found for FH SD-
score (mean difference 0.3 SD-score; 95% CI: -0.2, 0.6; p>0.2) and gain in 
height SD-score (mean difference 0.3 SD-score; 95% CI: -0.1, 0.7; p>0.1). 
When corrected for target height (TH), mean corrected FH SD-score was –0.2 
(0.8) for group A and –0.4 (0.9) for group B. Mean (SD) FH SD-score of the 
control group (–2.3 (0.7)) was significantly lower than that of the GH-treated 
group (p<0.001). Multiple regression analysis indicated the following 
predictive variables for FH SD-score: TH SD-score, height SD-score and CA 
minus BA (yrs) at start. GH dose had no significant effect. 
In conclusion, long-term continuous GH treatment in short children born SGA 
without signs of persistent catch-up growth leads to a normalisation of final 
height, even with a GH dose of 3 IU/m2/d (~ 0.033 mg/kg/d).  
 
Introduction 
 
To be born small-for-gestational-age (SGA) may have considerable 
consequences. Not only a significantly increased risk for reaching a final 
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height below - 2 SD score has been reported 143. There might also be an 
increased risk for diabetes mellitus type 2 and cardiovascular disease as has 
been described in adults who were born with a low birth weight 190. It is yet 
unclear if this will also concern SGA patients with persistent short stature, as 
no distinction was made for those who had a complete catch-up growth in 
height after birth and those with a persistent short stature.  
During the first two years of life about 10% of the children born SGA do not 
catch-up to a height above the - 2 SD-score. The majority of these children 
will reach a final height below - 2 SD-score 140, 143. The reason for these 
children remaining short is not completely understood. Sixty percent of short 
children born SGA have low serum growth hormone (GH) levels during a 24-
hour GH profile, but no relation was found between physiological GH levels 
and the growth response during GH treatment 145, 150, 191. There are several 
theories to explain their persistent short stature. One suggests that it is the 
result of a reduced sensitivity for growth factors, another suggests that it 
might be influenced by intrauterine re-programming or genetic background 
164, 192, 193. Recent studies have demonstrated that 5 years of GH treatment in 
short children born SGA results in a normalisation of height during 
childhood.150, 184 Final height results after long-term, continuous GH 
treatment, however, have not yet been published. 
In this article we present final height results of 54 short children born SGA 
who have been treated in a randomised, double-blind, dose-response GH trial 
evaluating the efficacy and safety of long-term, continuous GH treatment 
with either 3 or 6 IU GH/m2/day (0.033 or 0.067 mg/kg/day).   
 
Patients and Methods 
 
Study group 
Seventy-nine prepubertal short children born SGA participated in a multi-
centre double-blind randomised dose-response GH trial.  Of these 79 children 
6 children dropped out of the study for the following reasons: lack of 
motivation despite ongoing catch-up growth (n=4), treatment for precocious 
puberty (n=1), and biochemical signs of GH insensitivity (n=1). As these six 
children were lost to follow-up, their data were not included in the analysis. 
Of the remaining 73 children, 54 children reached final height and their data 
were evaluated for this study, whereas 19 children were not included because 
they had not yet reached final height. Those who had attained final height 
were approximately 3 years older at start of GH treatment compared to those 
who were still growing (mean (SD) CA 8.1 (1.9) years versus 5.4 (1.9) years, 
p<0.001), but the other clinical characteristics were similar at start of GH 
treatment (Table 1).  
The dose-response GH trial evaluated the effect of two dosages of GH, 3 or 6 
IU GH/m2 body surface/d (~ 0.033 or 0.067 mg/kg /d) on long-term growth 
and ultimately on FH. Inclusion criteria were: 1) birth length SD-score below 
-1.88 141, 2) chronological age (CA) between 3 and 11 year in boys and 3 and 
9 year in girls at start of study, 3) height SD-score for CA (height SD-score) 
below -1.88 62, 4) height velocity SD-score for CA ≤ zero 62 to exclude 
children presenting spontaneous catch-up growth, 5) prepubertal stage, 
defined as Tanner breast stage 1 for girls and a testicular volume of less than 
4 ml for boys 63, 6) uncomplicated neonatal period, that is without signs of 
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severe asphyxia (defined as an Apgar score below 3 after 5 minutes), without 
sepsis neonatorum and without long-term complications of respiratory 
ventilation. Exclusion criteria were: endocrine or metabolic disorders, 
chromosomal disorders, growth failure caused by other disorders (emotional 
deprivation, severe chronic illness, chondrodysplasia) or syndromes (except 
for Silver-Russell syndrome (SRS)) and previous or present use of drugs that 
could interfere with GH treatment. Twenty-seven of the 79 patients had 
partial GH-deficiency (GHD), which was defined as a maximal peak GH 
secretion between 10 and 20 mU/L during 2 GH provocation tests or during 
one provocation test and a 24-hour GH profile.65, 145  
The GH trial started in 1991 and was approved by the Ethics Committees of 
the four participating centres in the Netherlands. Due to ethical 
considerations the Ethics Committees did not allow for a control group until 
FH. Written informed consent was obtained from the parents or custodians of 
each child.  
 
Control group 
In 1990, 107 children, born in three academic hospitals with a birth length 
below –1.88 SD-score in the same time period as the GH-treated group 
(1980 until 1989) were included in a cohort study to evaluate natural growth 
in SGA children with short stature at the age of two years.140 Fifty-nine 
children were lost, due to either start of GH treatment (n=21), treatment for 
precocious puberty (n=1), spastic paraplegia (n=1), or lack of motivation or 
moving abroad (n=36). During the inclusion period of the GH trial twenty-
nine children met the inclusion criteria of our GH trial, including persistent 
short stature without signs of catch-up growth (HV SD-score < 0), but they 
remained untreated because their paediatrician did not participate in the GH 
trial. None of these children were GH deficient. This group was followed as 
control group for the GH trial. In 2001, fifteen children had reached FH and 
served as controls for comparison of growth and FH of the 54 GH-treated 
children. 
 
Design dose-response GH trial 
After stratification for chronological age (CA) and spontaneous GH secretion 
during a 24-hour GH profile 79 children were randomly and blindly assigned 
to one of two GH dosage groups: group A, 3 IU/m2/day, or group B, 6 
IU/m2/day (~ 0.033 or 0.067 mg/kg/day, respectively) 145, 150. The inclusion 
period started in April 1991 and ended in January 1993. Biosynthetic GH (r-
hGH Norditropin®, Novo Nordisk A/S, Denmark) was given subcutaneously 
once daily at bedtime with a pen injection system (Nordiject 24). Every 3 
months the total GH dose was adjusted to the calculated body surface. To 
ensure the double-blind design an equal volume of a reconstituted 
preparation was used.  
 
Growth evaluation 
During 11 years one physician (from ‘91-‘95 W de Waal, ‘95-‘98 Th Sas, ‘98-
’02 YvPareren) examined all children every three months and measured 
height according to Cameron using a Harpenden stadiometer.194 Four 
measurements per visit were taken and the mean was used for analysis. 
Height was expressed as SD-score for chronological age (CA) (height SD-
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score).62 Target height (TH) was adapted from Dutch reference data with 
addition of 3 cm for secular trend: 1/2 x (Heightfather + Heightmother + 12) 
+ 3 for boys and 1/2 x (Heightfather + Heightmother - 12) + 3 for girls.62 TH 
and body mass index (BMI) were expressed as SD-score using Dutch 
references.62 Target height range was defined as the mean TH +/- 2SD. Bone 
age (BA) was determined by the same investigators (‘91-‘98 ThS, ‘98-’01 
YvP) according to Tanner & Whitehouse radius, ulna, short-bones score (RUS 
TW-2).66 Bone maturation was expressed as the ratio of the change in BA to 
the change in CA (dBA/dCA). The difference between CA and BA was 
calculated as CA minus BA (CA-BA) in years. The same investigators 
assessed pubertal stage according to Tanner, using an orchidometer in boys. 
Start of puberty was defined as a Tanner breast stage 2 in girls and a 
testicular volume of 4 ml in boys.63  
 
Definition of final height 
Final height (FH) in GH-treated children was defined as the condition when 
height velocity (HV) had dropped below 0.5 cm during the previous 6 months 
and bone age was ≥ 15 years for girls and ≥ 16.5 years for boys. FH was 
reached either during GH treatment or during the 2-year follow-up after 
discontinuation of GH treatment. Corrected FH was calculated by subtracting 
the target height SD-score from the FH SD-score. GH treatment was 
discontinued after reaching FH or on patient’s decision at near final height 
(near FH), which was defined as a HV ranging between 0.5 and 2 cm during 
the previous 6 months. For the control group FH was defined as the condition 
when CA and/or BA had reached 18 years for boys and 16 years in girls.  
 
Biochemical parameters 
Before start and after discontinuation of GH treatment a standard arginine 
tolerance test (ATT) was performed.145 A standard oral glucose tolerance test 
(OGTT) was done at start of GH treatment and after six years of GH 
treatment.91 At start of GH treatment and during the dose-response GH trial 
additional blood samples were taken for determination of plasma levels of 
IGF-I and haemoglobin A1c levels. Plasma levels of IGFBP-3 were determined 
at start of GH treatment, after the first and second year and after the fifth 
year of GH treatment. After centrifugation, all samples were frozen (-20ºC) 
until assayed. 
 
Hormone Assays 
RIA measurements of plasma GH, IGF-I, IGFBP-3, and insulin were 
performed as described previously.69, 195-197 All measurements were 
performed in the same laboratories. Since plasma levels of both IGF-I and 
IGFBP-3 are dependent on age and sex, values were transformed to SD 
scores using reference values for healthy children determined in the same 
laboratory.70 
 
Statistical analyses 
To maintain the double-blind design until all participants have reached FH, an 
independent statistician (PM) performed the statistical analyses and 
summarized the results per treatment group in such a way that it was 
impossible for the investigator to identify individual patients. Accordingly, 
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data are expressed as mean (SD) values unless otherwise specified. 
Differences in continuous variables were tested by paired Student's t-tests. 
Differences between zero and SD-score values at various time-points during 
the study were tested by one-sample Student's t-tests. Differences between 
groups were tested using a Student's two-sample t-test. To test for 
relationships between continuous variables correlations were estimated, after 
adjustment for GH dosage. Multiple linear regression analyses were used to 
construct the best model for predicting final height SD-score. For this 
purpose, the variables GH dose, TH SD-score, height SD-score at start of GH 
treatment, the difference CA-BA at start of GH treatment, birth length SD-
score, gender, CA at start, bone maturation during the first year, age at 
onset of puberty and BMI SD-score at start were tested. A p-value < 0.05 
was considered significant. All calculations were executed in SPSS version 
9.0. 
 
Results 
 
GH trial 
Fifty-four children reached final height (FH) after a mean (SD) GH treatment 
period of 7.9 (1.7) years for group A and 7.5 (1.7) for group B. Pretreatment 
clinical data are listed in Table 1 for the total group and for the 54 children 
who reached final height (FH). Both groups had similar clinical characteristics 
at start of GH treatment, except for the age at start. 
 
Final height   
GH treatment resulted in a mean (SD) FH SD-score of -1.1 (0.7) for group A 
(3 IU/m2/day) and -0.9 (0.8) for group B (6 IU/m2/day) (Table 2). In both 
groups, FH SD-score was significantly higher compared to height SD-score at 
start of GH treatment (P<0.0001). The difference in FH SD-score between 
groups A and B did not reach significance (mean difference 0.3 SD-score; 
95% CI: -0.2, 0.6; p=0.3). Figure 1 gives the height SD-score at start, after 
2 and 5 years of GH treatment and at final height, and the gain in height SD-
score from start until FH. Mean (SD) gain in height SD-score from start until 
FH was not significantly different for group A (from -2.9 [0.8] at start to -1.1 
[0.7]) compared to group B (from –3.0 [0.7] to –0.9 [0.8]; mean difference 
0.3 SD-score; 95% CI: -0.1, 0.7; p=0.1). Table 2 lists the height SD-score 
throughout the study, TH SD-score, FH SD-score and the corrected FH SD-
score (FH SD-score minus TH SD-score). The mean (SD) TH SD-score was 
almost significantly lower for group A (–0.9 [1.0]) than for group B (–0.5 
[0.9]; mean difference 0.5; 95% CI: 0.1, 1.0; p=0.08). As a result the mean 
(SD) corrected FH SD-score was not significantly different between group A 
(-0.2 [0.8]) and group B (-0.4 [0.9]; mean difference 0.2; 95% CI: -0.2, 
0.7; p=0.2). Figure 2 shows the corrected height SD-score at the various 
time-points of the study. At start and after 2 years of GH treatment, the 
corrected height SD-score was significantly lower than zero for groups A and 
B (p<0.001, p<0.001). At final height the corrected height SD-score was 
comparable to zero for group A, but lower for group B (p<0.05). For boys, 
both TH SD-score and FH SD-score were significantly higher for group B than 
for group A (p<0.01, p<0.05, p<0.05, respectively)(Table 2).  
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TABLE 1. Baseline clinical data for the total group of 79 short children born 
SGA and for the 54 children who reached final height  
 
 
Total group 
N= 79 
Final height group 
N=54 
 
Group A 
(N=41) 
Group B 
(N=38) 
Group A 
(N=28) 
Group B 
(N=26) 
Male/Female 31/10 21/17 18/10 14/12 
Gestational age (wk) 37.3 (3.2) 36.0 (4.1) 37.1 (3.4) 36.2 (4.3) 
Birth length SD-score -3.6 (1.4) -3.7 (1.7) -3.5 (1.3) -3.6 (1.5) 
Birth weight SD-score -2.6 (1.2) -2.6 (1.0) -2.6 (1.1) -2.6 (0.8) 
Chronological Age (yr) 6.6 (2.4) 6.7 (2.9) 7.9 (1.9)* 8.2 (1.9)* 
Height SD-score -3.0 (0.7) -3.1 (0.7) -2.9 (0.8) -3.0 (0.7) 
Height velocity SD-
score 
-0.7 (1.1) -1.2 (1.3) -0.6 (1.1) -1.4 (1.4) 
Data expressed as mean (SD). *p < 0.001, mean (SD) CA of  54 children with FH (8.1 
(1.9)) versus 19 who were still growing (5.4 (1.9)) 
 
 
FIGURE 1. (Bottom panel) Height SD-score (+SD) during GH treatment and at final 
height, in relation to  target height (TH); (Top panel) Gain in height SD-score (+SD) from 
start until 2 years of GH treatment, until 5 years of GH treatment, and until final height 
(FH). Group A (white bar) and group B (black bar). 
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For girls, however, no difference was found for TH SD-score and FH SD-score 
between groups A and B (p>0.1). 
Final height of non-GH deficient versus partially GH deficient SGA children 
Final height SD-score of the non-GHD children was –1.1 (0.8) for group A 
and –0.9 (0.8) for group B, compared to –1.2 (0.7) for group A and –0.9 
(0.7) for group B in the partially GHD children (Table 2). Mean height gain 
SD-score of the non-GHD children was 1.9 (0.8) for group A and 2.1 (0.8) for 
group B, compared to 1.8 (0.5) for group A and 2.2 (0.6) for group B in the 
partially GHD children. Final height SD-score as well as height gain SD-score 
were not significantly different between the non-GHD and the partially GHD 
SGA children, even when corrected for GH dose and TH SD-score.  
 
Puberty 
Mean (SD) age at onset of puberty for boys was 11.7 (0.9) years in group A 
and 11.8 (0.7) years in group B, and for girls 10.9 (1.1) years in group A and 
10.8 (1.1) in group B, without significant differences between the GH dosage 
groups (p>0.1 for both sexes). For boys, the mean age (SD) at final height 
was 16.8 (0.9) years in group A versus 16.9 (1.1) years in group B, and for 
girls 14.8 (0.8) years versus 15.1 (1.2) years in groups A and B, 
respectively. The age at final height was not different between the GH dosage 
groups (p>0.1 for both sexes). Mean duration of puberty (from start of 
puberty until FH) for boys was 5.1 (1.2) years in group A and 5.2 (1.0) years 
in group B, and for girls 3.9 (1.0) years in group A and 4.3 (1.1) years in 
group B. 
 
Bone maturation 
The average bone maturation expressed as delta BA / delta CA per year, was 
throughout the study significantly higher than 1, regardless of GH dosage. 
During the first year of GH treatment median (range) bone maturation was 
1.5 (0.6-2.7) year for group A and 1.1 (0.2-3.2) years for group B. From 4 to 
5 years of GH treatment bone maturation was 1.1 (0.3-2.5) years for group A 
and 1.0 (0.3-2.2) year for group B, and from 5 years until discontinuation of 
GH treatment bone maturation was 1.0 (0.3-1.6) for group A and 1.1 (0.4-
1.7) for group B. The average difference between CA and BA (CA minus BA) 
at start of GH treatment, at 5 years of GH treatment, and at discontinuation 
of GH treatment was  0.5 (1.1), -1.0 (1.1), and -1.1 (1.1) respectively, 
without significant differences between groups A and B.   
 
GH, IGF-I and IGFBP-3 
The non-GHD SGA children who attained FH had at start of GH treatment a 
mean (SD) maximal GH peak during GH provocation test of 28.7 (11.5) 
mU/L, a mean (SD) GH peak during the 24-h GH profile of 37.2 (16.1) mU/L 
and mean IGF-1 SD-score of –0.5 (0.8). Seventeen of the 54 SGA children 
who attained FH had a maximal GH peak between 10 and 20 mU/L. In these 
partially GHD SGA children mean (SD) maximal GH peak during GH 
provocation test, GH peak during the 24-h GH profile, and mean IGF-1 SD-
score at start were 13.0 (5.8) mU/L, 20.9 (8.5) mU/L, and –1.8 (1.2), 
respectively, all being significantly lower than in the non-GHD SGA children 
(p<0.001, p<0.01, p<0.001, respectively). 
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TABLE 2. Final height SD-score and other auxological data in 54 SGA children at various time-points during the study. 
 
 
All children 
SGA 
Non-GH deficient 
SGA 
Partially GH deficient SGA 
 
         
 
(n=28) 
Group A 
(n=26) 
Group B 
(n=17) 
Group A 
(n=20) 
Group B 
(n=11) 
Group A 
(n=6) 
Group B 
Duration of GH treatment 7.9 (1.7) 7.5 (1.7) 8.1 (1.9) 7.6 (1.8) 7.7 (1.5) 7.2 (1.2)
Height SD-score       
          
          
           
          
         
       
At start 
 
-2.9 (0.8) -3.0 (0.7) -2.9 (0.7) -3.0 (0.8) -3.0 (0.8) -3.1 (0.3)
2 years -1.5 (0.7) -1.3 (0.7) -1.5 (0.7) -1.3 (0.8) -1.5 (0.7) -1.3 (0.3)
5 years
 
-0.7 (0.7) -0.7 (0.8) -0.7 (0.7) -0.6 (0.8) -0.8 (0.6) -0.9 (0.7)
FH -1.1 (0.8) -0.9 (0.8) -1.1 (0.8) -0.9 (0.8) -1.2 (0.7) -0.9 (0.7)
Corrected height SD-score     
(Height SD-score – TH 
SD-score) 
 
At start -2.0         
          
           
            
         
(0.9) -2.6 (0.8)* -2.2 (0.9) -2.7 (0.9) -1.9 (0.9) -2.2 (0.4)
2 years -0.6 (0.9) -0.8 (0.8) -0.7 (1.0) -1.0 (0.9) -0.4 (0.9) -0.3 (0.4)
5 years
 
0.2 (0.8) -0.2 (1.0) 0.1 (0.9) -0.3 (1.1) 0.4 (0.8) 0.0 (0.4)
FH -0.2 (0.8) -0.4 (0.9) -0.3 (0.8) -0.6 (1.0) -0.1 (0.7) 0.0 (0.2)#
Target height SD-score  -0.9 (1.0) -0.5 (0.9) -0.8 (1.0) -0.3 (0.9) -1.1 (0.9) -0.9 (0.6)
Final height (cm)              
 Boys           
          
        
169.3 (6.7) 173.7 (5.8) - - - - - - - -
Girls 160.1 (3.1) 159.2 (4.0) - - - - - - - -
Pubertal height gain (cm)     
          
          
Boys 27.3 (7.6) 30.0 (5.3) - - - - - - - -
Girls 18.8 (6.9) 19.4 (5.8) - - - - - - - -
Data expressed as mean (SD). FH: final height. TH: target height. Data on Final height (cm) and Pubertal height gain (cm) for non-GHD 
versus GHD are not shown due to the small number of children in each subgroup. 
*p < 0.05, Group A versus Group B; # p < 0.05, non-GH deficient versus partially GH deficient children 
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The changes in IGF-I SD-score and IGFBP-3 SD-score of the total group 
during 5 years of GH treatment were described previously 150. At 
discontinuation of GH treatment, mean IGF-I SD-score was 1.0 (1.1) for 
group A and 1.3 (1.2) for group B, being significantly different to zero for 
both groups (p<0.001 for both). Mean IGFBP-3 SD-score at discontinuation 
of GH treatment was –0.8 (0.9) for group A and –0.06 (0.7) for group B, 
being significantly lower than zero for group A only (p<0.001). Only for 
IGFBP-3 SD-score the difference between group A and B at discontinuation of 
GH treatment was significant (p<0.01).  
 
Predictors for final height 
All correlations were done for groups A and B together, after adjustment for 
GH dose, although no significant differences in FH SD-score and gain in 
height SD-score were found between groups A and B. FH SD-score correlated 
positively with height SD-score at start of GH treatment (r=0.49, p<0.001), 
with TH SD-score (r=0.49, p<0.001), and pre-treatment HV SD-score 
(r=0.32, p<0.05). FH SD-score was not significantly related to the following 
variables: CA and BA at start of GH treatment, birth length SD-score, 
maximal GH peak during ATT, characteristics of the 24-hour GH profiles, IGF-
I SD-score values at start of GH treatment, and the increment in IGF-I SD-
score during the first year of GH treatment.  
The gain in height SD-score from start of GH treatment until FH had a 
negative correlation with CA and BA at start of GH treatment (r=-0.36, 
p<0.01; r=-0.46, p<0.01, respectively). Birth length SD-score, TH SD-score, 
pre-treatment HV SD-score, IGF-I SD-score at start of GH treatment, the 
increase in IGF-I SD-score, mean maximal plasma GH response during ATT, 
and the characteristics of the 24-hour GH profiles did not correlate 
significantly with the gain in height SD-score from start of GH treatment until 
FH. 
Multiple regression analysis showed that a model, using the variables TH SD-
score, height SD-score at start of GH treatment, the difference CA-BA at start 
of GH treatment and the GH dose accounted for 42% (residual SD 0.60) of 
the variation in FH SD-score. Table 3 shows the results of the multiple 
regression analysis. Variables, which showed a non-significant effect on FH 
SD-score were gender, CA at start, bone maturation during the first year, age 
at onset of puberty, BMI SD-score at start, birth length SD-score, and GH 
dose. The model provided the following equation: Final height SD-score = 
0.02 + 0.29 x TH SD-score + 0.42 x height SD-score at start + 0.20 x (CA-
BA in years) at start + 0.07 x GH dose.  
 
Safety 
Treatment was well tolerated and no adverse events were detected that were 
considered to be GH-related. Our group has recently published 6-year results 
on fasting and stimulated glucose and insulin levels during an oral glucose 
tolerance test 91. In short, continuous GH treatment over a 6-year period 
showed no adverse effects on glucose levels. GH treatment induced higher 
fasting insulin levels and glucose-stimulated insulin levels, indicating relative 
insulin resistance. No significant differences between the two GH-dosage 
groups were found. None of the children developed diabetes mellitus.  
 
CHAPTER 8   Part ‘Small for Gestational Age’: Final height after long-term GH treatment 
FIGURE 2. Corrected height SD-score (+SD) during GH treatment and at final height (FH) 
for group A (white bar) and group B (black bar). 
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TABLE 3. Multiple regression analysis on final height SD-score. 
 
Independent  
Variable 
Regression 
Coefficient 
SE P-value 
TH SD-score 0.29 0.10 < 0.01 
Height SD-score at start  0.43 0.14 < 0.01 
Difference CA-BA at start (yr) 0.20 0.08 < 0.05 
GH Dose  
(3 vs 6 IU/m2/day) 
0.07 0.06 0.2 
TH: target height; SE: standard error; CA: chronological age; BA: bone 
age. Regression equation: FH SD-score = 0.02 + 0.29 x TH SD-score + 
0.43 x height SD-score at start + 0.20 x (CA-BA) at start + 0.07 x GH 
dose. 
 
 
TABLE 4. Examples of predicted final height SD-score resulting from the 
regression model. 
 
 
TH SD-score 
= 0 
 TH SD-score 
= -1 
 
TH SD-score 
= -2 
GH dose 
(IU/m2/day) 
3 6  3 6  3 6 
Height SD-
score at start 
        
-2 -0.6 -0.4  -0.9 -0.7  -1.2 -1 
-3 -1 -0.8  -1.3 -1.1  -1.6 -1.4 
-4 -1.5 -1.3  -1.8 -1.5  -2 -1.8 
TH: target height. 
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Control group  
The control group, 15 children (5 boys, 10 girls), had a mean (SD) birth 
length SD-score of –3.3 (1.2), birth weight SD-score of –2.7 (0.7) and a 
mean (SD) gestational age of 34.3 (2.3) weeks. At inclusion in the control 
group, mean (SD) age was 7.8 (1.7) years, height SD-score –2.6 (0.5), TH 
SD-score –1.1 (1.0) and corrected height SD-score –1.5 (0.9). No significant 
difference was found between the GH-treated group and the control group 
regarding pretreatment clinical characteristics except for gestational age 
(p<0.05).  
 
Final height of GH-treated versus control group 
The control group attained a mean (SD) FH SD-score of  –2.3 (0.7), after a 
mean (SD) follow-up of 7.5 (1.2) years from inclusion in the control group 
until FH. The mean (SD) gain in height SD-score until FH was 0.3 (0.7) SD-
score and the corrected FH was –1.2 (0.6) SD-score. Mean FH SD-score, gain 
in height SD-score until FH and corrected FH SD-score were all significantly 
lower than in the GH-treated group (mean differences [95% CI]: 1.3 [0.9, 
1.8], 1.7 [1.3, 2.3], 0.9 [0.4, 1.4], respectively; p<0.001 for all). 
 
Discussion 
 
Our study shows that in short children born SGA long-term continuous 
treatment with GH results in a normalisation of height during childhood and a 
normalisation of final height (FH) in most children. After a mean duration of 
7.8 years children treated with 3 IU GH/m2/day (group A) attained a mean 
(SD) FH SD-score of -1.1 (0.7), whereas those treated with 6 IU GH/m2/day 
(group B) attained a mean FH SD-score of –0.9 (0.8). GH treatment resulted 
in a FH within the normal range (above –2.0 SD-score) in 85% of the 
children and a FH within the target height range in 98%. Interestingly, FH 
SD-score was not significantly different between the two GH-dosage groups. 
Also, the mean gain in height SD-score from start of treatment until FH, 
being 1.8 (0.7) SD-score (~ an improvement of 12 cm for boys and 11 cm 
for girls) for group A and 2.1(0.8) SD-score (~ an improvement of 14 cm for 
boys and 13 cm for girls) for group B, were not significantly different 
between the two GH-dosage groups. 
When we corrected FH SD-score for TH SD-score, because group A had a 
significantly lower TH SD-score than group B, the mean corrected final height 
SD-score (FH SD-score minus TH SD-score) proved to be comparable for 
group A (-0.2[0.8]) and group B (-0.4 [0.9]). This means that when FH SD-
score was corrected for the genetic potential (TH), children who had been 
treated with the lower GH dose of 3 IU/m2/day had the same results. Our 
study shows that 98% of short children born SGA treated with long-term GH 
reached a final height within their target height range. 
Two non-randomised studies reported on final height in a group of short 
children born SGA with growth hormone deficiency (GHD).182, 183 They found 
a mean height SD-score gain from start until final height of 0.5 and 0.9 SD-
score, which is much lower than we now report. There are, however, several 
factors that can explain the discrepancy between their results and ours. Their 
children were older (10.9 and 10.7 years) at start and were treated for a 
much shorter period than our children (4.6 years for both studies). In 
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addition, in the study by Coutant et al. children were treated with a wide 
range of GH dosages and with a low mean GH dose of 1.8 IU/m2/day 
(=almost half of our lowest GH dose).  
As including a randomised control group as part of our GH trial until FH was 
not allowed by the Medical Ethics Committees, we compared our GH-treated 
patients with a longitudinally followed control group with the same inclusion 
criteria and age as the GH-treated patients at start of treatment who did not 
receive GH treatment because the paediatrician did not participate in the GH 
trial. The control group attained a mean (SD) final height SD-score of  –2.3 
(0.7), had a mean gain in height SD-score of 0.3 (0.7) until FH during the 
follow-up period of 7 ½ years and a corrected FH of –1.2 (0.6) SD-score. 
These data show that compared to untreated short children born SGA, those 
treated with GH significantly gained in final height SD-score. The proportion 
of girls in the control group, however, was larger than in the GH groups. It is 
unlikely this will affect the results as we show FH, expressed as SD-score, did 
not differ between genders.  
Our study demonstrates that most children reached a normal height after the 
first years of GH treatment and remained in the normal range until final 
height. This means that most of them had a normal height during childhood 
and puberty. At the end of GH treatment a slight decrease in height SD-score 
was found in comparison with height SD-score after 5 years of GH treatment. 
Possible explanations for this decline might be an early onset of puberty, 
short duration of puberty, and/or an acceleration of bone maturation. This 
would lead to attainment of final height at a relatively young age in 
comparison with peers, and/or a reduced pubertal height gain. We found, 
however, that for both GH dosage groups, mean age at onset of puberty was 
comparable to normal Dutch children (median age for healthy boys is 11.5 
years and for girls 10.7 years), whereas from the onset of puberty until final 
height the mean pubertal height gain was 29.8 cm for boys and 18.9 cm for 
girls 9. In accordance, during puberty, no acceleration of bone maturation 
was found until discontinuation. Previous publications have shown, however, 
that untreated children born SGA start their pubertal growth spurt earlier 
than normal children.148, 198 We found that the difference between CA and BA 
(CA-BA) after 5 years of GH treatment was -1.0, indicating a 1-year bone age 
advance. This might explain the slight decrease in height SD-score. As we 
found no significant difference between the two GH dosage groups, it is 
unlikely that the 1-year bone age advance was related to the GH treatment. 
Another factor that might explain the decrease in height SD-score is that 
some of the children did not reach their full height potential because they 
stopped GH treatment at near-final height.  
 Final height SD-score, when corrected for GH dosage was higher in children 
with the highest TH SD-score and height SD-score at start of GH treatment. 
Although age at start was weekly correlated with height gain from start until 
FH, it was not associated with FH SD-score. Why other studies did find an 
association might be explained by the fact that they started treatment at a 
later mean CA, which implied a shorter duration of GH treatment (4.6 years) 
until FH than in our group.182 On the long-term, other factors that influence 
FH (i.e. genetic background) might become more important. In our opinion, 
however, this should not lead to postponing GH treatment until puberty. Not 
only would the treatment period then be too short, but also the important 
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advantages of a normal height during childhood and adolescence would be 
lost. 
The GHD children included in our study were not severely GHD but only 
partially GHD. Their growth and FH results were similar to those without 
GHD. Also, in the total study group no correlation was found between 
spontaneous or stimulated GH secretion before start of GH treatment and FH 
SD-score or gain in height SD-score. Our findings agree with other reports 
showing no association between response to GH treatment and GH status 
before start 199, 200. This indicates that GH treatment is effective in short 
children born SGA, leading to a normal FH for most of them, regardless of the 
GH status at start.  
The recommended GH dose will depend on the ultimate goal one aims for in 
short children born SGA. First of all, one might aim for a normal FH, meaning 
a FH above –2 SD-score. Secondly, one could set out for a FH within the 
target height range SD-score. To visualize the effects of each of these goals 
on the decision of which GH dose to use, we constructed a prediction model 
(Table 3). The prediction model for FH SD-score shows that several variables 
influence FH SD-score: TH SD-score, height SD-score at start, and the 
difference CA-BA at start. For all these variables a higher value predicts an 
increment in FH SD-score. These variables are not surprising as they have 
also been found to predict height gain and final height in other patient 
groups, but it indicates that similar factors play a role in response to GH 
treatment in short SGA children 102, 201. Suppose a child born SGA starts GH 
treatment when he or she has a persistent short height of –2 SD-score and 
no bone age delay (CA-BA = 0) (Table 4). Our model then predicts that when 
this child has an average TH SD-score (TH SD-score = 0) it would achieve a 
FH of –0.6 SD-score after a dose of 3 IU GH/m2/day (95% prediction interval 
[PI] between –1.8 and 0.6 SD-score). For a child with a TH SD-score of –2, 
treated with the same GH dose, the predicted FH would be –1.2 SD-score 
(95% PI between –2.4 and 0). When one chooses the first goal, a final height 
above –2 SD-score, both children can be given 3 IU GH/m2/day. When one 
decides on the second goal, a final height near the target height SD-score, a 
higher GH dose of 6 IU GH/m2/day might be considered for a child with a 
higher target height SD-score. Our model, however, shows that by giving the 
child with a TH of 0 SD-score the higher dose, the predicted FH SD-score 
would only increase by 0.2 SD-score (–0.4 SD-score with 95% PI between –
1.6 and 0.8), while doubling the costs of treatment. Another possible reason 
for considering a higher GH dose could be when the child is very short at 
start of GH treatment. The model shows that, using the same values as 
before (no BA delay and TH SD-score=0), a child with a height SD-score at 
start of GH treatment of –3 would reach a FH SD-score of –1.0 (95% PI 
between –2.2 and 0.2) when using the low dose, and –0.8 SD-score (95% PI 
between –2.0 and 0.4) when using the high dose of GH. As before, the 
difference in final height would be quite small, while doubling the costs of 
treatment. Obviously, one should keep in mind that the model only predicts 
42% of the difference in FH, leaving 58% of the variation to be explained by 
other factors, such as genetic background.164, 193 For that reason, larger 
numbers of GH-treated short SGA children with detailed phenotypic and 
genetic data are required to allow for a prediction model with a higher 
predictive value.  
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In conclusion, long-term, continuous GH treatment in short children born 
SGA leads to a normalisation of height in childhood and adolescence. Eighty-
five percent will reach a normal final height, whereas 98% will reach a final 
height within their target height range. Based on our study we recommend 
considering GH treatment for short SGA children without signs of persistent 
catch-up growth and who are therefore at risk of significant height disability 
as adults. Interestingly, a dose of 3 IU/m2/day proved to be as effective as 
the higher GH dose of 6 IU/m2/day, for most children. Only children with 
extreme short stature or/and a target height below the normal range may 
need a higher GH dose to normalize height during childhood and in 
adulthood. Further studies should aim at optimizing GH treatment by 
developing advanced prediction models indicating the best treatment options 
for each child.        
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CHAPTER 9 
 
Part ‘Small for Gestational Age’: Effect of discontinuation of GH 
treatment on risk factors for cardiovascular disease in adolescents 
born small for gestational age 
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Effect of discontinuation of GH treatment on risk factors 
for cardiovascular disease in adolescents born small for 
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Abstract 
 
Hyperlipidaemia, diabetes mellitus type 2, and coronary heart disease have 
been associated with being born small for gestational age (SGA). It has been 
reported that GH treatment induced higher insulin levels, which has lead to 
concern regarding long-term effect of GH treatment in predisposed 
individuals such as children born SGA. In this study, we assessed the effect 
of discontinuation of long-term GH treatment in 47 adolescents born SGA on 
oral glucose tolerance tests, blood pressure (BP), and serum lipid levels, for 
two GH dosage groups (3 versus 6 IU/m2/day).  
At 6 months after discontinuation of GH treatment mean (SD) age was 16.0 
(2.1) years. Mean duration of GH treatment had been 6.9 (1.5) years. 
Fasting glucose levels and 120-minute area under the curve (AUC) for 
glucose 6 months after discontinuation of GH treatment showed no difference 
with pre-treatment levels for both GH dosage groups. After discontinuation of 
GH treatment fasting insulin levels returned to pre-treatment levels (8.4 
mU/l), whereas the 120-min AUC for insulin decreased compared to 6 year-
levels (P < 0.01), regardless of GH dosage group. No significant difference 
was found when levels were compared with a control group. In addition, for 
both GH dosage groups, no significant changes in systolic and diastolic BP 
SD-score, total cholesterol (TC) and atherogenic index (TC/HDL-c) were seen 
from 6-years of GH until 6 months after discontinuation of GH treatment.  
In conclusion, in children born SGA the GH induced insulin insensitivity 
disappeared after discontinuation of GH, even after long-term GH treatment. 
Furthermore, the beneficial effect of GH on blood pressure was not changed 
after discontinuation of GH and most children had normal lipid levels.  
 
Introduction 
 
Since the first reports of correlation between low birth weight (LBW) and high 
blood pressure in the 80’s 202, a large number of studies have elaborated on 
the consequences of LBW in relation to adult disease. Several other diseases 
such as hyperlipidaemia, diabetes mellitus (DM) type 2, and coronary heart 
disease (CHD) have also been associated with LBW 155, 190. Based on their 
findings, Barker and co-workers 203 suggested that the associated adult 
diseases, so-called syndrome X, are programmed by undernutrition in utero. 
Impaired foetal growth, especially when timed during the mid- to late 
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gestation, would lead to permanent changes in organ structure and 
physiology.  
Failure to show sufficient catch-up growth in childhood is a known 
phenomenon in about 10% of children born small for gestational age (SGA) 
140, 198. Several studies 150, 184 have shown accelerated growth during GH 
treatment. However, it has been established that GH treatment increases 
post-prandial insulin levels, probably due to a reduction in insulin sensitivity 
185. This finding has instigated several authors to express their concern 
regarding long-term effects of GH treatment in predisposed individuals such 
as SGA children 46.  
We previously reported on the effect of 6 years of GH treatment on 
carbohydrate metabolism, blood pressure and serum lipid levels in children 
born SGA 91, 204. The present paper focuses on the effect of discontinuation of 
long-term GH treatment on carbohydrate metabolism, blood pressure and 
serum lipid levels in children born SGA.  
 
Subjects and Methods 
 
Study group 
The study group comprised 47 children born SGA who were examined 6 
months after discontinuation of GH treatment. Thirty children had an OGTT at 
6 months after discontinuation of GH. They had participated in a multi-centre 
double-blind randomised dose-response GH trial in prepubertal short children 
born SGA. Four children who had discontinued GH treatment did not agree to 
an examination 6 months after discontinuation of GH treatment and 28 were 
still receiving GH treatment. 
The ongoing dose-response trial evaluates the effect of two dosages of GH (3 
or 6 IU GH/m2 BSA/day; approximately 0.03 or 0.07 mg/kg BW/day) on 
long-term growth and ultimately on final height.  
Inclusion criteria for the dose-response trial were described previously 150. In 
short, the children were included when prepubertal with a birth length SD-
score and height SD-score below -1.88, without spontaneous catch-up 
growth, and without growth failure caused by other disorders. Patients with 
Silver-Russell syndrome (SRS) and GH-deficiency, however, were included in 
this dose-response trial. The Ethics Committees of the four participating 
centres in the Netherlands approved the dose-response trial. Written 
informed consent was obtained from the parents or custodians of each child. 
 
Dose-response trial design  
After stratification for chronological age (CA) and for spontaneous GH 
secretion during a 24-hour GH profile, all children were randomly and blindly 
assigned to either 1 of 2 GH dosage groups: group A, 3 IU/m2 body 
surface/day, or group B, 6 IU/m2 body surface/day (approx. 0.03 or 0.07 
mg/kg/d, respectively) 145, 150. Biosynthetic GH (recombinant human GH 
Norditropin®, Novo Nordisk A/S, Denmark) was given subcutaneously once 
daily. To ensure the double-blind design an equal volume of a reconstituted 
preparation was used. Growth hormone treatment was discontinued after 
either reaching final height, defined as a height velocity (HV) below 0.5 cm 
over the last 6 months and/or bone age ≥ 15 years for girls and ≥ 16.5 years 
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for boys, or on the decision of the patient due to satisfaction with near final 
height. 
 
Physical examination 
Every three months one physician (‘91-‘95 WdW, ‘95-‘98 ThS, ‘98-’01 YvP) 
visited all children and measured height (H) 194 and weight (W). Height was 
expressed as SD-score for chronological age (CA) (Height SD-score) 62. Body 
mass index (BMI) was expressed as SD-score for sex and CA using Dutch 
references 62. Every 6 months blood pressure (BP) was measured. The same 
Dynamap Critikon 1846SX determined Systolic and diastolic BP with the 
children in sitting position using a cuff size corresponding to the size of their 
arm. BP was expressed as SD-score, using age and sex specific reference 
values 82. Pubertal stage was assessed by the same investigators according 
to Tanner 63, using an orchidometer in boys.  
 
Biochemical parameters 
At start, after one, and six years of GH treatment all children underwent an 
OGTT (oral glucose tolerance test) as previously described by Sas et al 91. For 
the present study we performed an OGTT 6 months after GH treatment in 
three of the four participating centres. To evaluate the overall responses to 
the oral glucose load, the following variables were described: 1) Impaired 
glucose tolerance (IGT) was defined according to The Expert Committee on 
the Diagnosis and Classification of Diabetes Mellitus 80: the 120-minute (120-
min) level > 7.8 mmol/L (140 mg/dl) and < 11.1 mmol/L (200 mg/dl). 2) 
The 120-minute area under the curve for time-concentration (AUC) during 
the OGTT was calculated using the trapezoidal rule. 3) The ratio insulin to 
glucose at 30 minutes (30' ratio) and the ratio at 120 minutes (120' ratio) 
was calculated as an index for relative insulin resistance. Results were 
compared with 24 normal adolescent girls aged 14.7 (0.98) years 81. 
At start, during the dose-response trial, and at 6 months after discontinuation 
of GH treatment additional non-fasting blood samples were taken for 
determination of haemoglobin A1c (HbA1c) levels, total serum cholesterol 
(TC), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein 
cholesterol (HDL-c). The atherogenic index was calculated as the ratio of TC 
to HDL-c. After centrifugation, all samples were frozen (-20ºC) until assayed. 
Serum TC, LDL-c, HDL-c levels, and atherogenic index were compared to a 
Dutch control group of the same age 83.  
 
Assays 
The plasma glucose level was measured at the local hospital laboratories with 
automatic analysers using a hexokinase catalysed-glucose oxidase method. 
Plasma insulin was determined in one laboratory by radioimmunoassay (RIA) 
(Medgenix, Fleurus, Belgium). The intra-assay coefficient of variation (CV) 
was 6% to 10% and the inter-assay CV was 6% to 11%. Fasting normal 
range was < 20 mU/L. Control samples were measured by a RIA, comparable 
to the RIA we used 81. 
HbA1c levels were measured in one laboratory using an automatic HPLC 
analyser (DIAMAT, BioRad, Edgemont, CA, USA). The upper-normal assay 
limit is 6.6%.  
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TABLE 1. Clinical data. 
 
N=47 
Group A 
(3 IU/m2/day) 
Group B 
(6 IU/m2/day) 
Male/Female 16/7 11/13 
Gestational age (wk) 37.7 (3.1) 36.3 (4.1) 
Birth length SD-score -3.4 (1.4) -3.8 (1.7) 
Birth weight SD-score -2.3 (1.2) -2.8 (0.9) 
Chronological Age (yr.) at start 8.6 (1.5) 8.3 (1.9) 
Height SD-score at start -2.9 (0.8) -2.8 (0.6) 
Body mass index SD-score at start -0.9 (1.5) -1.0 (1.0) 
GH duration 7.2 (1.2) 6.6 (1.7) 
Data expressed as mean (SD) 
 
 
FIGURE 1. Mean (+SD) fasting glucose levels and fasting insulin levels, before treatment, 
at 6 years of GH treatment, and at 6 months after discontinuation of treatment for group 
A (white bars) and for group B (black bars), respectively.  
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FIGURE 2. Mean glucose levels during OGTT for group A and group B, before treatment 
(black circles), at 6 years of GH treatment (black diamonds), at 6 months after 
discontinuation of treatment (white triangles), and for the control group (white squares). 
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The TC level was measured using an automated enzymatic method 205 with 
the CHOD-PAP High Performance reagent kit (Boehringer, Mannheim, 
Germany). TC analysis was subject to the quality-assessment program of the 
World Health Organisation Regional Lipid Reference Centre (Prague, Czech 
Republic). HDL and LDL-c were measured by the same method after 
precipitation. For HDL-c, the phosphotungstate method of Burstein was 
modified 206. LDL-c precipitation was performed with polyvinylsulfate 
(Boehringer). The overall coefficient of variance for TC, HDL-c, and LDL-c was 
2.9%, 3.7%, and 5.8%, respectively. Lipid levels for the control group were 
measured by the same assays in the same laboratory 83. Except for plasma 
glucose, all determinations were performed in the same laboratories.  
 
Statistical analyses 
To maintain the double-blind design until all participants have reached FH, an 
independent statistician (PM) performed the statistical analyses and 
summarised the results per treatment group in such a way that it was 
impossible for the investigator to identify individual patients. Accordingly, 
data are expressed as mean (SD) values unless otherwise specified. For the 
30' ratio, the 120' ratio, and the atherogenic index the geometric mean (95% 
range: the back transformed +/- 2 SD range of the log transformed variable) 
was used because of the positively skewed distributions involved. Differences 
in continuous variables were tested by paired Student's t-tests. Differences 
between zero and SD-score values at various time-points during the study 
were tested by one-sample Student's t-tests. Differences between groups 
were tested using a Student's two-sample t-test unless otherwise specified. 
Correlations were estimated after adjustment for GH dosage. A P-value < 
0.05 was considered significant. All calculations were performed by SPSS 
version 9.0.  
 
Results 
 
Table 1 shows the clinical data of the 47 children. Both GH dosage groups 
had similar initial characteristics. Three children had SRS. Seventeen children 
had GHD at start. Mean (SD) age at 6 months after discontinuation of GH 
treatment was 16.0 (2.1) years. No significant differences were found in 
clinical data and serum glucose or insulin levels between the 30 children who 
underwent an OGTT at 6 months after discontinuation of GH treatment, and 
the 17 children who did not. 
Fasting glucose levels at 6 years of GH treatment had increased significantly 
compared to pre-treatment (P < 0.05) but returned to pre-treatment level for 
both GH dosage groups at 6 months after discontinuation of GH treatment 
(Figure 1). The AUC for glucose showed neither a change at six years of GH 
treatment or at 6 months after discontinuation of GH treatment. Fasting 
glucose levels and the AUC for glucose were not significantly different 
between the GH dosage groups. Similarly, no significant differences were 
found between the GH-treated group and the control group (Figure 2).  
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FIGURE 3. Mean insulin levels during OGTT for group A and for group B, before treatment 
(black circles), at 6 years of GH treatment (black diamonds), at 6 months after 
discontinuation of treatment (white triangles), and for the control group (white squares). 
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FIGURE 4. Mean (SD) systolic blood pressure (BP) SD-score and diastolic BP SD-score 
using age-matched reference values, before GH treatment, at 6 years of GH treatment, 
and at 6 months after discontinuation of treatment for group A (white bars) and for 
group B (black bars).   
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TABLE 2. Serum lipid levels. 
 
 Group A Group B Control group 
TC mmol/l Pre GH 4.9 (0.7) 4.6 (0.8)   
 6 yr. GH 4.1 (0.5) 3.8 (0.6)   
 Post GH 4.1 (0.5) 4.0 (0.7) 4.6 (0.8) 
        
LDL-c mmol/l Pre GH 2.9 (0.5) 2.7 (0.9)   
 6 yr. GH 2.4 (0.5) 2.0 (0.7)   
 Post GH 2.5 (0.5) 2.3 (0.7) 2.8 (0.7) 
        
HDL-c mmol/l Pre GH 1.5 (0.3) 1.4 (0.2)   
 6 yr. GH 1.1 (0.2) 1.0 (0.2)   
 Post GH 1.1 (0.2) 1.1 (0.4) 1.3 (0.3) 
Atherogenic index* 
(TC/HDL-c) 
Post GH 3.0 (2.0-4.5) 3.0 (1.3-6.7) 3.7 (2.3-6.1) 
Data expressed as mean (SD). TC = Total Cholesterol; LDL-c = Low Density Lipoprotein-cholesterol; 
HDL-c = High Density Lipoprotein-cholesterol; * Geometric mean (95% range). 
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Fasting insulin levels had increased at 6 years of GH treatment compared to 
at pre-treatment (P < 0.001) but returned to pre-treatment levels at 6 
months after discontinuation of GH treatment (Figure 1). Also, the AUC for 
insulin showed a significant increase from 3349 (1643) min*mU/l pre-
treatment to 6157 (2368) min*mU/l at 6 years of GH treatment (P < 0.001). 
At 6 months after discontinuation of GH treatment the AUC for insulin, 4645 
(3641) min*mU/l, had significantly decreased compared to the 6 year-level 
(P < 0.01) but remained higher than pre-treatment (P < 0.05). Compared to 
the control group, however, the AUC for insulin at 6 months after 
discontinuation of GH treatment showed no significant difference. No 
significant differences between GH dosage groups were found for change in 
fasting insulin levels and AUC for insulin (Figure 3). 
The ratio for insulin to glucose at 30' (30' ratio) and 120' (120' ratio) had 
increased significantly at 6 years of GH treatment compared to pre-treatment 
levels (P < 0.001, P < 0.05, respectively). At 6 months after discontinuation 
of GH treatment the 30' ratio, returned to pre-treatment values for group A. 
For group B, however, the 30' ratio remained increased compared to pre-
treatment values (P < 0.001). The 120' ratio, at 6 months after 
discontinuation of GH treatment, was comparable to pre-treatment values, 
showing no differences between GH dosage groups.  
After six years of GH treatment, we found impaired glucose tolerance (IGT) in 
1 of 27 children (4%), and at 6 months after discontinuation of GH treatment 
IGT was present in 3 of 29 children (10%). One of the children with IGT at 
six years of GH treatment also had IGT at 6 months after discontinuation of 
GH treatment. The other children had IGT only once during GH treatment or 
after discontinuation of GH treatment. None of the children developed 
diabetes mellitus type 1 or 2. 
The HbA1c values after six years of GH treatment had significantly decreased 
from 5.1 (0.3) at pre-treatment to 4.8 (0.4) at 6 years of GH treatment (P < 
0.001), whereas no change was found at 6 months after discontinuation of 
GH treatment (4.7 (0.3)). Throughout the years, all individual HbA1c levels 
remained within normal range. 
BMI SD-score after 6 years of GH treatment had increased significantly 
compared to the pre-treatment BMI SD-score of -1.0 (1.2) (P < 0.001). As a 
result the mean BMI SD-score of -0.2 (1.1) at 6 years was not significantly 
different from zero. At 6 months after discontinuation of GH treatment mean 
BMI SD-score was –0.1 (1.3), showing no significant difference compared to 
6-year values. The change in BMI SD-score was not significantly different 
between GH dosage groups.  
Systolic BP and diastolic BP decreased significantly during 6 years of GH 
treatment (P < 0.05, P < 0.001, respectively) to values not significantly 
different from zero for systolic BP and significantly lower than zero for 
diastolic BP (P < 0.001)(Figure 4). After discontinuation of GH treatment no 
change in systolic and diastolic BP was seen. The changes in BP were not 
significantly different between GH dosage groups.  
Serum TC, LDL-c, and HDL-c levels significantly decreased after 6 years of 
GH treatment compared to start (P < 0.001 for all)(Table 2). After 
discontinuation of GH treatment, TC levels showed no change compared to 6-
year levels for both sexes, whereas LDL-c and HDL-c levels increased 
significantly for girls only (P < 0.01, p=0.01, respectively). Discontinuation of 
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GH treatment did not result in a change in atherogenic index compared to 6-
year values. Compared to the control group, serum TC, LDL-c, but also HDL-c 
levels were significantly lower in the GH-treated group at 6 months after 
discontinuation of GH treatment, after correction for age and gender (P < 
0.001, P < 0.01, P < 0.01, respectively). The atherogenic index, however, 
was not significantly different at 6 months after GH treatment, compared to 
the control group (Table 2). The changes in serum lipid levels were not 
significantly different between the GH dosage groups.  
A significant correlation was found between AUC for glucose and AUC for 
insulin at 6 months after discontinuation of GH treatment (r=0.67, P < 
0.0001). BMI SD-score correlated significantly with fasting insulin levels, 
systolic BP SD-score, and the atherogenic index at 6 months after 
discontinuation of GH treatment (r=0.58 (P < 0.01), r=0.32 (P < 0.05), and 
r=0.42, P < 0.05, respectively), but no correlation was found between BMI 
SD-score and diastolic BP SD-score, or 120-minute glucose level at 6 months 
after discontinuation of GH treatment. The atherogenic index at 6 months 
after discontinuation of GH treatment was also significantly correlated to 
diastolic BP SD-score (r=0.43, P < 0.05), but did not significantly correlate 
with systolic BP SD-score, fasting insulin, or 120-minute glucose levels. 
Regarding the change in fasting glucose, fasting insulin, 30' ratio, 120' ratio 
or AUC for insulin from start until 6 months after discontinuation of GH 
treatment, no correlation was found with the change in BMI-SD-score.  
 
Discussion 
 
We present the results describing the effect of discontinuation of long-term 
GH treatment on carbohydrate metabolism, body mass index, blood pressure, 
and serum lipid levels in children born small for gestational age. Our results 
show that discontinuation of long-term GH treatment in adolescents born 
SGA normalised both fasting insulin and stimulated insulin levels, after a 
significant increase during GH treatment. Furthermore, we found that 
discontinuation of GH did not alter the positive influence of GH on BMI and 
blood pressure and had no effect on the atherogenic index (TC/HDL-c). 
Previously, we have shown that stimulated glucose levels remained 
unchanged and fasting glucose levels rose slightly during 6 years of GH 
treatment. In addition, both fasting and stimulated insulin levels increased 
significantly 91. It has been reported that GH treatment increases serum 
insulin levels in conditions such as GHD, Turner syndrome, and renal diseases 
50, 51. This has been attributed to a GH induced reduction of insulin sensitivity. 
Also, it has been reported that post-prandial glucose levels increase in 
individuals with a reduced insulin sensitivity 207. 
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Our present results show that after discontinuation of GH treatment, fasting 
glucose and fasting insulin levels returned to pre-treatment levels. This 
indicates that the rise in glucose and insulin levels were indeed a result of GH 
treatment. In other patient groups, such as girls with Turner Syndrome, GHD 
adolescents, and non-GHD adolescents similar results were found after 
discontinuation of GH treatment 51, 84, 186. While fasting insulin levels at 6 
months after discontinuation of GH treatment decreased to pre-treatment 
levels, stimulated insulin levels did not. The reason why post-treatment 
stimulated insulin levels did not completely return to pre-treatment levels 
might have various reasons. Firstly, patients were prepubertal at start and 
postpubertal after discontinuation of GH treatment. Euglycaemic clamp tests 
or frequently sampling intravenous glucose tolerance tests have shown that 
insulin sensitivity in healthy children decreases during puberty. Also, in these 
studies, post-pubertal insulin sensitivity did not return to prepubertal values 
81, 86, 87. The higher insulin levels were attributed to a reduced insulin 
sensitivity in normal puberty and post-puberty 86. Thus, the reduced insulin 
sensitivity compared to baseline in our patients might be explained by their 
post-pubertal stage. This is supported by the fact that post-treatment 
stimulated insulin levels were comparable to those of healthy adolescent 
peers. Secondly, the BMI SD-score increased during GH treatment. Since a 
higher BMI is associated with higher insulin levels, this might also explain the 
higher post-treatment stimulated insulin levels compared to pre-treatment 
levels 88, 89. In accordance, we found that adolescents with high fasting and 
stimulated insulin levels after discontinuation of GH treatment had a 
significantly higher BMI SD-score. Thirdly, post-treatment stimulated insulin 
levels might be influenced by the fact that these adolescents were born SGA. 
Significantly higher insulin levels have been found after an oral glucose load 
in young adults born SGA compared to normal controls 208, 209.  
During the 6 years of GH treatment we found no differences between the two 
GH dosage groups regarding fasting or post-prandial glucose and insulin 
levels. After discontinuation of GH treatment, however, we observed that in 
the higher GH-dosage group (group B) the decrease in the 30-minute ratio 
for insulin/glucose was significantly less profound than in the lower GH-
dosage group (group A). As the 30-minute ratio for insulin/glucose is an 
indicator for insulin resistance, this finding might suggest that long-term 
treatment with a higher GH dose of 6 IU/m2/day (~ 0.07 mg/kg/day) 
increases the degree of insulin resistance in children born SGA even after 
discontinuation of GH treatment. Compared to the control group, however, 
the mean 30-minute ratio of group B still falls into the normal range.  
As insulin resistance, either on its own or in combination with beta-cell 
dysfunction, causes IGT, we evaluated the number of children in our group 
with IGT. We found that after six years of GH treatment 1 of 27 children had 
IGT (4%), and at 6 months after discontinuation of GH treatment IGT was 
present in 3 of 29 children (10%). This result might be explained by the fact 
that puberty induces higher 120-min glucose levels 86, 87. The predisposition 
for insulin resistance and IGT in this group of adolescents born SGA, 
however, might also be responsible. Several studies found evidence for 
insulin resistance in untreated short children born SGA 210, 211. Also, being 
born with a low birth weight is associated with IGT and diabetes mellitus type 
2 190, 212. On the other hand, mean glucose levels at 6 months after 
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discontinuation of GH decreased to pre-treatment levels, individual HbA1c 
levels never exceeded the normal range, and none of the children developed 
diabetes mellitus type 1 or 2.  
Systolic and diastolic blood pressure did not change after discontinuation of 
GH treatment. Another study evaluating the effect of discontinuation of GH in 
adolescents with GHD, showed similar results 92. It has been reported that 
children and young adults born with a low birth weight had a significantly 
higher systolic blood pressure 213-216. In some studies this relationship was 
also found when low birth weight was corrected for gestational age 216, but in 
others it was not 208, 217. We reported, previously, that before start of GH 
treatment children born SGA had a significantly higher systolic blood pressure 
than reference values, which decreased to normal during GH treatment 91. 
Our present study shows that after discontinuation of GH treatment, systolic 
blood pressure was not different to age-and sex-matched reference values, 
whereas diastolic blood pressure was even significantly lower than reference 
values. These results contrast with data of untreated subjects born SGA and 
might reflect a positive influence of GH on blood pressure in this patient 
group. 
During GH treatment serum TC, LDL-c, and HDL-c levels decreased. 
Discontinuation of GH treatment resulted in a slight increase in both LDL-c 
and HDL-c levels and no change in total cholesterol levels. Previous reports 
have shown that discontinuation of GH treatment in GHD adolescents had 
either no effect on serum lipids 218 or resulted in an increase in total 
cholesterol and LDL-c levels, without change in HDL-c levels 92, 93. The 
increase in both LDL-c and HDL-c in our children might also be an age-effect 
95, 96. We found that the atherogenic index after discontinuation of GH 
treatment was comparable with a control group of similar age. The lack of 
difference in serum lipid levels between the two GH dosage groups suggests 
that the changes in lipid levels were not related to GH treatment. 
After discontinuation of GH treatment, we found a positive correlation 
between the atherogenic index, BMI SD-score, systolic and diastolic blood 
pressure SD-score, and fasting insulin. This might suggest that some 
adolescents born SGA, a clustering of risk factors for cardiovascular disease, 
as described by Barker and co-workers, is already present 203. Since fasting 
insulin, systolic BP, and atherogenic index were positively correlated with BMI 
SD-score, a possible strategy to decrease risk for cardiovascular disease in 
subjects born SGA might be to prevent weight gain. 
In conclusion, in children born SGA the GH induced insulin insensitivity 
disappeared after discontinuation of GH, even after long-term GH treatment. 
Furthermore, the beneficial effect of GH on blood pressure was not changed 
by discontinuation of GH. Although most children had normal serum lipid 
levels, we did find a clustering of risk factors for cardiovascular disease, 
which may point to their predisposition. Whether long-term GH treatment will 
contribute to longevity, however, remains to be investigated  
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Abstract 
 
Short stature is not the only problem faced by small for gestational age 
(SGA) children. Being born SGA has also been associated with lowered 
intelligence, poor academic performance, low social competence, and 
behavioural problems. Although GH treatment in short children born SGA can 
result in a normalisation of height during childhood, the effect of GH 
treatment on intelligence and psychosocial functioning remains to be 
investigated. We show the longitudinal results of a randomised, double blind, 
GH-dose response study initiated in 1991 to follow growth, IQ and 
psychosocial functioning in SGA children during long-term GH treatment.  
Patients were assigned to one of two treatment groups (3 or 6 IU GH/m2 
body surface/day ~ 0.035 or 0.07 mg/kg/day). Intelligence and psychosocial 
functioning were evaluated at start of GH treatment (N=74), after 2 years of 
GH treatment (N=76), and in 2001 (N=53). IQ was assessed by a short form 
WISC-R or WAIS (Block-design and Vocabulary subtest). Behavioural 
problems were measured by the Achenbach CBCL or YABCL and self-
perception by the Harter Self-Perception Profile.  
Mean (SEM) birth length SD-score was –3.6 (0.2), mean age and height at 
start was 7.4 (0.2) years and –3.0 (0.1) SD-score, mean duration of GH 
treatment was 8.0 (0.2) years, mean age in 2001 16.5 (0.3) years. After 2 
years of GH treatment 96% of both GH groups showed a height gain SD-
score from start of 1 SD or more, resulting in a normal height (i.e. height ≥  
–2.0 SD for age and sex) in 70% of the children. In 2001 48 of the 53 
children, participating in this study, had reached a normal height (91%). 
Block-design s-score and the estimated Total IQ significantly increased (P < 
0.001, P < 0.001, respectively) from scores significantly lower than Dutch 
peers at start (P < 0.001, P < 0.001, respectively) to comparable scores in 
2001. The increase over time for the Vocabulary s-score was not significant. 
Internalizing behavior SD-scores remained comparable to Dutch peers, while 
Externalizing behavior SD-scores and Total problem behavior SD-scores 
improved significantly during GH therapy (P < 0.01, P < 0.05, respectively) 
to scores comparable to Dutch peers. Self perception SD-scores, improved 
 
* H.M.K. is currently working at the Department of Developmental Psychology, Free University 
Medical Centre, Amsterdam. 
 
CHAPTER 10   Part ‘Small for Gestational Age’: IQ and psychosocial status during GH 
 120
from start of GH treatment until 2001 (P < 0.001) to scores significantly 
higher than Dutch peers (P < 0.05). No significant differences between the 
two GH dosage groups were found. Improvement in Externalizing and Total 
problem behavior SD-scores over time was significantly related to change in 
height SD-score (P < 0.05, P < 0.01, respectively), while scores over time for 
Vocabulary, Block-design, Internalizing, or Total HSP were not related to 
change in height SD-scores. 
In conclusion, parallel to a GH-induced catch-up growth in adolescents born 
SGA, IQ, behaviour, and self-perception showed a significant improvement 
over time from scores below average to scores comparable to Dutch peers. In 
addition, children whose height over time became closer to that of their peers 
showed less problem behaviour.  
 
Introduction 
 
Ten percent of children born SGA do not catch-up in height and remain short 
140, 198. The reason for these children remaining short is not completely 
understood. Sixty percent of short children born SGA have low serum growth 
hormone (GH) levels during a 24-hour GH profile and most have low IGF-1 
levels, but no relation was found between physiological GH levels and the 
growth response during GH treatment 145, 150, 191, 219. Short stature, however, 
is not the only problem which SGA children face. Being born SGA, with or 
without catch-up growth, has also been associated with lower intelligence, 
poor academic performance, low social competence, and behavioural 
problems 165-171. Suggested explanations for this association are intrauterine 
malnutrition affecting brain development or relative deficiency of the GH-IGF-
1 axis 172-174. Although recent studies have demonstrated that GH treatment 
in short children born SGA can result in a normalisation of height during 
childhood 150, 184, the effect of GH treatment on intelligence and psychosocial 
functioning remains to be investigated. Therefore, in 1991, a randomised, 
double blind, GH-dose response study was initiated to follow growth, IQ and 
psychosocial functioning during long-term GH treatment. Previously, our 
group described the effect of two years of GH treatment in short children 
born SGA on IQ and psychosocial functioning. We then found a significant 
increase in total IQ-score, in ‘social acceptance’ scores, and in ‘general self-
worth’ scores 169, 188. In the present study, during 8 years of GH treatment, 
we evaluated IQ and psychosocial functioning in the same group of short 
children born SGA without spontaneous catch-up growth. Recent analysis of 
the growth data showed a further increase in height SD-scores and a 
normalisation of final height for most participants 220. In accordance with our 
clinical observation and the GH-induced catch-up growth, in the present 
study we expected to find a similar IQ to 2 years data and a further 
improvement in psychosocial functioning. 
 
Methods 
 
Patient group (GH group) 
Seventy-nine short children born SGA participated in a multi-centre 
randomised double-blind dose-response GH trial (Table 1). Of these 79 
children 6 children dropped out and were lost to follow-up. Fifty-three 
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children agreed to participate in the evaluation of IQ and psychosocial 
functioning in 2001, during a mean of 8 years of GH treatment, whereas 20 
children were not motivated to participate (T3: response rate 73%). In the 
previous evaluations at start (T1) and after 2 years of GH treatment (T2), a 
small part of the GH groups had not been able to participate due to the age 
minimum of the questionnaires. The response rates for the previous 
evaluations at start and after 2 years of GH treatment were 100% (74/74) 
and 97% (76/78), respectively. Sixty-three percent (50/79) was evaluated 
three times and 94% (74/79) participated at least twice in the evaluation of 
IQ and psychosocial functioning. 
The GH trial started at 1991 (T1) and evaluated the effect of GH on long-
term growth and ultimately on final height. Inclusion criteria for the GH dose-
response trial were: birth length SD-score below -1.88 (< P3), chronological 
age (CA) between 3 and 11 year in boys and 3 and 9 year in girls, height SD-
score for CA below -1.88, no spontaneous catch-up growth, prepubertal 
stage, uncomplicated neonatal period without severe asphyxia. Biosynthetic 
GH (r-hGH NorditropinR, Novo Nordisk A/S, Denmark) was given 
subcutaneously once daily. GH was given in a dosage of 3 or 6 IU (1 or 2 mg) 
GH/m2 body surface/day (~ 0.035 or 0.07 mg/kg /day). GH treatment was 
discontinued after reaching final height (height velocity < 0.5 cm in 6 
months) or on patient’s decision after reaching a satisfactory height (near 
final height). Of the participants in the evaluation of IQ and psychosocial 
functioning in 2001, 37 of the 53 adolescents (70%) had discontinued GH 
treatment. 
The evaluation of IQ and psychosocial functioning, being part of the GH trial, 
started in 1991 and was approved by the Ethics Committees of the 
participating centres in the Netherlands. Due to ethical considerations, the 
Ethics Committees did not allow for a control group until final height as part 
of the GH trial. Written informed consent was obtained from the parents or 
custodians of each child.  
 
Clinical evaluation 
Height was measured using a Harpenden stadiometer 194. Four 
measurements per visit were taken and the mean was used for analysis. 
Target height (TH) was adapted from Dutch reference data with addition of 3 
cm for secular trend: 1/2 x (Heightfather + Heightmother + 12) + 3 for boys 
and 1/2 x (Heightfather + Heightmother - 12) + 3 for girls.62 Height, TH, and 
head circumference were expressed as SD-score for chronological age (CA) 
and gender 9, 62.  
 
Evaluation of IQ and psychosocial functioning  
The evaluation of IQ and psychosocial functioning was performed at start 
(T1), after 2 years of GH treatment (T2), and in the year 2001 (T3) by an 
experienced psychologist. At start, all parents returned the questionnaires. In 
the evaluation at 2 years of GH treatment 2 parents did not return the 
questionnaires and in 2001 8 parents. Data on occupational levels were 
provided by both parents and adolescents. Parental occupational level (SES) 
ranged from 1 (lower occupation) to 3 (higher occupation). When both 
parents were employed the highest of the two SES levels was used. For 
unemployment the lowest SES was used 105.  
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Intelligence. To assess intelligence a short form of two subtests (Block-
design, a Performance IQ subtest and Vocabulary, a Verbal IQ subtest) of the 
Wechsler Intelligence Scale for Children – Revised, Dutch version (WISC-R) 
221, was used for children aged between 6 and 16 years and a short form 
(also Block-design and Vocabulary subtest) of the Wechsler Adult Intelligence 
Scale, Dutch version (WAIS) 222, for adolescents aged 17 years and older 
(only used in 2001). Good correlations have been found between the short 
form IQ and the full scale IQ both for the WISC-R and the WAIS 223. The 
subtest scores for Block-design (Bd) and Vocabulary (Vo) were expressed as 
normalised standard scores (s-scores) with a mean of 10, ranging from 1 (- 3 
SD) to 19 (+ 3 SD), based on Dutch population sample data for the same 
age 221, 222. S-scores for the WAIS and WISC-R were combined to enable time 
trend analysis of the subtests. In the time trend analysis a dummy variable 
(WAIS yes/no) was added, when significant, to correct for type of IQ test 
used in 2001. A higher s-score indicated a better result in the subtest. Total 
IQ score was calculated according to an equation, based on the outpatient 
population reference data of the Child Psychiatry Department of the Sophia 
Children’s Hospital (TIQ=45.3 + 2.91*Vocabulary s-score + 2.50*Block-
design s-score). 
 
Behaviour. Behavioural problems were measured by 3-point scale 
standardised questionnaires, designed by Achenbach, translated and 
validated in the Dutch language 104, 106, 107, 224, 225. For children aged between 
4 and 18 years, the 120-item Child Behavior Checklist (CBCL; filled in by 
parents) was used and for adolescents aged 19 years and older the 115-item 
Young Adult Behavior Checklist (YABCL; filled in by parents). Since all 
questionnaires were constructed in a similar way, SD-scores of three scales 
(Internalizing, Externalizing, and Total Problem score) were combined 
(CBCL/YABCL). A higher SD-score indicated more problem behaviour. 
Self-perception. The inventory, called in Dutch "Hoe ben ik" and in English 
"Harter Self Perception Profile" (HSPP), was designed by Harter to describe 
sense of self-worth and capability in several areas, using 4-point scales 111, 
112. At the T1 and T2 evaluation the 36-item child-version for children aged 8 
to 12 years (HSPP-c) was used, at the T3 evaluation the 45-item adolescent-
version (HSPP-a). Since both versions were constructed in a similar way, SD-
scores of one scale (Total HSP-score) could be combined to enable analysis of 
time-trend.  
 
SD-scores 
To allow combining outcome variables over time (CBCL/YABCL, HSPP-
c/HSPP-a) the psychosocial test scores were transformed into SD-scores. For 
the CBCL, YABCL, and HSPP-a a Dutch general population sample aged 
between 12 and 22 years was used to calculate SD-scores (N=600, SES 
1/2/3: 30/36/34%, male 40%, mean age 16.4 yr. +/- 0.13 SEM) 104. 
Comparison between the GH groups at T3 and the population sample by 
logistic regression (group as dependent variable and SES, gender, and age as 
independent variables) showed no significant differences in SES and age 
between the normative group and the GH groups, but a difference for gender 
(more males in GH group: P < 0.01). For the child-form HSPP (HSPP-c), used 
at T1 and T2, Dutch normative data of the same age-range (8-12 years) as 
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the GH groups at start were used (n=300, male 48%, mean age 9.7 +/- 0.06 
SEM) 226. Comparison between the GH groups who filled in the HSPP-c at T1 
and the population sample showed a significant difference for gender (more 
males in GH groups, P < 0.05), when logistic regression was applied (group 
as dependent variable, gender and age as independent variables).  
To correct for the skewed distribution in gender of the population sample, the 
mean and SD of the female and male outcome was averaged and used to 
calculate SD-scores. 
 
Statistical analysis 
To maintain the double-blind design until all participants have reached FH, an 
independent statistician (HJD) performed the statistical analyses. All data 
were expressed as mean (SEM) unless otherwise specified. To compare mean 
outcome scores with the normative means, one-sample t-tests were 
performed, using test value 10 for the s-scores and test value 0 for the SD-
scores. To estimate the time trend of the IQ and psychosocial test scores, the 
effect of height SD-score at time of evaluation, and the effect of GH dosage 
on the IQ and psychosocial test scores, Random Regression Models were 
used for continuous data (RRMs). The effect on IQ and psychosocial test 
scores was expressed as an unstandardised estimate (b). To find the optimal 
model fit, the following strategy was used: 1) fixed linear time trend with and 
without random linear time effect, 2) fixed linear and quadratic time trend, 3) 
model 1 or 2 with covariables age, gender (1/2: male/female), and GH 
dosage (1 or 2 mg/m2/day). To limit the effect of collinearity, variables 
height SD-score and age were centred (individual value minus mean value), 
and the variable time was divided by 2 (0, 1, 4.65 yr.). To correct for skewed 
distributions, the square roots of the CBCL/YABCL scores plus 1.5 were used 
for analysis. The effect of GH dosage was estimated by the addition of the 
interaction term GH dosage*time to the optimal model. The effect of change 
in height was estimated by the addition of height SD-score at time of 
evaluation to the optimal model. The advantage of using RRM, instead of a 
MANOVA for repeated measurements, is that RRM copes better with missing 
data because it estimates missing data based on non-missing data for that 
individual, assuming that missing data are missing at random 227, 228. In 
addition, in RRM using an "unstructured" error structure, variance and 
covariance are not assumed to be the same between time-points. All 
calculations were done by SPSS 9.0, except for RRMs (SAS 6.12). A two-
tailed P-value < 0.05 was considered significant. 
 
CHAPTER 10   Part ‘Small for Gestational Age’: IQ and psychosocial status during GH 
 124
 
 
TABLE 1. Characteristics at start of GH treatment for the total group of 79 
short children born SGA at start of GH treatment and for the children who 
participated in the evaluation at 2001. 
 
Evaluation 
At start 
(N=79) 
 In 2001 
(N=53) 
 3 IU/m2/day 6 IU/m2/day  3 IU/m2/day 6 IU/m2/day 
Male/Female 31/10 21/17  22/6 14/11 
Gestational age (wk) 37.3 (0.5) 36.0 (0.7)  37.8 (0.6) 36.3 (0.8) 
Birth length (SD-score) -3.6 (0.2) -3.7 (0.3)  -3.2 (0.2) -3.5 (0.3) 
Birth weight (SD-score) -2.6 (0.2) -2.6 (0.2)  -2.5 (0.2) -2.5 (0.2) 
Chronological age (yr.) 
at start 
7.3 (0.3) 7.6 (0.4) 
 
7.3 (0.4) 7.0 (0.5) 
Height (SD-score) 
at start 
-3.0 (0.1) -3.1 (0.1) 
 
-2.9 (0.1) -3.1 (0.1) 
Data expressed as mean (SEM). 
 
 
TABLE 2. Clinical characteristics of the participants of the IQ and psychosocial 
evaluations at start, after 2 years of GH treatment, and in 2001. 
 
Evaluation 
At start 
(N=74)# 
2 yr. GH 
(N=76) 
2001 
(N=53) 
 3 IU/m2/d 6 IU/m2/d 3 IU/m2/d 6 IU/m2/d 3 IU/m2/d 6 IU/m2/d 
Chronological age  
(yr.) at evaluation 
7.4 (0.3) 7.4 (0.4) 9.4 (0.3) 9.6 (0.4) 16.7 (0.4) 16.4 (0.6) 
Height (SD-score) 
at evaluation 
-3.0 (0.1) -3.0 (0.1) -1.6 (0.1)* -1.2 (0.1)* -1.0 (0.2) # -0.5 (0.3) # 
Target height  
(SD-score) 
-0.9 (0.1) -0.4 (0.2) -0.9 (0.1) -0.4 (0.2) -0.9 (0.2) -0.5 (0.2) 
Head circumference  
(SD-score)  
at evaluation 
-0.9 (0.1) -0.8 (0.2) -0.5 (0.2)* -0.2 (0.2)* -0.8 (0.2) # -0.6 (0.2)# 
Data expressed as mean (SEM). # At start of GH treatment 5 children were too young to participate in the 
evaluation. Paired t-test on both GH groups: * P < 0.001 (start GH versus 2 yr. GH); # P < 0.001 (2 yr. GH 
versus 2001). 
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Results 
 
Table 1 shows characteristics at start of GH treatment for all short children 
born SGA who were included in the GH trial, and for those who participated in 
the IQ and psychosocial evaluation in 2001. No significant differences in 
baseline characteristics were found between the 53 GH-treated children who 
participated in the IQ and psychosocial evaluation in 2001 and the 26 who 
did not participate. Table 2 shows the clinical characteristics at time of 
evaluation for the children who participated in the IQ and psychosocial 
evaluation at start (T1), after 2 years of GH treatment (T2), and in 2001 
(T3). After 2 years of GH treatment, 96% of both GH groups (73/76) showed 
a gain in height SD-score of 1 SD or more, measured from start of treatment. 
This already resulted in a normal height (i.e. height ≥ –2.0 SD for age and 
sex) after 2 years of GH treatment in 70% of the children (53/76). In 2001, 
48 of the 53 children who participated in the IQ and psychosocial evaluation 
had reached a normal height (91%). Mean (SEM) duration of GH treatment 
was 8.0 (0.2) years. In 2001, 24% of the parents had a lower occupation, 
35% an intermediate occupation, 41% a higher occupation.  
 
Psychosocial functioning and IQ over time 
 
Intelligence  
Block-design s-score, corrected for gender, age at start, and GH dosage, 
showed a significant linear increase of 2.2 s-score from start to 2001 
(b=0.48, P < 0.001) (Figure 1). Compared to the Dutch population sample, 
mean Block-design s-scores for the GH groups at start and after 2 years of 
GH treatment were significantly lower (P < 0.001 at both times). In 2001, 
mean Block-design s-score was comparable to the Dutch population sample 
mean. The increase over time for Vocabulary s-score was not significant. 
Compared to the Dutch population sample, mean Vocabulary s-scores for the 
GH groups at start, after 2 years of GH treatment, and in 2001 were 
significantly lower (P < 0.01, P < 0.001, and P < 0.05, respectively) (Figure 
2). To analyse whether the type of IQ test used in 2001 could explain the 
change in IQ s-scores, a dummy variable was added (1=WAIS at 2001, 
0=WISC-r at 2001). The dummy variable, however, had no significant 
explanatory effect on both the changes in Block-design and Vocabulary s-
scores. The estimate of the Total IQ, corrected for gender, age at start, GH 
dosage, and type of IQ test used in 2001, increased significantly by 7.0 s-
score over time (b=1.51, P < 0.001) (Figure 3). Compared to the mean of 
the Dutch population sample (Total IQ=100), mean Total IQ score for the GH 
groups at start and after 2 years of GH treatment were significantly lower (P 
< 0.001 and P < 0.001). In 2001, mean Total IQ score was comparable to 
the Dutch population sample mean. No significant difference between the two 
GH dosage groups was found in change over time for both subtests and Total 
IQ. 
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FIGURE 1. Block-design s-score for both GH groups during GH treatment, corrected for 
gender and age at start. (1 mg=3 IU) Significant increase from start: * P < 0.001.  
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FIGURE 2. Vocabulary s-score for both GH groups during GH treatment, corrected for 
gender and age at start. (1 mg=3 IU)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3. Estimated Total IQ s-score for both GH groups during GH treatment, corrected 
for gender and age at start. (1 mg=3 IU) Significant increase from start: * P < 0.001. 
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Behaviour  
The 3 scales of the behaviour checklist (CBCL/YABCL), Internalizing SD-
scores, Externalizing SD-scores, and Total problem behavior SD-scores, were 
analysed over time, corrected for gender and age at start. Over time 
Internalizing SD-scores did not change significantly. At start, after 2 years of 
GH treatment, and in 2001, mean Internalizing SD-score were comparable to 
the population sample mean (Figure 4). Externalizing SD-scores and Total 
problem behavior SD-scores, however, decreased linearly and significantly by 
0.7 and 0.5 SD-score, respectively, during GH therapy (b=-0.05, P < 0.01; 
b=-0.04, P < 0.05, respectively) (Figures 5 and 6). When comparing 
Externalizing SD-scores and Total problem behavior SD-scores for the GH 
groups with the Dutch population sample mean, at start and after 2 years of 
GH treatment, the GH groups had higher scores (Ext.: P < 0.001, P < 0.01, 
respectively; Tot.: P < 0.001, P < 0.01, respectively), indicating more 
problem behaviour. In 2001, however, the GH groups had Externalizing and 
Total problem behavior SD-scores comparable to the population sample 
mean. No significant difference between the two GH groups was found in 
change over time for Internalizing, Externalizing, and Total problem behavior 
SD-scores.  
 
Self-perception 
Mean self-perception scale, Total HSP SD-score, increased quadraticly by 1.6 
SD-score from start of GH treatment until 2001 (P < 0.001) (Figure 7). 
Compared to the Dutch population sample mean, the GH groups had 
significantly lower scores at start (P < 0.001). After 2 years of GH treatment 
mean Total HSP SD-score had increased to a mean SD-score comparable to 
the normative mean, while in 2001, mean Total HSP SD-score was 
significantly higher than the population sample mean (P < 0.05). No 
significant differences were found in change over time between the two GH 
groups.   
 
Effect of height  
Externalizing and Total problem behavior SD-scores over time were inversely 
related to change in height SD-score (b=-0.05, P < 0.05;b=-0.06, P < 0.01, 
respectively). To demonstrate the size of the effect of height SD-score on 
behavioural problems, suppose a short SGA child commenced GH treatment 
with a height of –3 SD-score, gained 1 SD-score after 2 years of GH 
treatment, and attained a final height of –1 SD-score in 2001. The child’s 
Externalizing problem behavior would have decreased 0.8 SD-score from 
start of GH treatment until 2001, while a short SGA child with no increase in 
height SD-score, would have a Externalizing problem behavior decrease of 
0.5 SD-score. When using the same height increase as in the previous 
example, the child’s Total problem behavior would have decreased 0.5 SD-
score from start of GH treatment until 2001, while a short SGA child with no 
increase in height SD-score, would have a Total problem behavior decrease 
of 0.1 SD-score. The scores over time for Vocabulary, Block-design, 
Internalizing, or Total HSP were not related to change in height SD-score. In 
2001, scores for Vocabulary, Block-design, Internalizing, Externalizing, Total 
problem behavior, or Total HSP were not related to height SD-score in 2001, 
neither with nor without correction for age, gender, or GH dosage.  
CHAPTER 10   Part ‘Small for Gestational Age’: IQ and psychosocial status during GH 
FIGURE 4. Internalizing problem behavior SD-score for both GH groups during GH 
treatment, corrected for gender and age at start. (1 mg=3 IU) 
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FIGURE 5. Externalizing problem behavior SD-score for both GH groups during GH 
treatment, corrected for gender and age at start. (1 mg=3 IU) Significant decrease from 
start: * P < 0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6. Total Problem Behavior SD-score for both GH groups during GH treatment, 
corrected for gender and age at start. (1 mg=3 IU) Significant decrease from start: * P < 
0.05. 
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Effect of head circumference 
Head circumference SD-score at start was positively and significantly related 
to Block-design and Vocabulary s-scores over time (b=0.65, P < 0.05; 
b=1.06, P < 0.01, respectively). Head circumference SD-score at start, 
however, was not related to the change over time for both Block-design and 
Vocabulary s-scores (interaction term: head circumference SD-score at 
start*time).  
In addition, change in head circumference SD-score was positively and 
significantly related to Block-design and Vocabulary s-scores over time 
(b=0.72, P < 0.01; b=0.75, P < 0.01, respectively). Correction of head 
circumference SD-score for height SD-score did not contribute to the models. 
 
Discussion 
 
Our study presents the first longitudinal results on IQ and psychosocial 
functioning after GH-induced catch-up growth in adolescents born small for 
gestational age (SGA) during long-term growth hormone treatment.  We 
show that during 8 years of GH treatment IQ scores, behaviour, and self-
perception had improved significantly over time to values comparable to their 
Dutch peers. In addition, we show that over time children whose height 
became closer to that of their peer group had less problem behaviour. 
Before start of GH treatment, all children had short stature, as this was an 
inclusion criterion for the trial. After 2 years of GH treatment 96% of both GH 
groups showed a gain in height SD-score of 1 SD or more, measured from 
start of treatment. GH treatment, therefore, already resulted in a normal 
height (i.e. height ≥ –2.0 SD for age and sex) after 2 years of GH treatment 
in 70% of the children (53/76), while this percentage had increased to 91% 
in 2001. In the present study, as part of a randomised, double-blind, GH-
dose response study, we evaluated the effect of long-term GH therapy on IQ 
and psychosocial functioning, measured by standardised IQ subtests and 
standardised questionnaires on behavioural problems, and self-perception. 
From start of GH treatment until 2001 we found a significant linear 
improvement in mean Block-design s-score, a Performance IQ subtest, and 
estimated total IQ. Both s-scores increased from values significantly lower 
than the mean of Dutch peers to values comparable to the mean of Dutch 
peers. Vocabulary s-score, which is a Verbal IQ subtest, however, remained 
lower than the mean of their Dutch peers. Regarding behavioural problems 
reported by the parents, we found a significant linear decrease over time of 
Externalizing behavior SD-score, indicating a decrease in behavioural 
problems. Both Externalizing and Total problem behavior scores decreased 
from values above the mean of the reference population sample to values 
comparable to the reference mean. Also, Self-perception (total HSP SD-
score) improved quadraticly over time during GH treatment, showing that the 
largest improvement occurred in the first 2 years of GH treatment. Self-
perception increased from a score below the mean of their Dutch peers to a 
score above the mean.  
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FIGURE 7. Self Perception total HSP SD-score for both GH groups during GH treatment, 
corrected for gender and age at start. (1 mg=3 IU) Significant increase from start: * P < 
0.001.   
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While one study found little difference in quality of life between growth 
hormone deficient adults and same sex siblings 229, several other studies in 
growth hormone deficient children and adults, some placebo-controlled, have 
shown that GH treatment had a beneficial effect on cognition, energy, mood, 
and behaviour 187, 230-234. The increase in test scores might therefore be a 
direct effect of GH itself on cerebral functioning. Only Block-Design s-scores, 
a subtest for Performance IQ, improved over time, without change in the 
Verbal IQ subtest, Vocabulary s-scores, possibly indicating a GH effect on the 
right hemisphere of the brain 235. Hopefully, further studies, for instance into 
processing speed, will show the mechanisms behind this improvement.  
Although we did not find any significant differences in IQ test results and 
psychosocial functioning between the two GH dosage groups, this might have 
been because 3 IU/m2/day was enough to achieve the optimal effect on IQ 
and psychosocial functioning. This is similar to our findings regarding the 
effect of GH dosage on final height 220. Another possible explanation for the 
improvement in IQ and psychosocial functioning might be the extra medical 
attention. Unfortunately, due to ethical considerations, it was not possible for 
us to include a non-treated randomised control group as part of the GH trial 
to explore the effect of the extra medical attention. We did not, however, 
provide psychological counselling to treat the behavioural problems found at 
start of GH treatment.  
Interestingly, no differences in Internalizing problem behavior scores were 
found compared to Dutch peers, only in Externalising problem behavior 
scores. A possible reason might be the way short children are treated, 
unintentionally, by adults. They tend to treat short children as younger and 
evade age-appropriate demands on their intellect and behaviour. This may 
lead to feelings of frustration, which, in this study group, was acted out by 
‘childish’ (age-inappropriate) and/or aggressive externalising behaviour. 
Most children showed a considerable catch-up in height during 8 years of GH 
treatment, paralleled by an improvement in scores for IQ, behaviour, and 
self-perception. Previous studies in other patient groups, such as idiopathic 
short stature, childhood GH deficiency, and Turner syndrome, an effect of 
height gain during GH treatment on psychosocial functioning was found 53, 236, 
237. To test whether the considerable increase in height SD-score in our study 
group could explain the improvement of the scores, we added height SD-
score over time to the models. Interestingly, the addition of height SD-score 
to the regression model for Externalizing behavior SD-score, corrected for 
age and gender, showed a significant negative correlation, indicating that 
over time children whose height became closer to that of their peer group 
had less problem behaviour. This finding might suggest that the decrease in 
externalising behavioural problems was caused by the increase in height. For 
IQ and Self-perception, however, the addition of height SD-score had no 
effect on the model, indicating that height SD-score at time of evaluation was 
not related to IQ or Self-perception test scores. Several reasons might 
explain why we did not find such a relation. For IQ, the influence of other 
factors, such as genetic predisposition, might have masked the effect of 
increase in height. As all children showed GH-induced catch-up growth after 
start of GH treatment, the GH groups might have been too homogenous 
regarding height and too heterogeneous regarding factors such as genetic 
predisposition, to show a relation between increase in height and IQ. Another 
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possibility is that the effect of GH treatment was a result of its direct action 
on cerebral functioning, as mentioned above, and was therefore not related 
to its effect on increase in height. For self-perception, factors such as 
physical appearance and coping strategy but also the non-linear increase in 
self-perception might have masked the effect of increase in height.  
One factor, previously reported to be positively related to intelligence, is head 
circumference 173. We show that this relation between head circumference 
and IQ also exists in short children born SGA, both at start of the GH trial as 
well as during GH treatment. In addition, we show that the head 
circumference SD-score was low normal at start of treatment and remained 
so during GH treatment. Thus, head circumference SD-score did not improve 
with IQ scores during GH treatment. Height SD-score, however, also 
increased during GH treatment, leading to a head circumference SD-score 
more in proportion to height SD-score. One of the suggested reasons for a 
decreased IQ in SGA children was that brain development was affected by 
intrauterine malnutrition 172. As a deficit in brain development is often 
accompanied by a smaller head circumference, it would be interesting to see 
whether head circumference before GH treatment would predict IQ 
development during treatment. We show that head circumference SD-score 
at start of treatment did not predict the IQ increase during GH treatment. 
This indicates that IQ scores improved in short children born SGA during GH 
treatment, regardless of whether head circumference had been spared from 
previous growth retardation. 
In conclusion, parallel to a considerable GH-induced catch-up growth, 
children born small for gestational age showed a significant improvement in 
IQ scores, behaviour, and self-perception over time. During eight years of GH 
treatment, IQ and psychosocial functioning had improved from scores 
significantly below average to scores comparable to Dutch peers. In addition, 
the taller the child became over time, the less problem behaviour it showed. 
Although, in general, a child with a smaller pre-treatment head circumference 
had a lower IQ at start of GH treatment, the increase in its IQ score during 
GH treatment occurred regardless of whether its head circumference had 
been spared from growth retardation. Considering the positive effects on IQ 
and psychosocial functioning, in addition to the catch-up growth during GH 
treatment, we recommend GH treatment for short SGA children without signs 
of persistent catch-up growth. Whether GH treatment also has an effect on 
their life achievements in the future, further follow-up will show.
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General Discussion and conclusions 
 
 
In this chapter we discuss the long-term results of a randomised multi-centre 
dose-response growth hormone (GH) trial evaluating the efficacy, safety and 
psychosocial effect of long-term GH treatment. A group of short children born 
small for gestational age (SGA) participated in a double-blind dose-response 
trial using 3 or 6 IU GH/m2/day (~1 or 2 mg/m2/day; 0.033 or 0.067 
mg/kg/day). The trial started in 1991 and four paediatric departments in The 
Netherlands participated. We start by discussing the results of the SGA trial. 
Finally, conclusions are drawn from the discussion and recommendations for 
future research are given. 
 
Effect of long-term continuous GH treatment on final height in 54 
short children born small for gestational age (SGA) 
 
In chapter 8 of this thesis we described the first results on final height after 
long-term, continuous GH treatment with either a GH dosage of 3 or 6 
IU/m2/day. We showed that GH treatment resulted in a final height within the 
normal range (above –2.0 SD score) in 85% of the children and a final height 
within the target height range in 98%. The mean final height using a GH 
dosage of 3 IU/m2/day was –1.1 (0.7) SD score and the mean final height 
using 6 IU GH/m2/day was –0.9 (0.8) SD score when using references for 
normal Dutch children of the same age. As target height SD score was a 
strong predictor for final height, and the 3 IU group (1 mg) had a 
significantly lower target height SD score than the 6 IU group (2 mg), we 
corrected the final height for target height. The mean corrected final height 
SD score (final height SD score minus target height SD score) proved to be 
comparable for the 3 IU group (–0.2[0.8]) and the 6 IU group (–0.4 [0.9]). 
The mean gain in height SD score from start of treatment until final height 
was 1.8 (0.7) SD score (~ an improvement of 12 cm for boys and 11 cm for 
girls) for the 3 IU dosage group (1 mg). For the 6 IU dosage group (2 mg) 
the gain was 2.1(0.8) SD score (~ an improvement of 14 cm for boys and 13 
cm for girls). The difference in height gain between the two dosage groups 
was not significant.   
To estimate the effect of GH treatment, we compared our final height results 
with non-GH treated short children born SGA from a longitudinally followed 
control SGA group with the same inclusion criteria and age as the GH-treated 
patients at start of treatment. Including a randomised control group as part 
of our GH trial until attainment of final height was not allowed by the Medical 
Ethics Committees. The group attained a mean (SD) final height SD score of  
–2.3 (0.7) and had a mean gain in height SD score of 0.3 (0.7) until final 
height during the follow-up period of 7½ years.  
These results showed that GH treatment in short children born SGA leads to a 
significant gain in final height, while a dose of 3 IU/m2/day (1 mg/m2/day) 
proved to be as effective as the higher GH dose of 6 IU/m2/day (2 
mg/m2/day), for most children. Based on these results, in 2003, the 
European Agency for the Evaluation of Medicinal Products (EMEA) and the 
Dutch government acknowledged GH as a treatment for short stature in 
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children born SGA. GH treatment for short stature in children born SGA has 
now become an accepted treatment in many countries. 
Other studies reporting on final height in short children born SGA found a 
considerably lower height gain than in our group 182, 183, 238. Several factors 
can explain the discrepancy between their results and ours. Their children 
were older at start, were treated for a much shorter period, or they were 
treated with a lower GH dose.  
Recent studies have shown a potential danger of having high circulating IGF-
1 levels. As mentioned in the Turner syndrome Discussion, it was reported 
that men (Physicians' Health Study) with serum IGF-I levels in the upper 
quartile showed an increased risk of developing colorectal cancer after 14 
years of follow-up 78. Another study found that after 7 years of follow-up, 
serum IGF-I levels in premenopausal nurses (Nurses’ Health Study cohort) in 
the upper tertile were associated with an increased risk of breast cancer 79. 
These studies, however, did not show a causal relationship between high 
circulating IGF-I levels and cancer. Therefore, whether recombinant GH 
treatment during childhood and adolescence might lead to an increased risk 
of cancer remains to be investigated. Pending these investigations, however, 
high dosages of GH should be given with caution. Although in this trial we did 
not find a significant difference between the two GH dosage groups in IGF-1 
SD-scores at discontinuation, Sas et al. described a significantly higher IGF-1 
SD-score in the 6 IU group (2 mg) during the first years of GH treatment 44, 
150. In addition, a higher dose increases the already high cost of treatment. 
Our study showed that the majority of short SGA children can be effectively 
treated and reach a normal final height with a dose of 3 IU GH/m2/day (1 mg 
GH/m2/day). We therefore suggest to limit high dose treatment to children 
with extremely short stature and/or advanced chronological age and in that 
case only for induction of a fast catch-up growth during a few years. 
Previous publications have shown that untreated children born SGA start their 
pubertal growth spurt relatively early in the normal age range 148, 198. As a 
shorter growth spurt might result in a reduction in final height, we 
investigated the growth spurt and its effect on height SD score in our GH 
treated group. For both GH dosage groups, mean age at onset of puberty 
was comparable to normal Dutch children (median age for healthy boys is 
11.5 years and for girls 10.7 years) 9. In addition, mean pubertal height gain 
(from the onset of puberty until final height) was 29.8 cm for boys and 18.9 
cm for girls. During puberty no acceleration of bone maturation occurred until 
discontinuation. The slight decrease in height SD-score at the end of GH 
treatment might indicate a slightly shorter growth spurt than normal Dutch 
children. Another explanation might be that some of the children did not 
reach their full height potential because they discontinued GH treatment at 
near-final height. 
 
Several parameters to predict final height SD score  
 
Multiple regression analysis with final height as dependant variable which is 
presented in chapter 8 showed the following variables significantly influencing 
final height SD score: target height SD score, height SD score at start, and 
chronological age minus-bone age at start. For all variables a higher value 
predicted an increase in final height SD score. To explain the impact of a 
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higher GH dose, we considered the following case. Suppose a child born SGA 
started GH treatment when he or she had a persistent short stature of –3 
SD-score, no bone age delay, and a mean target height of 0 SD score. 
According to the model, this child would reach a final height SD score of –1.0 
(95% Probability interval between –2.2 and 0.2) when using 3 IU GH (1 mg), 
and –0.8 SD-score (95% Probability interval between –2.0 and 0.4) when 
using 6 IU (2 mg) of GH. The difference in final height would be quite small, 
while doubling the costs of treatment. The model, however, could only 
explain 42 percent of the variation in final height SD score, leaving 58 
percent of the variation to be explained by other factors, such as genetic 
background 164, 193. Future research should be aimed at creating a prediction 
model based on larger groups of short children born SGA, using more 
detailed phenotypic and genetic data. In future, this would support 
individualisation of GH treatment. 
 
Carbohydrate metabolism in short children born SGA after 
discontinuation of long-term GH treatment 
 
It has been established that GH treatment increases post-prandial insulin 
levels, probably due to a reduction in insulin sensitivity 185. Especially in 
individuals born SGA, who might have a predisposition for diabetes mellitus 
type 2, monitoring of the carbohydrate metabolism is an important safety 
parameter during long-term GH treatment 190. Previously, Sas et al. showed 
that stimulated glucose levels remained unchanged and fasting glucose levels 
rose slightly during 6 years of GH treatment, while both fasting and 
stimulated insulin levels increased significantly 44, 91. In chapter 9 we showed 
that 6 months after discontinuation of long-term GH treatment in adolescents 
born SGA both fasting glucose and insulin levels returned to pre-treatment 
levels. Stimulated insulin levels remained slightly higher than pre-treatment 
levels, but we could not expect stimulated insulin levels to return to 
prepubertal levels since all participants were postpubertal after 
discontinuation of GH treatment 81, 86, 87. The stimulated insulin levels were, 
however, comparable to those of healthy adolescent peers indicating that 
discontinuation of GH treatment resulted in a normalisation of stimulated 
insulin levels 81. In different patient groups, such as Turner syndrome, similar 
results were found after discontinuation of GH treatment 51, 84, 186. All insulin 
levels showed no significant differences between the GH dosage groups. After 
discontinuation of GH treatment we found an increase in the prevalence of 
Impaired Glucose Tolerance, according to The Expert Committee on the 
Diagnosis and Classification of Diabetes Mellitus (120-minute stimulated 
glucose level above 7.8 mmol/L), from three percent during treatment to ten 
percent after discontinuation of treatment 80. These results emphasise the 
importance of regular monitoring of fasting glucose and insulin levels, also 
after GH treatment has been discontinued 210, 211.  
 
Several factors that may predict development of cardiovascular 
disease, such as blood pressure, body mass index and blood lipid 
levels in short children born SGA after discontinuation of GH 
treatment 
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In chapter 9 we described that discontinuation of GH treatment did not alter 
the previously described normalisation of blood pressure and body mass 
index (BMI) during GH treatment 44, 91. Another study evaluating the effect of 
discontinuation of GH on blood pressure in adolescents with GHD, showed 
similar results 92. After discontinuation of GH treatment, in our study, the 
decrease in serum total cholesterol (TC), low-density lipoprotein-cholesterol 
(LDL-c), and high-density lipoprotein-cholesterol (HDL-c) during GH 
treatment, remained present for TC levels, whereas only for the female 
participants LDL-c and HDL-c levels increased significantly. Compared to a 
control group, serum lipid levels after discontinuation of GH treatment, 
including HDL-c, were significantly lower in the GH-treated group. The 
atherogenic index (TC/HDL-c), a more potent risk factor for the development 
of cardiovascular disease (CVD), did not change after discontinuation of GH 
treatment and was comparable to the control group. BMI SD-score correlated 
significantly with fasting insulin levels, systolic BP SD-score, and the 
atherogenic index at 6 months after discontinuation of GH treatment which 
might indicate that the clustering of risk factors for cardiovascular disease in 
adults with low birth weight was already present in the more obese subjects 
in young adulthood. These results also suggest prevention of obesity as a 
possible strategy to decrease risk for CVD in subjects born SGA. 
 
IQ and psychosocial functioning of short children born SGA during 
and after long-term GH treatment 
 
In chapter 8 we showed that long-term GH treatment for most SGA children 
resulted into a normalisation of height. Previously, children born SGA have 
been associated with lower intelligence, poor academic performance, low 
social competence, and behavioural problems 165-171. The effect of GH 
treatment and the resulting normalisation of intelligence and psychosocial 
functioning were discussed in chapter 10. We found that during GH treatment 
both Block-design s-score, a Performance IQ subtest, and estimated total IQ 
increased significantly from low values to values comparable to scores for 
Dutch peers, whereas Vocabulary s-score, which is a Verbal IQ subtest, 
remained normal during treatment. Externalising problem behaviour of the 
short SGA children, as reported by the parents, decreased significantly over 
time. Both scores for Externalizing behavior and Total problem behavior 
decreased to values comparable to the same age reference sample. Similarly, 
self-perception (total HSP SD-score) improved over time during GH 
treatment, showing the largest improvement during the first 2 years of GH 
treatment. Self-perception scores rose from below the mean of Dutch peers 
to a score above the mean. 
A possible explanation for the increase in performance IQ was a direct effect 
of GH itself or IGF-I on cerebral functioning. Support for this explanation 
could be found in the beneficial effect of GH treatment on cognition, energy, 
mood, and behaviour in growth hormone deficient children and adults 187, 230-
234. The finding that only Block-Design s-scores, a subtest for Performance 
IQ, improved over time, without change in the Verbal IQ subtest, (Vocabulary 
s-scores), might indicate a GH effect targeting the right hemisphere of the 
brain 235. The improvement in psychosocial functioning, and possibly IQ, 
could also be explained by the extra medical attention. Although we did not 
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provide psychological counselling for behavioural problems, the effect of 
extra medical attention could not be excluded without the presence of a non-
treated randomised control group as part of the GH trial. Another possible 
aetiology for our findings might be the unintentional lack of age-appropriate 
demands on intellect and behaviour before start of GH treatment on our 
group of SGA children due to their short stature. The subsequent frustration 
might have led to ‘childish’ (age-inappropriate) and/or aggressive behaviour. 
This mechanism might explain lower psychosocial functioning scores and 
possibly lower IQ scores at start of GH treatment and normalisation of scores 
coinciding with normalisation of height during and after GH treatment. The 
positive association between increase in height and decrease in problem 
behaviour supported this theory.  
 
Conclusions 
 
Long-term, continuous GH treatment in short children born SGA leads to a 
normalisation of height in childhood and a normal final height for most 
children. A dose of 3 IU/m2/day (1 mg/ m2/day) proved to be as effective as 
the higher GH dose of 6 IU/m2/day (2 mg/m2/day), for most children. Only 
children with extreme short stature may need a higher GH dose to normalise 
final height. Further studies should aim at optimising GH treatment by 
developing advanced prediction models indicating the best treatment options 
for each child. 
GH induced higher insulin levels reduced after discontinuation of GH, while 
the beneficial effect of GH on blood pressure remained after discontinuation 
of GH. Although most children had normal serum lipid levels, we found an 
indication for clustering of risk factors for diabetes mellitus type 2 and 
cardiovascular disease, in adolescents with relatively higher BMI. Whether 
long-term GH treatment will contribute to a reduction of adult diseases and 
longevity, however, remains to be investigated. 
During eight years of GH treatment, for most children test scores for IQ and 
psychosocial functioning improved from scores significantly below average to 
scores comparable to Dutch peers. In addition, the taller the child became 
over time, the less problem behaviour it showed. Whether GH treatment also 
has an effect on their life achievements in future, further follow-up will show. 
Based on our studies we recommend considering GH treatment for short SGA 
children without signs of persistent catch-up growth and who are therefore at 
risk of short stature as adults. GH treatment, however, not only improves 
final height, it also improves blood pressure and serum lipids, without a 
rebound effect after discontinuation of GH treatment. Furthermore, it 
improves IQ and psychosocial functioning. In other words, GH treatment in 
short children born SGA might have several positive effects on the long-term.  
 
Recommendations and future research 
 
For most children, long-term, continuous GH treatment in a dose of 3 
IU/m2/day (1 mg/ m2/day) in short children born SGA leads to a normal final 
height. A higher GH dose of 6 IU/m2/day (2 mg/m2/day) is not more effective 
for most children. We therefore suggest to limit high dose treatment to 
CHAPTER 11   Part ‘Small for Gestational Age’: General Discussion and Conclusions 
 140
children with extremely short stature and/or advanced chronological age and 
in that case only for induction of a fast catch-up growth during a few years. 
To find the best treatment strategy for each child GH treatment should 
become more individualised. Based on larger groups of short children born 
SGA more detailed phenotypic and genetic data could be collected. The aim 
would be to create an advanced prediction model to aid individualisation of 
treatment. 
As mentioned previously in the TS part of the thesis, recent studies have 
shown a potential danger of high circulating IGF-1 levels 78, 79. The causality 
in the relationship between high circulating IGF-1 levels and cancer remains 
to be investigated. Until causality can be ruled out, epidemiological studies on 
individuals treated with recombinant GH should monitor for an increased risk 
of colorectal or breast cancer in this group. 
GH treatment in short SGA children improves blood pressure and serum 
lipids, without a rebound effect after discontinuation of GH treatment. Follow-
up of larger groups of GH treated short SGA children will show whether long-
term GH treatment will lead to a significant reduction in adult disease. 
In addition, we found an indication for clustering of risk factors for diabetes 
mellitus type 2 and cardiovascular disease, in adolescents with relatively 
higher BMI. Whether being born SGA causes a clustering of risk factors for 
CVD or whether factors associated with SGA, such as obesity or (lack of) 
catch-up growth, are responsible, is currently under debate. Investigating the 
cause for the predisposition will aid in preventing CVD in adult life.  
IQ and psychosocial functioning improved during GH treatment for most 
children. Whether GH treatment also has an effect on life achievements in 
future, epidemiological studies of larger groups of GH-treated SGA adults in 
comparison to untreated SGA adults will show.  
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Summary 
 
During the first two years of life about 10% of the children born SGA do not 
catch-up to a normal height. The majority of these children will become short 
adults. The reason for these children remaining short is not completely 
understood. There are several theories, such as reduced sensitivity for 
growth factors, intrauterine re-programming or genetic background. Recent 
studies have demonstrated that 5 years of GH treatment in short children 
born SGA results in a normalisation of height during childhood.  
In this chapter the results and conclusions are summarised of a multi-centre 
randomised double-blind dose-response growth hormone (GH) trial 
evaluating the efficacy, safety and psychosocial effect of long-term GH 
treatment on short children born small for gestational age (SGA). The SGA 
trial consisted of 79 untreated short children, aged between 3 and 11 years, 
born SGA. The children were randomly assigned to a group using 3 or 6 IU 
GH/m2/day.  
 
Chapter 7 introduces the characteristics and incidence of short children born 
SGA. In addition, it describes the aetiology, post-natal growth and risk 
factors for cardiovascular disease (CVD) associated with SGA. Subsequently, 
it describes short-term results of GH treatment on final height  and CVD risk 
factors in short children born SGA. 
Chapter 8 shows the effect of long-term continuous GH treatment on final 
height (FH) in a group of 54 children born SGA. Long-term treatment with GH 
in short children born SGA results in a normalisation of FH in most children. 
After a mean duration of almost 8 years of GH treatment 85% of the children 
reach a FH within the normal range, and 98% within the target height range. 
A higher GH dose of 6 IU GH/m2/day does not result in a significantly higher 
FH. Compared to a group of short children born SGA of the same age who did 
not receive GH treatment, those treated with GH significantly gain in final 
height. Factors that seem to predict gain in final height are target height, 
height at start, and bone age delay at start. 
Chapter 9 presents the effect of discontinuation of long-term GH treatment 
on carbohydrate metabolism, body mass index, blood pressure, and serum 
lipid levels in children born SGA. Discontinuation of long-term GH treatment 
in adolescents born SGA normalises carbohydrate metabolism, after a 
significant change during GH treatment. Furthermore, discontinuation of GH 
does not alter the positive influence of GH on body mass index (BMI) and 
blood pressure, while serum lipid levels remain normal. 
Chapter 10 describes longitudinal results on IQ and psychosocial functioning 
after GH-induced catch-up growth in adolescents born small for gestational 
age (SGA) during long-term growth hormone treatment.  During 8 years of 
GH treatment IQ scores, behaviour, and self-perception had improved 
significantly over time to values comparable to their Dutch peers. In addition, 
we show that over time children whose height became closer to that of their 
peer group had less problem behaviour. 
Chapter 11 discusses the results presented in the previous chapters and 
relates them to relevant literature. In addition, conclusion are drawn and 
recommendations are given together with suggestions for future research. 
Chapter 13 synthesises the results for the SGA trial. 
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Finally, Chapter 13 synthesises the results from the TS trial and the SGA trial 
and discusses the similarities and differences. 
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Samenvatting 
 
Ongeveer tien procent van de kinderen die te klein worden geboren slaagt er 
niet in om de groeiachterstand in de eerste twee jaar in te halen. De meeste 
van deze kinderen zullen eindigen als volwassenen met een te kleine lengte. 
De oorzaak van de te kleine lengte is vaak onbekend. Er zijn verschillende 
theorieën, zoals verminderde gevoeligheid voor groeifactoren , re-
programmering in de baarmoeder, en genetische achtergrond. Recent 
onderzoek heeft uitgewezen dat vijf jaar GH behandeling in te kleine kinderen 
die te klein zijn geboren (SGA) resulteert in normalisatie van lengte als kind. 
In dit hoofdstuk worden de resultaten en conclusies samengevat van een 
gerandomiseerd dubbelblind dosisrespons onderzoek dat heeft gelopen op 
verschillende kinderafdelingen verspreid door Nederland. Het onderzoek 
evalueerde het effect en de veiligheid van langdurige GH behandeling van te 
kleine SGA kinderen. De doseringen van het GH werden ad random 
toegekend aan twee groepen van onbehandelde te kleine SGA kinderen 
tussen de 3 en 11 jaar: Groep A (4 IU/m2/dag), Groep B (6 IU/m2/dag). De 
doseringen werden niet bekend gemaakt aan de 79 patiënten, hun 
behandelaars, en degenen die de studie uitvoerden.  
 
Hoofdstuk 7 introduceert de kenmerken van SGA en de frequentie van 
voorkomen. Het beschrijft verder de etiologie, de postnatale groei en het 
risico op hart- en vaatziekten. Vervolgens beschrijft het hoofdstuk het korte 
termijn effect van GH behandeling op eindlengte en op risicofactoren voor 
hart- en vaatziekten. 
Hoofdstuk 8 laat het effect zien van langdurige continue GH behandeling 
(bijna 8 jaar) op eindlengte in 54 SGA kinderen. Langdurige GH behandeling 
resulteert in een normale eindlengte bij de meeste SGA kinderen. Van de 
hele groep heeft 85 procent van de SGA kinderen een normale eindlengte 
behaald en 98 procent een eindlengte in hun target height interval 
(eindlengte gebaseerd op ouderlengte). Hogere dosering van GH (groep B) 
resulteert niet in een langere eindlengte dan in groep A. In vergelijking met 
een groep onbehandelde SGA kinderen, bereikt de behandelde groep SGA 
kinderen een significant hogere eindlengte. Factoren die toename in 
eindlengte voorspellen zijn target height, lengte bij start, gecorrigeerd voor 
leeftijd en geslacht (lengte SD-score), en achterstand in botleeftijd bij start. 
Hoofdstuk 9 beschrijft het effect van het staken van de GH behandeling op 
het koolhydraat metabolisme, op de body mass index (BMI), op de 
bloeddruk, en op het vetgehalte in het bloed. Na staken van de behandeling 
blijkt het effect van GH op het koolhydraat metabolisme te verdwijnen. De 
positieve effecten van GH op bloeddruk en vetgehalte blijven bestaan na het 
staken van de GH behandeling, terwijl het vetgehalte gedurende en na de GH 
normaal blijft.  
Hoofdstuk 10 presenteert het psychosociaal functioneren tijdens en na 
langdurige GH behandeling. Gedurende de GH behandeling zien we een 
verbetering van IQ, gedrag, en zelfbeeld in SGA kinderen. De resultaten 
verschuiven van waarden onder het gemiddelde, voor de behandeling, naar 
waarden vergelijkbaar met het gemiddelde van leeftijdgenoten tijdens en na 
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de behandeling. Daarnaast blijkt dat hoe normaler de lengte is tijdens de GH 
behandeling, des te minder probleemgedrag de kinderen vertonen. 
Hoofdstuk 11 bediscussieert de resultaten van de voorgaande hoofdstukken 
en betrekt daarin relevante literatuur. Daarnaast worden er conclusies 
getrokken en suggesties gedaan voor toekomstig onderzoek. 
Als laatste wordt er in Hoofdstuk 13 een vergelijking gemaakt tussen de 
resultaten van het SGA onderzoek en het TS onderzoek. 
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Synthesis 
 
 
In the previous chapters we have discussed the effect of long-term GH 
treatment on final height, carbohydrate metabolism, risk factors for 
cardiovascular disease, and psychosocial functioning. The first chapters 
described and discussed the results of the TS trial, and the following chapters 
described and discussed the results of the SGA trial. In this part of the thesis 
we compare results of both trials.  
 
Effect of long-term GH treatment on final height 
 
In the TS trial we showed that 83% of the TS girls reached a normal final 
height (SD-score above -2). In the SGA trial we showed GH treatment 
resulted in a final height (FH) within the normal range in 85% of the children. 
These percentages are similar for the two patient groups. Although the 
percentages for a final height within the target height range (TH ± 1.3 SD) 
were different, namely 63% in the TS trial and 98% in the SGA trial, this 
result does not indicate a different growth response. It only reflects the 
difference in TH between the two patient groups. In the TS trial the mean TH 
was normal, while in the SGA trial TH was in the low normal range. A 
Swedish study, investigating an untreated SGA cohort, also found a low mid-
parental height in the SGA children with reduced post-natal catch-up growth 
143. This might indicate that at least part of the post-natal persistent short 
stature in SGA can be explained by an inherited genetic background. To 
reach the same percentage in the normal range for FH, however, a different 
dosage is necessary for TS and SGA. In the TS trial a dosage of 6 IU/m2/day 
(2 mg) led to a significantly higher FH than a lower dosage of 4 IU/m2/day 
(1.3 mg), while in the SGA trial the 3 IU/m2/day (1 mg) dosage was as 
effective as 6 IU/m2/day. The mean gain in height SD-score (increase in 
height SD-score from start until FH) was similar in both patient group using 
the most effective dosage (TS trial: 1.9 (0.5) SD-score in the 6 IU group; 
SGA trial: 1.8 (0.7) SD-score in the 3 IU group). Most likely, the difference in 
GH dosage reflects the different aetiology of the growth retardation. The 
higher GH dose required for optimal height gain in TS girls might confirm the 
previously suggested diminished sensitivity for growth factors 12, 14. Given the 
heterogeneity in aetiology of SGA (Chapter 7, Table 1), it is likely that factors 
that contribute to the lack in postnatal catch-up will also vary. Suggested 
causes for post-natal persistent short stature in SGA are low GH levels, or a 
diminished sensitivity for growth factors 144-146. The fact that short SGA 
children require a lower GH dose than the TS girls for reaching normal 
stature might suggest that in short SGA children either the main cause for 
the growth failure is low GH levels, or the lower sensitivity for growth factors 
is of a less severe nature than in TS. 
 
Parameters to predict final height SD-score 
 
When analysing the factors most likely to influence final height SD-score, 
different factors were found to be significant. In the TS trial we found height 
SD-score at start, GH dosage, age at start, and first year height velocity 
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influencing FH SD-score outcome. In contrast, in the SGA trial, the factors 
target height SD-score, height SD-score at start, and bone age delay at start 
predicted FH SD-score outcome. Another difference in the two trials was that 
the explained part of the variation in final height SD-score in the TS trial was 
higher than in the SGA trial, respectively 76% and 42%. A likely explanation 
is that the SGA patient group is a more diverse group, as mentioned 
previously. Diversity in aetiology of post-natal catch-up growth might lead to 
a difference in factors that influence growth during GH treatment. It has been 
suggested that genetic factors, such as deletions or polymorphism in the 
genes encoding for growth factors or growth factor receptors, might play a 
role in the aetiology of the post-natal growth retardation. Possibly, identifying 
such factors will lead to a more reliable prediction of response to GH 
treatment in SGA 164, 193.  
 
Carbohydrate metabolism after discontinuation of long-term GH 
treatment 
 
After discontinuation of GH treatment, in both patient groups the glucose-
stimulated insulin levels remained above pre-treatment levels, while levels 
were similar to normal peers of the same age range 83. The reason for the 
increased stimulated insulin levels, in normal peers and in both patient 
groups after GH treatment, is that during puberty insulin sensitivity 
decreases 81, 86, 87.  
Fasting insulin levels in the SGA trial decreased to pre-treatment levels after 
discontinuation of GH treatment. In the TS trial, however, fasting insulin 
levels remained higher than pre-treatment after discontinuation. Although 
the levels were still comparable to normal peers, a possible explanation for 
this result might be the difference in BMI SD-score. In the TS group the BMI 
SD-score after GH discontinuation was significantly higher than for normal 
girls, while in the SGA group the mean BMI SD-score after GH discontinuation 
was normal. Another explanation might be that slightly higher insulin levels 
are an early sign of the TS predisposition for type 2 diabetes mellitus. If the 
TS predisposition for diabetes is based primarily on beta-cell dysfunction in 
stead of on insulin resistance, this explanation does not hold 30. In both trials 
no significant differences in glucose or insulin levels were found between 
dosage groups. 
 
Several factors that may predict development of cardiovascular 
disease after discontinuation of GH treatment 
 
Adult cardiovascular disease (CVD) and risk factors for CVD seem to occur 
more often in both TS and SGA populations 24-29, 155, 156. In this thesis, we 
describe that blood pressure, in both patient groups, declined significantly 
compared to pre-treatment data. In the TS group, however, blood pressure 
remained slightly higher than in peers. It is generally taken that having 
Turner syndrome predisposes for hypertension 25. But the aetiology of the 
predisposition remains unclear 31. 
The atherogenic index (TC/HDL-c) in the TS group decreased to pre-
treatment levels during and after discontinuation of GH treatment, to levels 
even lower than for normal peers. For the SGA group the atherogenic index 
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remained at pre-treatment level during and after discontinuation of GH 
treatment, and was similar to normal peers.  
Clustering of risk factors for CVD at 6 months after discontinuation of GH 
treatment was found only for insulin levels and BMI SD-score in TS group, 
while in the SGA group BMI SD-score correlated significantly with fasting 
insulin levels, systolic BP SD-score, and the atherogenic index. In normal 
children a relationship between BMI SD-score and insulin levels is also found 
89, 100. The clustering of risk factors for CVD in the SGA group might indicate 
that obese SGA subjects have an increased risk for adult CVD which is 
already present in young adulthood. Prevention of obesity, however, appears 
to be important for both patient groups.  
 
Psychosocial functioning after long-term GH treatment 
 
In the TS group, in Chapter 4, we describe psychosocial functioning after  
discontinuation of GH treatment. In the SGA group, in Chapter 10, we 
describe IQ and psychosocial functioning before, during, and after 
discontinuation of GH treatment. In both patient groups, we investigated 
problem behaviour scores and self-perception after discontinuation of GH 
treatment. Problem behaviour after discontinuation of GH treatment were 
comparable to normal peers in both trials. The longitudinal data in the SGA 
group showed that scores for in particularly externalising problem behaviour 
during GH treatment had decreased to values comparable to the same age 
reference sample. In addition, in the SGA trial, children whose height became 
closer to that of their peers during GH treatment, had less problem 
behaviour. 
Self-perception in the TS group after discontinuation of GH treatment was 
less positive than for peers, while in the SGA group self-perception was 
slightly better than for peers. Longitudinal self-perception scores in the SGA 
group demonstrated an increase in self-perception during the first years of 
GH treatment, in parallel with the improvement in height. The difference in 
self-perception between the two patient groups after discontinuation of GH 
treatment seems to indicate that in TS not only short stature has an influence 
on self-perception, but also that other factors, most likely related to other TS 
features, are partly accountable for a lower self-perception score. In the 
discussion of the TS results in Chapter 5, it is postulated that the typical 
physical TS features or a suggested lack in social graces play a part in their 
lower self-perception. 
In addition to psychosocial functioning, in the SGA trial, intelligence was 
investigated over time. As described in Chapter 10, during GH treatment, a 
significant increase in IQ was found. 
 
In conclusion 
 
After synthesis of results of the two trials, it can be concluded that for both 
patient groups GH treatment results in normalisation of final height in most 
children. For the TS group, a higher dosage is necessary to achieve the 
highest percentage of normalisation. This finding seems to reflect the 
difference in aetiology of the growth retardation in the two patient groups.  
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The GH-induced increase in insulin levels during GH treatment reduces after 
discontinuation of GH treatment to levels comparable to normal peers, in 
both patient groups. In the TS group, however, insulin levels remain slightly 
higher than pre-treatment, after discontinuation of GH treatment. Most likely 
this can be explained by the higher BMI SD-score in the TS group after GH 
discontinuation.  
 
Clustering of risk factors for CVD in TS girls seems to be limited to a 
clustering of insulin levels and BMI SD-score, which is also found in normal 
children. In the SGA children, there is a clustering of several risk factors. It is 
not yet known whether the clustering is an early sign of the SGA 
predisposition for adult CVD. The lack of clustering in the TS girls of the 
slightly higher post-treatment blood pressure with other risk factors possibly 
indicates a different aetiology or timing for the TS predisposition for CVD. 
 
Long-term GH treatment, and additional oestrogen therapy in TS, in most 
children, improved psychosocial functioning in both GH trials. In case of TS, 
however, other TS features which were not treated, most likely prevented the 
self-perception scores to normalise. This results emphasise the importance of 
further studies determining factors which significantly influence the 
psychosocial status in TS, and by doing so optimise the treatment strategy 
for TS. In the SGA group the normalisation of behaviour and self-perception 
during GH treatment most likely demonstrates the psychosocial importance 
of GH treatment for short SGA children. 
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